image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
157ada06900921db483a5f11c7a2a07b742a4a98b5dbef2e588bea0f56a5b106.png | simple | <table><tr><td>Type of complication </td><td>Prevalence <i>N</i> (%)</td></tr><tr><td>Retinopathy</td><td>6 (0.9)</td></tr><tr><td>LVH</td><td>12 (2)</td></tr><tr><td>IHD</td><td>51 (8.3)</td></tr><tr><td>HF</td><td>75 (12.2)</td></tr><tr><td>CKD</td><td>20 (3.3)</td></tr><tr><td>Hypertensive urgency</td><td>39 (6.4)</td></tr><tr><td>Sexual dysfunction</td><td>4 (0.67)</td></tr><tr><td>Stroke</td><td>34 (5.5)</td></tr><tr><td>AF</td><td>6 (0.9)</td></tr><tr><td>Total TOD</td><td>247 (100.0)</td></tr></table> |
0c4a7ac7a349f8d94950880e065badff4fd02d7062c789f87868260d5f2a2b2a.png | simple | <table><tr><td>Parameters</td><td>Total (N = 268 )</td><td>Test (N = 134)</td><td>Control (N = 134)</td><td>P value</td></tr><tr><td>Female</td><td>110</td><td>57</td><td>53</td><td>0.619</td></tr><tr><td>Age (months)*</td><td>46.3 ± 30.3</td><td>44.5 ± 29.6</td><td>48.13 ± 31.1</td><td>0.331</td></tr><tr><td>12–17</td><td>35 (13%)</td><td>21 (16%)</td><td>14 (10%)</td><td>0.282</td></tr><tr><td>18–59</td><td>160 (60%)</td><td>81 (60%)</td><td>79(59%)</td><td>0.282</td></tr><tr><td>60 and over</td><td>73 (27%)</td><td>32 (24%)</td><td>41(31%)</td><td>0.282</td></tr><tr><td>Weight (Kg)*</td><td>14.1 ± 6.5</td><td>14.21 ± 7.75</td><td>14.1 ± 5.0</td><td>0.834</td></tr><tr><td>Temperature (°C)</td><td>36.7</td><td>36.7</td><td>36.7</td><td>0.519</td></tr><tr><td>Pulse Rate (per minute)**</td><td>85.7 ± 8.1</td><td>85.66 ± 8.12</td><td>85.7 ± 8.2</td><td>0.946</td></tr><tr><td>Hemoglobin (g/dl)*</td><td>11.2 ± 1.2</td><td>11.2 ± 1.1</td><td>11.2 ± 1.3</td><td>0.819</td></tr><tr><td>TLC (mm<sup>3</sup>)*</td><td>10,762.3 ± 3,466.5</td><td>11,062.0 ± 3,627.3</td><td>10,462.7 ± 3,284.0</td><td>0.157</td></tr><tr><td>Neutrophils (%) *</td><td>42.1 ± 13.0</td><td>42.6 ± 13.9</td><td>41.61 ± 12.0</td><td>0.554</td></tr><tr><td>Lymphocytes (%) *</td><td>45.1 ± 12.7</td><td>44.4 ± 13.1</td><td>45.8 ± 12.3</td><td>0.410</td></tr><tr><td>Eosinophils (%) *</td><td>5.4 ± 4.7</td><td>5.46 ± 5.1</td><td>5.39 ± 4.3</td><td>0.902</td></tr><tr><td>Basophils (%) *</td><td>0.4 ± 0.5</td><td>0.39 ± 0.3</td><td>0.44 ± 0.6</td><td>0.359</td></tr><tr><td>Monocytes (%) *</td><td>6.4 ± 3.1</td><td>6.44 ± 2.8</td><td>6.32 ± 3.3</td><td>0.760</td></tr><tr><td>Platelet Count (lakhs/mm<sup>3</sup>) *</td><td>3.2 ± 1 .2</td><td>3.3 ± 1 .0</td><td>3.2 ± 1.4</td><td>0.403</td></tr></table> |
538453cf37586177867020487c1c6aef7ae65c1fe38d9ce1400fe12576a15087.png | complex | <table><tr><td>Variable</td><td>Active group</td><td>Control group</td><td>df</td><td>x2/ T</td><td>P</td></tr><tr><td> </td><td>N = 80</td><td>N = 80</td><td> </td><td> </td><td> </td></tr><tr><td>Age* (y)</td><td>63.66 ± 6.37</td><td>63.1 ± 6.85</td><td>158</td><td>−0.53</td><td>0.59</td></tr><tr><td>Sex (n%)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>43(53.75)</td><td>42(52.5)</td><td>1</td><td>0.025</td><td>0.87</td></tr><tr><td> Male</td><td>37(46.25)</td><td>38(47.5)</td><td> </td><td> </td><td> </td></tr><tr><td>Diabetes duration* (y)</td><td>9.56 ± 2.92</td><td>9.65 ± 2.93</td><td>158</td><td>0.18</td><td>0.85</td></tr><tr><td>Education (n%)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> High school</td><td>55(8.75)</td><td>56(70)</td><td>1</td><td>0.029</td><td>0.86</td></tr><tr><td> Higher</td><td>25 (31.25)</td><td>24(30)</td><td> </td><td> </td><td> </td></tr><tr><td>BMI*</td><td>27.49 ± 0.88</td><td>27.32 ± 0.87</td><td>158</td><td>−1.24</td><td>0.21</td></tr><tr><td>HbA1<sub>C</sub>* (mmol/lit)</td><td>7.13 ± 0.16</td><td>7.17 ± 0.23</td><td>158</td><td>1.50</td><td>0.13</td></tr><tr><td>MMSE Score*</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> MMSE total</td><td>28.2 ± 2.18</td><td>25.23 ± 1.75</td><td>158</td><td>−8.08</td><td>0.001</td></tr><tr><td> MMSE in female</td><td>28.2 ± 2.4</td><td>25.19 ± 1.77</td><td>83</td><td>−6.94</td><td>0.001</td></tr><tr><td> MMSE in male</td><td>28.2 ± 1.98</td><td>25.28 ± 1.76</td><td>73</td><td>−5.58</td><td>0.001</td></tr><tr><td>Foot care practice*</td><td>4.77 ± 0.77</td><td>4.45 ± 0.83</td><td>158</td><td>−2.54</td><td>0.01</td></tr><tr><td colspan="2">(day/week)</td><td> </td><td> </td><td> </td><td> </td></tr></table> |
d164aa97ed18e2f5c0f739a045191ab46aed959a0a1a9c7f5f67edd18ace3a8b.png | complex | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Conc. (μg/ml)</td><td colspan="2">Mean absorbance ± SD</td><td rowspan="2">Percentage inhibition of haemolysis</td></tr><tr><td>Heated solution</td><td>Unheated solution</td></tr><tr><td>Control</td><td>-</td><td>0.67 ± 0.13</td><td>0.3 ± 0.01</td><td> </td></tr><tr><td rowspan="4">Extract</td><td>100</td><td>0.25 ± 0.04**</td><td>0.4 ± 0.01</td><td>66.46 ± 2.89</td></tr><tr><td>200</td><td>0.28 ± 0.04**</td><td>0.08 ± 0.03</td><td>65.14 ± 4.58</td></tr><tr><td>400</td><td>0.42 ± 0. 07**</td><td>0.12 ± 0.03</td><td>46.53 ± 2.52</td></tr><tr><td>600</td><td>0.42 ± 0.06**</td><td>0.25 ± 0.06</td><td>61.88 ± 4.51</td></tr><tr><td> </td><td>800</td><td>0.43 ± 0.09**</td><td>0.38 ± 0.08</td><td>86.67 ± 3.06</td></tr><tr><td>Indomethacin</td><td>200</td><td>0.05 ± 0.01***</td><td>0.02 ± 0.00</td><td>95.32 ± 3.51</td></tr></table> |
0d64dc1534a641bbd5ccc430462fc4e06e42ee96ad8004c681e11eb5a0942e5d.png | complex | <table><tr><td rowspan="2">Malalignment parameter</td><td colspan="2">Difference compared to pre-opMedian (IQR)</td><td rowspan="2">Significance<sup>a</sup></td></tr><tr><td>Cutting guide (<i>n</i> = 4)</td><td>Visualisation (<i>n</i> = 4)</td></tr><tr><td>Coronal shift in mm, ulnar (−), radial (+)</td><td>3.1 (1.9 to 10.0)</td><td>−2.6 (−3.0 to 3.5)</td><td>0.200</td></tr><tr><td>Sagittal shift in mm, volar (−), dorsal (+)</td><td>10.2 (−7.3 to 18.1)</td><td>−6.7 (−26.4 to −2.6)</td><td>0.200</td></tr><tr><td>Radial length in mm</td><td>2.2 (−2.0 to 15.7)</td><td>4.3 (0.3 to 5.4)</td><td>0.686</td></tr><tr><td>Palmar tilt in deg, dorsal (−), volar (−)</td><td>−6.8 (−24.5 to 4.4)</td><td>8.5 (5.2 to 14.9)</td><td>0.114</td></tr><tr><td>Radial inclination in deg, ulnar (−), radial (+)</td><td>−3.2 (−9.3 to 5.7)</td><td>0.3 (−11.4 to 5.3)</td><td>1.000</td></tr><tr><td>Axial rotation in deg, pronation (−), supination (+)</td><td>23.0 (11.5 to 30.6)</td><td>1.8 (−13.1 to 30.0)</td><td>0.343</td></tr></table> |
afef55cfc383a5cc87eb4cc5ac75db744cc33312b54171340ce32ba2241cb265.png | complex | <table><tr><td rowspan="2">Analyte</td><td colspan="2">Concn (ng/ml)</td></tr><tr><td>Low</td><td>High</td></tr><tr><td>Amodiaquine</td><td>4.0</td><td>4,192</td></tr><tr><td>Desethylamodiaquine</td><td>4.0</td><td>4,192</td></tr><tr><td>Lumefantrine</td><td>25</td><td>20,000</td></tr><tr><td>Chloroquine</td><td>4.0</td><td>4,192</td></tr><tr><td>Desethylchloroquine</td><td>4.0</td><td>4,192</td></tr><tr><td>Dihydroartemisinin</td><td>1.6</td><td>2,875</td></tr><tr><td>Piperaquine</td><td>1.2</td><td>575</td></tr><tr><td>Mefloquine</td><td>70</td><td>4,000</td></tr><tr><td>Carboxymefloquine</td><td>70</td><td>4,000</td></tr><tr><td>Primaquine</td><td>10</td><td>400</td></tr><tr><td>Carboxyprimaquine</td><td>50</td><td>4,000</td></tr></table> |
a2c46f331cb8b0ea0c18f626c2ce4ed7ad185366d8a0be20910abaf174a872bf.png | complex | <table><tr><td></td><td>Panitumumab + mFOLFOX6 (<i>n =</i> 88)</td><td>Bevacizumab + mFOLFOX6 (<i>n =</i> 82)*</td></tr><tr><td>Median DoR, months (95% CI)</td><td>11.4 (10.0, 16.3)</td><td>9.0 (7.6, 9.5)</td></tr><tr><td> HR<sup>†</sup> (95% CI)</td><td colspan="2">0.59 (0.39, 0.88)</td></tr><tr><td> <i>p</i> value<sup>‡</sup></td><td colspan="2">0.011</td></tr><tr><td>Median TTR, months (95% CI)</td><td>2.3 (1.9, 3.7)</td><td>3.8 (2.1, 5.7)</td></tr><tr><td> HR<sup>†</sup> (95% CI)</td><td colspan="2">1.19 (0.81, 1.74)</td></tr><tr><td> <i>p</i> value<sup>‡</sup></td><td colspan="2">0.37</td></tr><tr><td>Median DpR, % (Q1, Q3)</td><td>65.0 (45.7, 89.5)</td><td>46.3 (29.5, 63.3)</td></tr><tr><td> <i>p</i> value<sup>¶</sup></td><td colspan="2">0.0018</td></tr><tr><td>Any resection, <i>n</i> (%)</td><td>12 (14)</td><td>9 (11)</td></tr><tr><td> Liver only<sup>§</sup></td><td>9 (75)</td><td>6 (67)</td></tr><tr><td>Complete resection</td><td>9 (10)</td><td>7 (9)</td></tr><tr><td> Liver only<sup>^</sup></td><td>7 (78)</td><td>6 (86)</td></tr><tr><td>Time to resection, months – median (range)</td><td>5.1 (3–19)</td><td>4.4 (3–12)</td></tr><tr><td>Progression-free at 6 months, <i>n</i> (%)</td><td colspan="2"></td></tr><tr><td> Patients with resection</td><td>8/12 (67)</td><td>4/9 (44)</td></tr><tr><td> Patients without resection</td><td>45/76 (59)</td><td>48/73 (66)</td></tr><tr><td>Alive at 2 years, <i>n</i> (%)</td><td colspan="2"></td></tr><tr><td> Patients with resection</td><td>8/12 (67)</td><td>8/9 (89)</td></tr><tr><td> Patients without resection</td><td>18/76 (24)</td><td>12/73 (16)</td></tr></table> |
5eef7cfa67dc704b5f28d70970bfb031560f099030698fdf59d4c350932fda42.png | complex | <table><tr><td> </td><td> </td><td colspan="3">High-risk subject</td><td colspan="4">Low-risk subject</td></tr><tr><td> </td><td> </td><td>N</td><td>Mean<sup>a</sup></td><td>CI</td><td>N</td><td>Mean<sup>a</sup></td><td>CI</td><td>P</td></tr><tr><td><i>Women</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>.022</td></tr><tr><td rowspan="2"> </td><td>Divorced</td><td>118</td><td>.51</td><td>.36–.67</td><td>516</td><td>.20</td><td>.13–.26</td><td> </td></tr><tr><td>Not divorced</td><td>1051</td><td>.07</td><td>.01–.12</td><td>11068</td><td>-.03</td><td>-.05– -.02</td><td> </td></tr><tr><td> </td><td>Total</td><td>1169</td><td>.12</td><td> </td><td>11584</td><td>-.02</td><td> </td><td> </td></tr><tr><td><i>Men</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>.108</td></tr><tr><td rowspan="2"> </td><td>Divorced</td><td>122</td><td>.67</td><td>.49–.86</td><td>438</td><td>.26</td><td>.18–.34</td><td> </td></tr><tr><td>Not divorced</td><td>1264</td><td>.18</td><td>.12–.23</td><td>8934</td><td>-.06</td><td>-.07– -.04</td><td> </td></tr><tr><td> </td><td>Total</td><td>1386</td><td>.22</td><td> </td><td>9372</td><td>-.04</td><td> </td><td> </td></tr></table> |
d5945e7028169a7202f6b545ce70ff207109c0879849237ae0a1621b134c046a.png | simple | <table><tr><td>Gene</td><td>Encoded protein</td><td>Fold change</td><td>Cell cycle</td></tr><tr><td>AURKA</td><td>Aurora kinase A</td><td>−2.712</td><td>STOP</td></tr><tr><td>AURKB</td><td>Aurora kinase B</td><td>−4.146</td><td>STOP</td></tr><tr><td>CCNA2</td><td>Cyclin A2</td><td>−4.652</td><td>STOP</td></tr><tr><td>CCNB1</td><td>Cyclin B1</td><td>−5.752 −5.820 −5.857</td><td>STOP</td></tr><tr><td>CCNB2</td><td>Cyclin B2</td><td>−3.392</td><td>STOP</td></tr><tr><td>CCND1</td><td>Cyclin D1</td><td>−2.476</td><td>STOP</td></tr><tr><td>CCND3</td><td>Cyclin D3</td><td>−1.539</td><td>STOP</td></tr><tr><td>CCNE1</td><td>Cyclin E1</td><td>−1.777</td><td>STOP</td></tr><tr><td>CCNE2</td><td>Cyclin E2</td><td>−2.847</td><td>STOP</td></tr><tr><td>CCNF</td><td>Cyclin F</td><td>−3.211</td><td>STOP</td></tr><tr><td>CDC6</td><td>Cell division cycle 6</td><td>−1.936</td><td>STOP</td></tr><tr><td>CDC20</td><td>Cell division cycle 20</td><td>−3.113</td><td>STOP</td></tr><tr><td>CDC25B</td><td>Cell division cycle 25B</td><td>−1.636</td><td>STOP</td></tr><tr><td>CDC25C</td><td>Cell division cycle 25C</td><td>−2.414</td><td>STOP</td></tr><tr><td>CDC45</td><td>Cell division cycle 45</td><td>−1.769</td><td>STOP</td></tr><tr><td>CDCA2</td><td>Cell division cycle associated 2</td><td>−3.461</td><td>STOP</td></tr><tr><td>CDCA3</td><td>Cell division cycle associated 3</td><td>−3.003</td><td>STOP</td></tr><tr><td>CDCA5</td><td>Cell division cycle associated 5</td><td>−3.053</td><td>STOP</td></tr><tr><td>CDCA7L</td><td>Cell division cycle associated 7-like</td><td>−4.123</td><td>STOP</td></tr><tr><td>CDCA8</td><td>Cell division cycle associated 8</td><td>−3.467</td><td>STOP</td></tr><tr><td>CDK1</td><td>Cyclin-dependent kinase 1</td><td>−3.227</td><td>STOP</td></tr><tr><td>CDK15</td><td>Cyclin-dependent kinase 15</td><td>1.618</td><td><i>GO </i></td></tr><tr><td>CDK19</td><td>Cyclin-dependent kinase 19</td><td>1.619</td><td><i>GO </i></td></tr><tr><td>CDK5R1</td><td>Cyclin-dependent kinase 5, regulatory subunit 1 (p35)</td><td>1.597</td><td>—</td></tr><tr><td>CENPA</td><td>Centromere protein A</td><td>−1.895</td><td>STOP</td></tr><tr><td>CENPE</td><td>Centromere protein E, 312 kDa</td><td>−4.140</td><td>STOP</td></tr><tr><td>CENPF</td><td>Centromere protein F, 350/400 kDa</td><td>−3.927</td><td>STOP</td></tr><tr><td>CENPI</td><td>Centromere protein I</td><td>−2.899</td><td>STOP</td></tr><tr><td>CENPK</td><td>Centromere protein K</td><td>−2.813</td><td>STOP</td></tr><tr><td>CENPL</td><td>Centromere protein L</td><td>−1.864</td><td>STOP</td></tr><tr><td>CENPM</td><td>Centromere protein M</td><td>−3.407</td><td>STOP</td></tr><tr><td>CENPN</td><td>Centromere protein N</td><td>−2.465</td><td>STOP</td></tr><tr><td>CENPU</td><td>Centromere protein U</td><td>−1.624</td><td>STOP</td></tr><tr><td>SKA1</td><td>Spindle and kinetochore associated complex subunit 1</td><td>−1.532</td><td>STOP</td></tr><tr><td>SKA2</td><td>Spindle and kinetochore associated complex subunit 2</td><td>−1.582</td><td>STOP</td></tr><tr><td>SKA3</td><td>Spindle and kinetochore associated complex subunit 3</td><td>−3.490</td><td>STOP</td></tr><tr><td>SKP2</td><td>S-phase kinase-associated protein 2, E3 ubiquitin protein ligase</td><td>−1.845</td><td>STOP</td></tr><tr><td>SPC25</td><td>SPC25, NDC80 kinetochore complex component</td><td>−4.148</td><td>STOP</td></tr></table> |
485055b527c04212475eba00c45cb53d1c8fa73a578bb4251a01a82b238de8a0.png | simple | <table><tr><td></td><td>Criteria</td><td>Assessment</td></tr><tr><td>1</td><td>A diagnosis of PD</td><td>Queen's Square Brain Bank Criteria</td></tr><tr><td>2</td><td>PD developed prior to the onset of dementia</td><td>Patient/caregiver history or ancillary records</td></tr><tr><td>3</td><td>PD associated with a decreased global cognitive efficiency</td><td>MMSE < 26</td></tr><tr><td>4</td><td>Cognitive deficiency severe enough to impair daily life</td><td>Caregiver interview or pill questionnaire</td></tr><tr><td>5</td><td>Impairment of more than one cognitive domain</td><td>Impairment of at least two of the following domains</td></tr><tr><td></td><td></td><td>Attention</td></tr><tr><td></td><td></td><td>Executive function</td></tr><tr><td></td><td></td><td>Visuo-constructive ability</td></tr><tr><td></td><td></td><td>Memory</td></tr></table> |
7589227fff4dd418cfe7fa45645c783eab26d7ed86fefb7985b4d590b88d9503.png | simple | <table><tr><td>Case/sex/age (years)</td><td>Initial treatment</td><td>Associated pseudocyst</td><td>Rebleeding</td><td>Secondary treatment</td><td>Length of follow-up (months)</td><td>Outcome</td></tr><tr><td>1/M/59</td><td>A</td><td>No</td><td>No</td><td>No</td><td>57</td><td>S</td></tr><tr><td>2/M/33</td><td>TG, L</td><td>No</td><td>No</td><td>No</td><td>38</td><td>S</td></tr><tr><td>3/M/46</td><td>E</td><td>Yes*</td><td>Yes</td><td>E<sup>‡</sup>, L, ED</td><td>4</td><td>D</td></tr><tr><td>4/F/71</td><td>E</td><td>No</td><td>Yes</td><td>E</td><td>18</td><td>S</td></tr><tr><td>5/M/36</td><td>Nearly TP, Sp</td><td>No</td><td>No</td><td>No</td><td>50</td><td>S</td></tr><tr><td>6/M/33</td><td>DP<sup>+</sup></td><td>Yes*</td><td>Yes</td><td>E<sup>‡</sup>, L, ED</td><td>87</td><td>S</td></tr><tr><td>7/M/28</td><td>DP, Sp</td><td>Yes<sup>+</sup></td><td>No</td><td>GC<sup>+</sup></td><td>15</td><td>S</td></tr><tr><td>8/M/38</td><td>A, ED</td><td>Yes<sup>+</sup></td><td>No</td><td>RD</td><td>51</td><td>S</td></tr><tr><td>9/M/35</td><td>DP, Sp</td><td>Yes</td><td>No</td><td>No</td><td>10</td><td>S</td></tr></table> |
811d341a37d0fc9f21fd34a59879e961a07fe8739e81144220edd01483d8a5f5.png | complex | <table><tr><td>Materials</td><td colspan="3">Size (L = Length; W = Width; H = Height)</td></tr><tr><td>Grinding media</td><td>Steel ball (∅15 mm)</td><td>Square (L: 12 × W: 12 × H: 12 mm)</td><td>Cylinder (∅12 × H: 16 mm)</td></tr><tr><td>Iron ore particle</td><td colspan="3">2–2.8 mm</td></tr><tr><td>Lifter</td><td>L: 40 × W: 20 × H: 10 mm</td><td>L: 40 × W: 20 × H: 15 mm</td><td>L: 40 × W: 20 × H: 20 mm</td></tr></table> |
d195e7a265f6d78e75804cfc4af6bd3bb9eb98eb5703b0b2a9e77c927fbcbbc8.png | complex | <table><tr><td rowspan="2">Variables</td><td>TSH 0.40–2.49 mIU/L</td><td>TSH 2.50–4.99</td><td rowspan="2"><i>p-</i>value</td></tr><tr><td>(<i>n</i> = 26)</td><td>(<i>n</i> = 12)</td></tr><tr><td>Intrauterine fetal death</td><td>2 (7.7%)</td><td>0</td><td>1.00</td></tr><tr><td>Preterm birth</td><td>2 (7.7%)</td><td>1 (8.3%)</td><td>1.00</td></tr><tr><td>Term birth</td><td>22 (84.6%)</td><td>11 (91.7%)</td><td>0.55</td></tr><tr><td>Duration of gestation (d)</td><td>263.83 ± 15.8</td><td>266.6 ± 19.6</td><td>0.66</td></tr><tr><td>C/S section</td><td>15/24 (62.5%)</td><td>6 /12 (50%)</td><td>0.47</td></tr><tr><td>NICU administration</td><td>2 (7.7%)</td><td>2 (16.6%)</td><td>0.57</td></tr><tr><td>Birth weight(g)</td><td>2923 ± 728</td><td>3102 ± 628</td><td>0.47</td></tr></table> |
5cddea329055b359b87b58eb57560ca20d53fd53208ed7f097d0e7314f61accf.png | complex | <table><tr><td></td><td colspan="4">Newly referred patients</td><td colspan="4">Long-term follow-up patients</td></tr><tr><td></td><td>Level 1 (<i>n</i> = 9)</td><td>Level 2 (<i>n</i> = 125)</td><td>Level 3 (<i>n</i> = 111)</td><td>All (<i>n</i> = 245)</td><td>Level 1 (<i>n</i> = 18)</td><td>Level 2 (<i>n</i> = 236)</td><td>Level 3 (<i>n</i> = 165)</td><td>All (<i>n</i> = 419)</td></tr><tr><td>Age (years, range)</td><td>55.3 (42–62)</td><td>62.3 (23–89)</td><td>65.8 (23–93)</td><td>63.6 (23–93)</td><td>55.3 (28–68)</td><td>63.6 (19–89)</td><td>68.6 (38–93)</td><td>65.2 (19–93)</td></tr><tr><td>Male sex – no. (%)</td><td>3 (33.3)</td><td>82 (65.6)</td><td>71 (64.0)</td><td>156 (63.7)</td><td>9 (50)</td><td>160 (67.8)</td><td>113 (68.5)</td><td>282 (67.3)</td></tr><tr><td>BMI (kg/m2)a</td><td>30.3 ± 8.2</td><td>30.5 ± 6.2</td><td>29.6 ± 5.3</td><td>30.1 ± 6.1</td><td>28.0 ± 5.3</td><td>30.1 ± 5.6</td><td>30.5 ± 5.9</td><td>30.2 ± 5.7</td></tr><tr><td>Diabetes duration - years</td><td>3.9 ± 5.1</td><td>5.4 ± 5.8</td><td>7.9 ± 8.0</td><td>6.5 ± 7.0</td><td>6.2 ± 5.3</td><td>8.5 ± 6.0</td><td>11.5 ± 7.1</td><td>9.6 ± 6.6</td></tr><tr><td>SBP (mmHg)</td><td>120.6 ± 7.0</td><td>140.6 ± 15.8</td><td>142.3 ± 24.4</td><td>140.7 ± 19.8</td><td>114.8 ± 9.1</td><td>134.0 ± 13.8</td><td>136.7 ± 17.4</td><td>134.3 ± 15.7</td></tr><tr><td>DBP (mmHg)</td><td>70.9 ± 5.2</td><td>81.1 ± 9.5</td><td>80.0 ± 12.7</td><td>80.3 ± 11.1</td><td>72.3 ± 5.3</td><td>78.2 ± 8.7</td><td>76.8 ± 10.1</td><td>77.4 ± 9.2</td></tr><tr><td>HbA1c (%) (mmol/mol)</td><td>6.3 ± 2.4 (45 ± 3)</td><td>7.1 ± 3.1 (54 ± 10)</td><td>8.5 ± 4.5 (69 ± 26)</td><td>7.7 ± 4.1 (61 ± 21)</td><td>6.1 ± 2.7 (43 ± 6)</td><td>6.8 ± 3.1 (51 ± 10)</td><td>7.6 ± 3.9 (60 ± 19)</td><td>7.1 ± 3.5 (54 ± 15)</td></tr><tr><td>TC (mmol/l)</td><td>4.8 ± 0.8</td><td>4.4 ± 1.0</td><td>4.3 ± 1.2</td><td>4.3 ± 1.1</td><td>4.2 ± 1.4</td><td>4.0 ± 0.8</td><td>4.1 ± 1.1</td><td>4.0 ± 0.9</td></tr><tr><td>LDL-C (mmol/l)</td><td>2.3 ± 0.7</td><td>2.2 ± 1.0</td><td>2.1 ± 0.9</td><td>2.2 ± 0.9</td><td>2.2 ± 1.1</td><td>1.8 ± 0.6</td><td>1.9 ± 1.0</td><td>1.8 ± 0.8</td></tr><tr><td>HDL-C(mmol/l)</td><td>1.7 ± 0.4</td><td>1.3 ± 0.5</td><td>1.2 ± 0.4</td><td>1.3 ± 0.5</td><td>1.4 ± 0.4</td><td>1.3 ± 0.4</td><td>1.3 ± 0.4</td><td>1.3 ± 0.4</td></tr><tr><td>TG (mmol/l)</td><td>1.9 ± 0.6</td><td>2.0 ± 1.2</td><td>2.3 ± 1.5</td><td>2.1 ± 1.3</td><td>1.2 ± 0.6</td><td>2.1 ± 1.2</td><td>2.2 ± 1.3</td><td>2.1 ± 1.2</td></tr><tr><td>Retinopathy – no. (%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Any stage</td><td>0</td><td>3 (2.4)</td><td>6 (5.4)</td><td>9 (3.7)</td><td>0</td><td>20 (8.5)</td><td>35 (21.2)</td><td>55 (13.1)</td></tr><tr><td>Macular oedema or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>proliferative retinopathy</td><td>0</td><td>0</td><td>3 (2.7)</td><td>3 (1.2)</td><td>0</td><td>0</td><td>4 (2.4)</td><td>4 (1.0)</td></tr><tr><td>Neuropathy – no. (%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Peripheral neuropathy or insufficiency</td><td>0</td><td>60 (48.0)</td><td>58 (52.3)</td><td>118 (48.2)</td><td>0</td><td>128 (54.2)</td><td>111 (67.3)</td><td>139 (33.2)</td></tr><tr><td>Previous or existing ulcer or Charcot foot</td><td>0</td><td>0</td><td>8 (7.2)</td><td>8 (3.3)</td><td>0</td><td>0</td><td>13 (7.9)</td><td>13 (3.1)</td></tr><tr><td>Nephropathy – no. (%)</td><td>0</td><td>0</td><td>36 (32.4)</td><td>36 (14.7)</td><td>0</td><td>0</td><td>89 (53.9)</td><td>89 (21.2)</td></tr><tr><td>Former MACE – no. (%)</td><td>0</td><td>25 (20.0)</td><td>34 (30.6)</td><td>59 (24.1)</td><td>0</td><td>45 (19.1)</td><td>51 (30.9)</td><td>96 (22.9)</td></tr><tr><td>>1 MACE, symptomatic CVD or NYHA II-IV – no. (%)</td><td>0</td><td>0</td><td>26 (23.4)</td><td>26 (10.6)</td><td>0</td><td>0</td><td>56 (33.9)</td><td>56 (13.4)</td></tr></table> |
633c982e8df4c5daf0cfca3f3e09abccbf33e0e3e70e067e238e0c981604fedd.png | complex | <table><tr><td rowspan="3">Number of examined samples</td><td colspan="2">n (%)</td></tr><tr><td>Pure buffalo samples</td><td>Adulterated samples</td></tr><tr><td>50</td><td>5 (10)</td><td>45 (90)</td></tr></table> |
b62778fdc2283365baddeeae3d9bb7dc7807aeb97245ef988ab55033925057f3.png | complex | <table><tr><td>SI</td><td></td><td colspan="3">Prediction method</td><td></td><td></td></tr><tr><td><i>Feature selection method</i></td><td><i># of SNP</i></td><td><i>LR</i></td><td><i>SVM</i></td><td><i>RF</i></td><td><i>EN</i></td><td><i>LDA</i></td></tr><tr><td>LR</td><td>100</td><td>0.7597</td><td>0.7171</td><td>0.7067</td><td>0.7670</td><td>0.7605</td></tr><tr><td></td><td>500</td><td><underline>0.8792</underline></td><td>0.9139</td><td><underline>0.8132</underline></td><td><underline>0.9038</underline></td><td><underline>0.8964</underline></td></tr><tr><td>SVM</td><td>100</td><td>0.6819</td><td>0.6421</td><td>0.6204</td><td>0.6794</td><td>0.6813</td></tr><tr><td></td><td>500</td><td>0.7953</td><td>0.8178</td><td>0.6930</td><td>0.7943</td><td>0.8075</td></tr><tr><td>RF</td><td>100</td><td>0.5961</td><td>0.6101</td><td>0.5980</td><td>0.5848</td><td>0.5957</td></tr><tr><td></td><td>500</td><td>0.6185</td><td>0.6312</td><td>0.6138</td><td>0.6010</td><td>0.6210</td></tr><tr><td>EN</td><td>100<sup>a</sup></td><td><underline>0.7930</underline></td><td><underline>0.7708</underline></td><td><underline>0.7336</underline></td><td><underline>0.7929</underline></td><td>0.7937</td></tr><tr><td></td><td>163<sup>a</sup></td><td>0.8157</td><td>0.8084</td><td>0.7454</td><td>0.8188</td><td>0.8180</td></tr><tr><td>LDA</td><td>100</td><td>0.6338</td><td>0.5925</td><td>0.5807</td><td>0.6273</td><td>0.6343</td></tr><tr><td></td><td>500</td><td>0.7387</td><td>0.7503</td><td>0.6212</td><td>0.7176</td><td>0.7464</td></tr></table> |
b358f9ac2caefc799fda3d8921ddf571d7fe1df4aca70e3a168eff4ac51c3c94.png | complex | <table><tr><td>Menopausal symptoms</td><td>Number (%)</td><td>Severe</td><td>Very severe</td></tr><tr><td colspan="4">Somatic</td></tr><tr><td>Sleeping problems</td><td>574 (78.7)</td><td>93</td><td>1</td></tr><tr><td>Hot flushes, sweating</td><td>508 (69.7)</td><td>157</td><td>75</td></tr><tr><td>Joint and muscular discomfort</td><td>500 (68.6)</td><td>86</td><td>0</td></tr><tr><td>Heart discomfort</td><td>360 (49.4)</td><td>0</td><td>0</td></tr><tr><td colspan="4">Psychological</td></tr><tr><td>Physical and mental exhaustion</td><td>536 (73.5)</td><td>68</td><td>4</td></tr><tr><td>Depressive mood</td><td>402 (55.2)</td><td>109</td><td>12</td></tr><tr><td>Irritability</td><td>339 (46.5)</td><td>105</td><td>10</td></tr><tr><td>Anxiety</td><td>334 (45.8)</td><td>114</td><td>7</td></tr><tr><td colspan="4">Urogenital</td></tr><tr><td>Dryness of vagina</td><td>449 (61.6)</td><td>102</td><td>4</td></tr><tr><td>Bladder problems</td><td>385 (52.8)</td><td>38</td><td>2</td></tr><tr><td>Sexual problems</td><td>343 (47.1)</td><td>56</td><td>6</td></tr></table> |
6cd7d20d0d54d35fb74369966bcd42e4ca088fefd260584ca2977e729f090198.png | simple | <table><tr><td>Variable</td><td>No post-pyloric tubeMedian (IQR)</td><td>Post-pyloric tubeMedian (IQR)</td></tr><tr><td>Age</td><td>53 (42-64)</td><td>56 (40-67)</td></tr><tr><td>Sex (M:F)</td><td>35:29</td><td>19:25</td></tr><tr><td>APACHE II score</td><td>26 (21-31.5)</td><td>28.5 (22.5-33.5)</td></tr><tr><td>Length of stay in days</td><td>4.97 (2.0-10.0)</td><td>5.57 (2.8-9.8)</td></tr><tr><td>Ventilator days</td><td>3.43 (1.6-8.4)</td><td>4.92 (2.3-8.2)</td></tr><tr><td>Number of interal feed days</td><td>3.1 (1.3-6.6)</td><td>4.02 (1.9-7.5)</td></tr></table> |
0cb9fd73cfb7818d68a0f28816661937ec2c99180d8c606c9ee357793063bee0.png | simple | <table><tr><td>Reading Task</td><td>Times New Roman</td><td>EasyReadingTM</td></tr><tr><td>Excerpt (<i>t</i><sub>(531)</sub> = −32.12, <i>p</i> < 0.001) </td><td>3.50 ± 0.94 </td><td>4.16 ± 1.09 </td></tr><tr><td>Words (<i>t</i><sub>(532)</sub> = −18.14, <i>p</i> < 0.001) </td><td>3.03 ± 0.88 </td><td>3.33 ± 0.93</td></tr><tr><td>Non-words (<i>t</i><sub>(532)</sub> = −10.37, <i>p</i> < 0.001) </td><td>1.86 ± 0.60 </td><td>2.04 ± 0.61 </td></tr></table> |
3a3ddbe917a355959ab467c857dff0cb31a652231391bcc1fe19ec4daa4aa64a.png | simple | <table><tr><td>Mechanism</td><td>Source</td><td>Description</td></tr><tr><td>Soluble CD25</td><td>RS cells</td><td>Prevent interaction of IL-2 with IL-2Rs</td></tr><tr><td>IL-10</td><td>RS cells, Tregs, cells of TME</td><td>Repress IL-2 and IFN-γ production</td></tr><tr><td>TGF-β</td><td>RS cells, Tregs, cells of TME</td><td>Repress IL-2 and IFN-γ productionDownregulate activating receptors (NKG2D, NKp30) and corresponding ligands (MICA, ULBP2, ULBP4)</td></tr><tr><td>IL-15</td><td>RS cells</td><td>Competition of RS cells and NK cells</td></tr><tr><td>CXCL9, CXCL10</td><td>RS cells (mainly EBV<sup>+</sup>)</td><td>Attract CD56<sup>bright</sup>–CD16<sup>dim</sup> NK cells</td></tr><tr><td>HLA-G and HLA-E</td><td>RS cells</td><td>Bind to inhibitory receptors on NK cells</td></tr><tr><td>Soluble MICA</td><td>RS cells</td><td>Endocytosis and degradation of NKG2D</td></tr><tr><td>BAG6/BAT3</td><td>RS cells</td><td>Endocytosis and degradation of NKp30</td></tr><tr><td>Rosetting</td><td>Macrophages, Tregs, Th2 T-helper cells</td><td>Physical shield of HRS cells from NK cells</td></tr><tr><td>c-FLIP</td><td>Overexpressed by RS cells</td><td>NK FasL-mediated apoptosis resistance</td></tr><tr><td>FasL</td><td>RS cells</td><td>Apoptosis of Fas-expressing NK cells</td></tr><tr><td>PD-L1</td><td>RS cells</td><td>Suppression of NK cell activation</td></tr><tr><td>MHC-I</td><td>RS cells (EBV<sup>+</sup>)</td><td>Bind to KIRs, inhibit NK cell activation</td></tr></table> |
a4a6bf5e7116aabb9a2206f98bf6a71a7984aa3b75822b971925155a8af2ae2c.png | complex | <table><tr><td> </td><td>PTSD Prevalence</td><td>War victims</td><td>Crime victims</td><td>Natural disaster</td><td>Road fatalities</td></tr><tr><td>PTSD Prevalence</td><td>-</td><td>0.87***</td><td>0.69*</td><td>0.29</td><td>-0.16</td></tr><tr><td>War victims</td><td> </td><td>-</td><td>0.73*</td><td>0.57*</td><td>0.22</td></tr><tr><td>Crime victims</td><td> </td><td> </td><td>-</td><td>0.48</td><td>-0.08</td></tr><tr><td>Natural disaster</td><td> </td><td> </td><td> </td><td>-</td><td>0.04</td></tr><tr><td>Road fatalities</td><td> </td><td> </td><td> </td><td> </td><td>-</td></tr><tr><td>Individual values</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Security</td><td>0.35</td><td>0.57</td><td>0.46</td><td>0.19</td><td>0.50</td></tr><tr><td>Conformity</td><td>-0.32</td><td>-0.29</td><td>-0.25</td><td>-0.33</td><td>-0.37</td></tr><tr><td>Tradition</td><td>-0.09</td><td>-0.17</td><td>-0.24</td><td>0.16</td><td>-0.16</td></tr><tr><td>Benevolence</td><td>0.002</td><td>-0.08</td><td>0.20</td><td>-0.54</td><td>-0.33</td></tr><tr><td>Universalism</td><td>-0.36</td><td>-0.48</td><td>-0.42</td><td>0.07</td><td>-0.27</td></tr><tr><td>Self-direction</td><td>-0.14</td><td>-0.39</td><td>-0.47</td><td>-0.45</td><td>-0.80**</td></tr><tr><td>Stimulation</td><td>0.44</td><td>0.73*</td><td>0.62<sup>†</sup></td><td>0.15</td><td>0.59<sup>†</sup></td></tr><tr><td>Hedonism</td><td>-0.04</td><td>0.19</td><td>0.04</td><td>0.48</td><td>0.44</td></tr><tr><td>Achievement</td><td>-0.31</td><td>-0.37</td><td>-0.35</td><td>-0.01</td><td>-0.17</td></tr><tr><td>Power</td><td>-0.25</td><td>-0.48</td><td>-0.37</td><td>0.00</td><td>-0.40</td></tr><tr><td colspan="6">Aggregated values</td></tr><tr><td>Traditional</td><td>0.13</td><td>0.36</td><td>0.25</td><td>-0.00</td><td>0.24</td></tr><tr><td>Modern</td><td>0.28</td><td>0.56</td><td>0.36</td><td>0.23</td><td>0.44</td></tr></table> |
f5d47d7732ef780159a9f1a7b63cfdbca123ec1d89692c74730594c28a39667e.png | complex | <table><tr><td> </td><td colspan="3">Controls</td><td colspan="3">Cases</td></tr><tr><td> </td><td>All</td><td>Male</td><td>Female</td><td>All</td><td>Male</td><td>Female</td></tr><tr><td>CAD</td><td>2292</td><td>1245(0.54)</td><td>1047(0.46)</td><td>2323</td><td>1777(0.76)</td><td>546(0.24)</td></tr><tr><td>MI</td><td>853</td><td>558(0.65)</td><td>295(0.35)</td><td>2180</td><td>1682(0.77)</td><td>498(0.23)</td></tr><tr><td>T2DM</td><td>954</td><td>524(0.55)</td><td>430(0.45)</td><td>1589</td><td>1175(0.74)</td><td>414(0.26)</td></tr><tr><td>HTN</td><td>1559</td><td>828(0.53)</td><td>731(0.47)</td><td>1962</td><td>1474(0.75)</td><td>488(0.25)</td></tr><tr><td>hChol</td><td>593</td><td>312(0.53)</td><td>281(0.47)</td><td>1078</td><td>796(0.74)</td><td>282(0.26)</td></tr><tr><td>lHDL</td><td>729</td><td>487(0.67)</td><td>242(0.33)</td><td>1181</td><td>979(0.83)</td><td>202(0.17)</td></tr><tr><td>hTG</td><td>427</td><td>267(0.63)</td><td>160(0.37)</td><td>728</td><td>554(0.76)</td><td>174(0.24)</td></tr><tr><td>hLDL</td><td>886</td><td>456(0.51)</td><td>430(0.49)</td><td>965</td><td>717(0.74)</td><td>248(0.26)</td></tr><tr><td>FH</td><td>542</td><td>299(0.55)</td><td>243(0.45)</td><td>359</td><td>287(0.80)</td><td>72(0.20)</td></tr><tr><td>OBS</td><td>888</td><td>385((0.43)</td><td>503(0.57)</td><td>857</td><td>573(0.67)</td><td>284(0.33)</td></tr><tr><td>Smokers</td><td>685</td><td>639(0.93)</td><td>46(0.07)</td><td>1059</td><td>1031(0.97)</td><td>28(0.03)</td></tr><tr><td>VD 1</td><td>0</td><td>0</td><td>0</td><td>885</td><td>642(0.73)</td><td>243(0.27)</td></tr><tr><td>2</td><td>0</td><td>0</td><td>0</td><td>456</td><td>356(0.78)</td><td>100(0.22)</td></tr><tr><td>3</td><td>0</td><td>0</td><td>0</td><td>965</td><td>717(0.74)</td><td>248(0.26)</td></tr><tr><td>Clinical characteristics</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Age</td><td>50.6 ± 0.4</td><td>51.2 ± 0.5</td><td>49.8 ± 0.5</td><td>60.3 ±0.2</td><td>59.8 ± 0.3</td><td>61.8 ± 0.54</td></tr><tr><td>BMI</td><td>29.0 ±0.2</td><td>27.97 ± 0.2</td><td>30.3 ± 0.3</td><td>28.9 ± 0.1</td><td>28.3 ± 0.1</td><td>31.0 ± 0.3</td></tr><tr><td>Total Chol</td><td>4.51 ± 0.02</td><td>4.42 ± 0.03</td><td>4.62 ± 0.03</td><td>4.48 ± 0.02</td><td>4.43 ±0.03</td><td>4.66 ± 0.05</td></tr><tr><td>HDL-Chol</td><td>1.26 ±0.01</td><td>1.18 ±0.03</td><td>1.33 ±0.01</td><td>1.15 ±0.01</td><td>1.15 ± 0.01</td><td>1.25 ± 0.02</td></tr><tr><td>LDL-Chol</td><td>2.76 ± 0.02</td><td>2.73 ± 0.03</td><td>2.80 ±0.03</td><td>2.71 ±0.02</td><td>2.68 ± 0.02</td><td>2.84 ±0.06</td></tr><tr><td>TG</td><td>1.52 ± 0.02</td><td>1.60 ± 0.03</td><td>1.44 ± 0.03</td><td>1.78 ± 0.02</td><td>1.78 ± 0.03</td><td>1.78 ± 0.05</td></tr><tr><td>Fasting glucose</td><td>6.87 ± 0.16</td><td>6.80 ± 0.23</td><td>6.92 ± 0.22</td><td>9.45 ± 0.31</td><td>9.27 ± 0.37</td><td>9.88 ± 0.56</td></tr><tr><td>BP</td><td>120/83</td><td>119/81</td><td>121/82</td><td>128/84</td><td>130/85</td><td>127/83</td></tr></table> |
6e87ab5e74c4b99ad154fecd9e5b9ea54687fbf1ab617289ace7567280ddc244.png | simple | <table><tr><td>Range of ages (months)</td><td>Average age (SD)</td><td>Rang of intelligibility</td><td>Average intelligibility scores (SD)</td></tr><tr><td>48–59</td><td>CI: 51.66 (3.87)N: 54.15 (3.69)</td><td>CI: 56–100</td><td>68.52 (1.47)100 (0.00)</td></tr><tr><td>60–71</td><td>CI: 64.25 (4.19)N: 65.75 (3.27)</td><td>CI: 58.46–63.07</td><td>60.76 (1.97)100 (0.00)</td></tr><tr><td>72–83</td><td>CI: 76.57 (2.87)N: 75.55 (3.67)</td><td>CI: 55.38–66.15</td><td>60.87 (3.85)100 (0.00)</td></tr><tr><td>84–95</td><td>CI: 90.66 (3.77)N: 88.00 (3.79)</td><td>CI: 47.69–76.92</td><td>61.79 (1.14)100 (0.00)</td></tr></table> |
aeeffdfe91dabe824a388bca84010c542b18df1aad51a9111059987878bcbf3b.png | simple | <table><tr><td>Variables</td><td>Lower-Grade Glioma</td><td>Glioblastoma</td></tr><tr><td>Numbers</td><td>170</td><td>133</td></tr><tr><td>Median age (range)</td><td>39 (10–75)</td><td>49 (8–81)</td></tr><tr><td>Sex (male)</td><td>103</td><td>86</td></tr><tr><td>Pathology (Astrocytic)</td><td>69</td><td>-</td></tr><tr><td>IDH1 mutational status</td><td>-</td><td>-</td></tr><tr><td>IDH1 mutation</td><td>100</td><td>18</td></tr><tr><td>IDH1 wild-type</td><td>34</td><td>78</td></tr><tr><td>1p/19q status</td><td>-</td><td>-</td></tr><tr><td>1p/19q co-deletion</td><td>34</td><td>2</td></tr><tr><td>No 1p/19q co-deletion</td><td>108</td><td>106</td></tr></table> |
b3f4e53f3ca95bbc5dd2059311ae94a1d66f13d7231da23bf964603fca05dc80.png | complex | <table><tr><td colspan="2"> </td><td colspan="8">Age at death (years)</td></tr><tr><td colspan="2"> </td><td colspan="2">Never smoked</td><td colspan="2">Light smoker</td><td colspan="2">Medium smoker</td><td colspan="2">Heavy smoker</td></tr><tr><td colspan="2">Predicted survival percentile<sup>1</sup></td><td>Men</td><td>Women</td><td>Men</td><td>Women</td><td>Men</td><td>Women</td><td>Men</td><td>Women</td></tr><tr><td colspan="2">Age at 1<sup>st</sup> Jan 1965</td><td colspan="3"> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>25 years</td><td>5%</td><td>54.92</td><td>59.50</td><td>52.33</td><td>53.33</td><td>49.08</td><td>51.67</td><td>47.08</td><td>51.42</td></tr><tr><td> </td><td>50%</td><td>82.83</td><td>85.83</td><td>80.75</td><td>81.33</td><td>77.17</td><td>80.17</td><td>75.50</td><td>80.00</td></tr><tr><td> </td><td>95%</td><td>100.50</td><td>103.92</td><td>96.33</td><td>94.08</td><td>91.25</td><td>92.08</td><td>89.17</td><td>91.83</td></tr><tr><td>45 years</td><td>5%</td><td>55.25</td><td>58.92</td><td>54.00</td><td>55.00</td><td>52.00</td><td>53.92</td><td>51.17</td><td>90.50</td></tr><tr><td> </td><td>50%</td><td>78.50</td><td>84.33</td><td>75.92</td><td>78.42</td><td>72.08</td><td>76.75</td><td>70.33</td><td>76.50</td></tr><tr><td> </td><td>95%</td><td>98.00</td><td>102.58</td><td>93.75</td><td>92.75</td><td>88.67</td><td>90.83</td><td>86.58</td><td>53.75</td></tr><tr><td>65 years</td><td>5%</td><td>66.75</td><td>68.42</td><td>66.62</td><td>67.00</td><td>66.00</td><td>66.75</td><td>65.83</td><td>66.75</td></tr><tr><td> </td><td>50%</td><td>78.58</td><td>83.33</td><td>76.75</td><td>79.08</td><td>74.58</td><td>77.75</td><td>73.33</td><td>77.58</td></tr><tr><td> </td><td>95%</td><td>94.00</td><td>100.08</td><td>90.58</td><td>91.25</td><td>86.58</td><td>89.50</td><td>85.17</td><td>89.25</td></tr></table> |
fcc97f5bf274c3dded881a26a6b9e6e709cb74ef1c66874d7c2c0c4035c7b21d.png | complex | <table><tr><td>Characteristic</td><td>N (%) or Mean ± SD</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Female</td><td>183 (70.4 %)</td></tr><tr><td> Male</td><td>77 (29.6 %)</td></tr><tr><td>Age (years)</td><td>38.8 (13.7)</td></tr><tr><td colspan="2">Referral source</td></tr><tr><td> Primary Care</td><td>231 (88.8 %)</td></tr><tr><td> Respirologist</td><td>7 (2.7 %)</td></tr><tr><td> Allergist</td><td>2 (0.8 %)</td></tr><tr><td> Other</td><td>10 (3.8 %)</td></tr><tr><td> Unknown</td><td>10 (3.8 %)</td></tr><tr><td colspan="2">Diagnosis of atopy</td></tr><tr><td> Allergic rhinitis</td><td>120 (46.2 %)</td></tr><tr><td> Asthma</td><td>90 (34.6 %)</td></tr><tr><td> Atopic dermatitis</td><td>61 (23.5 %)</td></tr><tr><td> Venom allergy</td><td>5 (1.9 %)</td></tr><tr><td> Drug allergy</td><td>42 (16.2 %)</td></tr><tr><td> Urticaria</td><td>60 (23.1 %)</td></tr><tr><td> Eczema</td><td>61 (23.5 %)</td></tr><tr><td> Pollen food syndrome</td><td>35 (13.5 %)</td></tr></table> |
55d8537a94af878f6318e175994e7b9734778eecc8c4f37a1c858f8c589855dc.png | simple | <table><tr><td>Absorbed dose to the thyroid (Gy)</td><td>Number of differentially expressed transcripts</td><td>Number of up- and down-regulated transcripts</td></tr><tr><td>0.05</td><td>1,225</td><td>↑ 338</td></tr><tr><td> </td><td> </td><td>↓ 887</td></tr><tr><td>0.5</td><td>1,636</td><td>↑ 480</td></tr><tr><td> </td><td> </td><td>↓ 1,156</td></tr><tr><td>1.4</td><td>544</td><td>↑ 284</td></tr><tr><td> </td><td> </td><td>↓ 260</td></tr><tr><td>11</td><td>575</td><td>↑ 412</td></tr><tr><td> </td><td> </td><td>↓ 163</td></tr><tr><td>32</td><td>425</td><td>↑ 293</td></tr><tr><td> </td><td> </td><td>↓ 132</td></tr></table> |
6edac71a5201b32e5fac678b9230c4f3affb8c418623ede273e286fb095ade53.png | simple | <table><tr><td>Sample</td><td>shell</td><td><i>N</i></td><td><i>R</i>(Å)</td><td>σ2(×10<sup>-3</sup> Å2)</td><td>Δ<i>E</i><sub>0</sub>(eV)</td></tr><tr><td>Standard ZnS</td><td>Zn-S</td><td>4</td><td>2.35 ± 0.02</td><td>4.6 ± 0.3</td><td>4.6</td></tr><tr><td> </td><td>Zn-S-Zn</td><td>12</td><td>3.85 ± 0.02</td><td>15.3 ± 0.9</td><td>5.1</td></tr><tr><td> </td><td>Zn-S</td><td>9</td><td>4.55 ± 0.02</td><td>12.5 ± 1.9</td><td>8.5</td></tr><tr><td>PCMS-0.5</td><td>Zn-S</td><td>2.3</td><td>2.32 ± 0.02</td><td>6.9 ± 2.2</td><td>3.0</td></tr><tr><td> </td><td>Zn-O</td><td>1.7</td><td>1.99 ± 0.03</td><td>6.5 ± 4.0</td><td>3.0</td></tr><tr><td>PCMS-1</td><td>Zn-S</td><td>3.5</td><td>2.33 ± 0.02</td><td>5.2 ± 0.5</td><td>3.7</td></tr><tr><td> </td><td>Zn-O</td><td>1</td><td>1.97 ± 0.02</td><td>6.9 ± 3.2</td><td>3.7</td></tr><tr><td> </td><td>Zn-S-Zn</td><td>4.5</td><td>3.84 ± 0.04</td><td>15.9 ± 3.3</td><td>5.1</td></tr><tr><td> </td><td>Zn-S</td><td>3</td><td>4.51 ± 0.10</td><td>15.5 ± 9.6</td><td>8.5</td></tr><tr><td>PCMS-2.5</td><td>Zn-S</td><td>4</td><td>2.34 ± 0.02</td><td>5.4 ± 0.6</td><td>4.6</td></tr><tr><td> </td><td>Zn-S-Zn</td><td>5</td><td>3.83 ± 0.03</td><td>15.8 ± 4.1</td><td>5.1</td></tr><tr><td> </td><td>Zn-S</td><td>3</td><td>4.52 ± 0.07</td><td>14.8 ± 12.3</td><td>8.5</td></tr><tr><td>PCMS-5</td><td>Zn-S</td><td>4</td><td>2.33 ± 0.02</td><td>5.1 ± 0.5</td><td>3.7</td></tr><tr><td> </td><td>Zn-S-Zn</td><td>6</td><td>3.82 ± 0.02</td><td>16.1 ± 2.8</td><td>5.1</td></tr><tr><td> </td><td>Zn-S</td><td>4</td><td>4.55 ± 0.05</td><td>15.1 ± 7.8</td><td>8.5</td></tr></table> |
682d3fdd7e67b72f190559da8297c52140ec947c6b86cf9ca2a8bcecea8ec291.png | simple | <table><tr><td></td><td>N (%)</td></tr><tr><td>Lesion location</td><td></td></tr><tr><td>Right upper lobe</td><td>40/68 (58.8)</td></tr><tr><td>Right middle lobe</td><td>21/68 (30.9)</td></tr><tr><td>Right lower lobe</td><td>22/68 (32.4)</td></tr><tr><td>Left upper lobe</td><td>33/68 (48.5)</td></tr><tr><td>Left lower lobe</td><td>21/68 (30.9)</td></tr><tr><td>Lesion distribution</td><td></td></tr><tr><td>Bilateral</td><td>30/68 (44.1)</td></tr><tr><td>Multilobar (≥3 lobes with abnormalities)</td><td>21/68 (30.9)</td></tr><tr><td>Lesion characteristics</td><td></td></tr><tr><td>Multiple nodules</td><td>42/68 (61.8)</td></tr><tr><td>Bronchiectasis</td><td>24/68 (35.3)</td></tr><tr><td>Cavity</td><td>13/68 (19.1)</td></tr><tr><td>Unilateral</td><td>9/68 (13.2)</td></tr><tr><td>Bilateral</td><td>4/68 (5.9)</td></tr><tr><td>Radiographic classification</td><td></td></tr><tr><td>Upper lobe cavitary pattern</td><td>12/68 (17.6)</td></tr><tr><td>Nodular bronchiectatic pattern</td><td>17/68 (25.0)</td></tr><tr><td>Unclassifiable</td><td>39/68 (57.4)</td></tr></table> |
c0b74e64e498ac2b0bd0edb932c9a8a20bef1a3e1e2a8aaad27de11f4280d346.png | simple | <table><tr><td>Element</td><td>Al<sub>2</sub>O<sub>3</sub></td><td>CaO</td><td>Fe<sub>2</sub>O<sub>3</sub></td><td>K<sub>2</sub>O</td><td>MgO</td><td>SO<sub>3</sub></td><td>SiO<sub>2</sub></td><td>TiO<sub>2</sub></td><td>LOI</td></tr><tr><td>SO1</td><td>3,94</td><td>70,20</td><td>0,19</td><td>0,18</td><td>0,25</td><td>0,00</td><td>23,36</td><td>0,10</td><td>0,40</td></tr><tr><td>SO2</td><td>3,66</td><td>70,22</td><td>0,14</td><td>0,18</td><td>0,25</td><td>0,00</td><td>24,28</td><td>0,11</td><td>0,60</td></tr><tr><td>SO3</td><td>3,95</td><td>70,56</td><td>0,17</td><td>0,18</td><td>0,89</td><td>0,10</td><td>23,75</td><td>0,09</td><td>0,33</td></tr><tr><td>SO4</td><td>3,83</td><td>69,85</td><td>0,25</td><td>0,16</td><td>0,25</td><td>0,04</td><td>24,39</td><td>0,13</td><td>0,41</td></tr><tr><td>SO5</td><td>3,95</td><td>70,00</td><td>0,24</td><td>0,17</td><td>0,27</td><td>0,00</td><td>24,40</td><td>0,17</td><td>0,32</td></tr><tr><td>SO6</td><td>4,08</td><td>70,04</td><td>0,31</td><td>0,18</td><td>0,27</td><td>0,00</td><td>24,46</td><td>0,15</td><td>0,53</td></tr></table> |
dda81ccdd4b2311d9cb3a1c9ee2704bff7c04f607884a52879f2240b3c91d417.png | simple | <table><tr><td>Frequency</td><td>Sensitivity</td><td>Specificity</td></tr><tr><td>≥0.05</td><td>99.17% (SNV 99.30%; indel 96.60%)</td><td>>99.5%</td></tr><tr><td>≥0.10</td><td>99.66% (SNV 99.76%; indel 97.67%)</td><td>>99.5%</td></tr><tr><td>>0.20</td><td>99.70% (SNV 99.80%; indel 96.40%)</td><td>>99.5%</td></tr></table> |
2cc8613c474d4b6cca16411d66e192940de6c5bcf08a54c43a611fb3f802ec27.png | complex | <table><tr><td> </td><td>Normal</td><td>Borderline</td><td>Case</td></tr><tr><td colspan="3">Anxiety</td><td> </td></tr><tr><td>Baseline (n=37)</td><td>28</td><td>6</td><td>3</td></tr><tr><td>3 months (n=37)</td><td>30</td><td>5</td><td>2</td></tr><tr><td>6 months (n=28)</td><td>20</td><td>6</td><td>1</td></tr><tr><td colspan="3">Depression</td><td> </td></tr><tr><td>Baseline (n=37)</td><td>31</td><td>4</td><td>2</td></tr><tr><td>3 months (n=37)</td><td>31</td><td>4</td><td>2</td></tr><tr><td>6 months (n=28)</td><td>23</td><td>4</td><td>1</td></tr></table> |
e51f000c614b2e9343aa4b6dd07ab5a052f9dc8dca5b8b59d7e13ed88e6c88af.png | simple | <table><tr><td>Variants</td><td><i>P</i>-value</td></tr><tr><td>Age at diagnosis</td><td>0.249</td></tr><tr><td>Gender</td><td>0.543</td></tr><tr><td>WBC at diagnosis</td><td>0.533</td></tr><tr><td>Bone marrow blasts</td><td>0.733</td></tr><tr><td>Peripheral blasts</td><td>0.406</td></tr><tr><td>FLT3-ITD positive</td><td>0.153</td></tr><tr><td>NPM1 mutation</td><td>0.031</td></tr><tr><td>CEBPA mutation</td><td>0.050</td></tr></table> |
3b60cbf1d0f9334473d2dc950f62396dfa089b3a42cae74fa89804b86a1d14b5.png | simple | <table><tr><td>Coefficients</td><td>Estimate</td><td>Std. Error</td><td>t Value</td></tr><tr><td>(Intercept)</td><td>−1.222e + 02</td><td>1.251e + 02</td><td>−0.977</td></tr><tr><td>SWB</td><td>−4.421e − 03</td><td>4.916e − 02</td><td>−0.090</td></tr><tr><td>SDI</td><td>9.152e − 02</td><td>5.400e − 02</td><td>1.695</td></tr><tr><td>Dallas Theological Seminary</td><td>−5.706e − 01</td><td>1.473e + 00</td><td>−0.387</td></tr><tr><td>Denver Seminary</td><td>1.066e − 00</td><td>1.629e + 00</td><td>0.655</td></tr><tr><td>Gordon-Conwell Seminary</td><td>2.005e − 01</td><td>1.541e + 00</td><td>0.130</td></tr><tr><td>Oral Roberts University</td><td>2.190e − 02</td><td>2.209e + 00</td><td>0.010</td></tr><tr><td>Male</td><td>−3.381e + 00</td><td>1.364e + 00</td><td>−2.478</td></tr><tr><td>Birth Year</td><td>7.702e − 02</td><td>6.276e − 02</td><td>1.227</td></tr><tr><td>Non-Hispanic White or Euro-American</td><td>2.627e + 00</td><td>1.295e + 00</td><td>2.028</td></tr><tr><td>Latino or Hispanic American</td><td>8.577e + 00</td><td>2.872e + 00</td><td>2.987</td></tr><tr><td>Other/Multi-Racial</td><td>−5.138e + 00</td><td>3.248e + 00</td><td>−1.582</td></tr></table> |
4dbbf37667dfc589cf62ab6a53de7db34126404d5577dda9c77bd48d6dc34cda.png | complex | <table><tr><td rowspan="2">Concentration μg/mL</td><td colspan="7">Viability (%)/compound</td></tr><tr><td>9</td><td>10</td><td>11a</td><td>11b</td><td>12</td><td>13</td><td>14</td></tr><tr><td>500</td><td>8.43</td><td>8.32</td><td>23.84</td><td>10.32</td><td>4.29</td><td>4.83</td><td>3.74</td></tr><tr><td>250</td><td>15.82</td><td>16.01</td><td>48.67</td><td>19.47</td><td>11.82</td><td>12.56</td><td>8.91</td></tr><tr><td>125</td><td>24.67</td><td>23.65</td><td>72.89</td><td>27.93</td><td>20.49</td><td>19.74</td><td>14.82</td></tr><tr><td>62.5</td><td>30.93</td><td>29.86</td><td>90.31</td><td>38.76</td><td>26.54</td><td>28.63</td><td>20.94</td></tr><tr><td>31.25</td><td>41.28</td><td>37.40</td><td>98.16</td><td>50.37</td><td>32.75</td><td>35.16</td><td>25.86</td></tr><tr><td>15.6</td><td>48.71</td><td>46.89</td><td>100</td><td>68.24</td><td>41.87</td><td>46.29</td><td>31.43</td></tr><tr><td>7.8</td><td>62.39</td><td>58.62</td><td>100</td><td>81.49</td><td>55.46</td><td>57.18</td><td>37.82</td></tr><tr><td>3.9</td><td>78.24</td><td>73.94</td><td>100</td><td>90.65</td><td>73.82</td><td>70.42</td><td>45.27</td></tr><tr><td>2</td><td>88.65</td><td>81.47</td><td>100</td><td>97.34</td><td>81.46</td><td>83.29</td><td>50.94</td></tr><tr><td>1</td><td>94.27</td><td>89.53</td><td>100</td><td>100</td><td>88.73</td><td>89.64</td><td>62.35</td></tr><tr><td>0</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td></tr></table> |
1d9c41e505253dd66c038d78bbd116b85e397c65fa21062556caf369cb030417.png | simple | <table><tr><td>Organism</td><td>HIV seropositive cases(<i>n</i> = 144)</td><td>HIV seronegative subjects(<i>n</i> = 50)</td><td><i>P</i> value (chi-square test)</td></tr><tr><td><i>C. parvum </i></td><td>87 (60.42%)</td><td>1 (2.00%)</td><td>0.0001</td></tr><tr><td><i>I. belli </i></td><td>13 (9.03%)</td><td>1 (2.00%)</td><td>0.082</td></tr><tr><td><i>Cyclospora </i>spp.</td><td>2 (1.39%)</td><td>0</td><td>—</td></tr><tr><td><i>Microsporidium </i>spp.</td><td>1 (0.69%)</td><td>0</td><td>—</td></tr><tr><td><i>E. histolytica </i></td><td>7 (4.86%)</td><td>1 (2.00%)</td><td>0.343</td></tr><tr><td><i>G. lamblia </i></td><td>3 (2.08%)</td><td>2 (4.00%)</td><td>0.726</td></tr><tr><td><i>A. lumbricoides </i></td><td>5 (3.47%)</td><td>1 (2.00%)</td><td>0.514*</td></tr><tr><td><i>C. difficile </i></td><td>26 (18.06%)</td><td>3 (6.00%)</td><td>0.040</td></tr><tr><td>Diarrheagenic<i> E. coli </i></td><td>16 (11.11%)</td><td>2 (4.00%)</td><td>0.166*</td></tr><tr><td><i>Shigella </i> spp.</td><td>4 (2.78%)</td><td>0</td><td>—</td></tr><tr><td><i>C. albicans </i></td><td>37 (25.69%)</td><td>2 (4.00%)</td><td>0.0001</td></tr></table> |
35f572f882e832bf65dd28e354167165fa6746d076dc1cd5a3335035e130e2c9.png | complex | <table><tr><td></td><td colspan="3">Univariate Analysis</td><td colspan="3">Multivariate Analysis</td></tr><tr><td>Variable</td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td></tr><tr><td>Age, years (continuous)</td><td>1.01</td><td>0.96-1.06</td><td>0.78</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Gender (female [n = 12] vs male [n = 40])</td><td>0.48</td><td>0.11-2.10</td><td>0.33</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Stage (UICC II and higher [n = 32] vs. UICC I [n = 20])</td><td>3.72</td><td>1.07-12.98</td><td>0.04</td><td>2.00</td><td>0.42-9.09</td><td>0.39</td></tr><tr><td>Grade (3+4 [n = 22] vs. 1+2 [n = 30])</td><td>1.43</td><td>0.55-3.71</td><td>0.46</td><td>-</td><td>-</td><td>-</td></tr><tr><td>T category (T3/T4 [n = 8] vs. T1/T2 [n = 44])</td><td>2.48</td><td>0.80-7.68</td><td>0.11</td><td>-</td><td>-</td><td>-</td></tr><tr><td>N category (. N+ [n = 28] vs N0 [n = 24])</td><td>3.27</td><td>1.06-10.02</td><td>0.04</td><td>2.04</td><td>0.51-8.33</td><td>0.32</td></tr><tr><td>Number of metastatic lymph nodes (continuous)</td><td>1.35</td><td>1.17-1.56</td><td><0.001</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="7">TILs and macrophages in primary tumour site (high vs. low)</td></tr><tr><td></td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td></tr><tr><td>Intraepithelial</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CD3+ TIL</td><td>0.76</td><td>0.29-1.98</td><td>0.58</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD8+ TIL</td><td>1.26</td><td>0.48-3.32</td><td>0.63</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD20+ TIL</td><td>2.05</td><td>0.79-5.32</td><td>0.14</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD68+ TIM</td><td>0.69</td><td>0.27-1.80</td><td>0.45</td><td>-</td><td>-</td><td>-</td></tr><tr><td>FoxP3+ TIL</td><td>0.78</td><td>0.30-2.03</td><td>0.61</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Granzyme B+ TIL</td><td>0.72</td><td>0.21-2.53</td><td>0.61</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Stromal</td><td></td><td></td><td></td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD3+ TIL</td><td>0.86</td><td>0.33-2.23</td><td>0.76</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD8+ TIL</td><td>0.85</td><td>0.33-2.20</td><td>0.74</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD20+ TIL</td><td>0.80</td><td>0.31-2.08</td><td>0.65</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CD68+ TIM</td><td>0.81</td><td>0.31-2.10</td><td>0.66</td><td>-</td><td>-</td><td>-</td></tr><tr><td>FoxP3+ TIL</td><td>0.23</td><td>0.08-0.72</td><td>0.01</td><td>0.25</td><td>0.08-0.78</td><td>0.016</td></tr><tr><td>Granzyme B+ TIL</td><td>0.87</td><td>0.33-2.29</td><td>0.78</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Ratio stromal CD68 (primary tumour)/stromal FoxP3 (primary tumour)</td><td>4.02</td><td>1.31-12.36</td><td>0.02</td><td></td><td></td><td></td></tr><tr><td colspan="7">TIL and macrophages in metastatic tissue (high vs. low)</td></tr><tr><td>Intraepithelial</td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td><td></td><td></td><td></td></tr><tr><td> CD3+ TIL</td><td>0.32</td><td>0.09-1.12</td><td>0.07</td><td></td><td></td><td></td></tr><tr><td> CD8+ TIL</td><td>1.14</td><td>0.35-3.76</td><td>0.83</td><td></td><td></td><td></td></tr><tr><td> CD20+ TIL</td><td>0.20</td><td>0.03-1.58</td><td>0.13</td><td></td><td></td><td></td></tr><tr><td> CD68+ TIM</td><td>0.96</td><td>0.29-3.16</td><td>0.95</td><td></td><td></td><td></td></tr><tr><td> FoxP3+ TIL</td><td>0.58</td><td>0.17-1.99</td><td>0.39</td><td></td><td></td><td></td></tr><tr><td> Granzyme B+ TIL</td><td>0.88</td><td>0.19-4.09</td><td>0.87</td><td></td><td></td><td></td></tr><tr><td>Stromal</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> CD3+ TIL</td><td>0.61</td><td>0.19-2.03</td><td>0.42</td><td></td><td></td><td></td></tr><tr><td> CD8+ TIL</td><td>1.16</td><td>0.35-3.81</td><td>0.81</td><td></td><td></td><td></td></tr><tr><td> CD20+ TIL</td><td>0.51</td><td>0.15-1.75</td><td>0.28</td><td></td><td></td><td></td></tr><tr><td> CD68+ TIM</td><td>1.30</td><td>0.40-4.28</td><td>0.66</td><td></td><td></td><td></td></tr><tr><td> FoxP3+ TIL</td><td>0.81</td><td>0.25-2.69</td><td>0.74</td><td></td><td></td><td></td></tr><tr><td> Granzyme B+ TIL</td><td>0.75</td><td>0.23-2.46</td><td>0.63</td><td></td><td></td><td></td></tr><tr><td colspan="7">Lymphocytes and macrophages in uninvolved regional lymph node (high vs. low)</td></tr><tr><td></td><td>Hazard ratio</td><td>95% C.I.</td><td>P</td><td></td><td></td><td></td></tr><tr><td>CD3+</td><td>0.47</td><td>0.17-1.26</td><td>0.13</td><td></td><td></td><td></td></tr><tr><td>CD8+</td><td>0.84</td><td>0.32-2.19</td><td>0.72</td><td></td><td></td><td></td></tr><tr><td>CD20+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CD68+</td><td>0.56</td><td>0.21-1.47</td><td>0.24</td><td></td><td></td><td></td></tr><tr><td>FoxP3+</td><td>1.03</td><td>0.40-2.68</td><td>0.95</td><td></td><td></td><td></td></tr><tr><td>Granzyme B+</td><td>0.35</td><td>0.12-0.99</td><td>0.05</td><td></td><td></td><td></td></tr></table> |
6b63dfe953e9742525e8c26f3e5ee6aba0363e20b9733df61d3f65336c569232.png | complex | <table><tr><td></td><td></td><td colspan="2">Patient A</td><td colspan="2">Patient B</td><td colspan="2">Patient C</td><td colspan="2">Patient D</td><td colspan="2">Patient E</td></tr><tr><td rowspan="3">Parameters obtained from data</td><td>Hb (g dl<sup>−1</sup>)</td><td colspan="2">10.5</td><td colspan="2">10.8</td><td colspan="2">11.5</td><td colspan="2">9.8</td><td colspan="2">9</td></tr><tr><td>CO (l min<sup>−1</sup>)</td><td colspan="2">11.1</td><td colspan="2">7.2</td><td colspan="2">5.6</td><td colspan="2">7.7</td><td colspan="2">5.9</td></tr><tr><td>F<sub>I</sub>O<sub>2</sub></td><td colspan="2">0.8</td><td colspan="2">0.9</td><td colspan="2">0.5</td><td colspan="2">0.8</td><td colspan="2">1</td></tr><tr><td rowspan="4">Parameters obtained through optimization</td><td>VR (b min<sup>−1</sup>)</td><td colspan="2">12.25</td><td colspan="2">12.14</td><td colspan="2">16.04</td><td colspan="2">17.68</td><td colspan="2">17.0</td></tr><tr><td>IE</td><td colspan="2">0.28</td><td colspan="2">0.25</td><td colspan="2">0.38</td><td colspan="2">0.38</td><td colspan="2">0.43</td></tr><tr><td>RQ</td><td colspan="2">0.6</td><td colspan="2">0.6</td><td colspan="2">0.9</td><td colspan="2">0.7</td><td colspan="2">0.61</td></tr><tr><td>VO<sub>2</sub> (ml min<sup>−1</sup>)</td><td colspan="2">294.3</td><td colspan="2">300</td><td colspan="2">200</td><td colspan="2">257.2</td><td colspan="2">246.8</td></tr><tr><td></td><td>% of compartments collapsed</td><td colspan="2">26</td><td colspan="2">29</td><td colspan="2">12</td><td colspan="2">20</td><td colspan="2">21</td></tr><tr><td rowspan="2">Parameters fixed for RM trials</td><td>P<sub>v</sub> (cm H<sub>2</sub>O)</td><td colspan="2">15</td><td colspan="2">15</td><td colspan="2">15</td><td colspan="2">15</td><td colspan="2">15</td></tr><tr><td>PEEP (cm H<sub>2</sub>O)</td><td colspan="2">5</td><td colspan="2">5</td><td colspan="2">5</td><td colspan="2">5</td><td colspan="2">5</td></tr><tr><td></td><td></td><td>Data</td><td>Model</td><td>Data</td><td>Model</td><td>Data</td><td>Model</td><td>Data</td><td>Model</td><td>Data</td><td>Model</td></tr><tr><td rowspan="4">Results of fitting the model to the data</td><td>PvO<sub>2</sub> (mmHg)</td><td>47.3</td><td>49.5</td><td>38.3</td><td>39.4</td><td>48</td><td>45.4</td><td>42.83</td><td>42.2</td><td>34.5</td><td>30.3</td></tr><tr><td>PvCO<sub>2</sub> (mmHg)</td><td>44.4</td><td>46.2</td><td>55.5</td><td>54.4</td><td>47.6</td><td>49.9</td><td>51</td><td>48.8</td><td>33.82</td><td>36.07</td></tr><tr><td>Qs/Qt (%)</td><td>28.6</td><td>31.8</td><td>31.7</td><td>33.9</td><td>22.6</td><td>19.4</td><td>32.3</td><td>31.4</td><td>43.1</td><td>39.14</td></tr><tr><td>PaO<sub>2</sub> (mmHg)</td><td>153.7</td><td>149.9</td><td>85.5</td><td>87.9</td><td>130.5</td><td>129.6</td><td>110.3</td><td>109.6</td><td>64.5</td><td>64.95</td></tr></table> |
0260dbeb9753d094a5f6a5200ad522457b598b33fd6e5db6fb0cf371ef46e5e7.png | complex | <table><tr><td></td><td>Non-nosocomial (<i>n</i> = 352)</td><td>Nosocomial (<i>n</i> = 25)</td><td><i>P</i> value</td></tr><tr><td>Median week from admission</td><td></td><td>3 (2–4)</td><td></td></tr><tr><td>Male (%)</td><td>65·9 (230/349)</td><td>60·0 (15/25)</td><td>0·664</td></tr><tr><td>Age (weeks, median)</td><td>16·2 (8·8–43·5)</td><td>9·0 (6·5–14·7)</td><td>0·001</td></tr><tr><td>Preterm birth (<37 weeks)</td><td>26·8 (94/351)</td><td>44 (11/25)</td><td>0·103</td></tr><tr><td>Birthweight (kg)</td><td>2·7 (2·2–3·0)</td><td>2·5 (2·2–3·1)</td><td>0·113</td></tr><tr><td>Previous hospitalization (%)</td><td>40·2 (140/348)</td><td>56 (14/25)</td><td>0·143</td></tr><tr><td>Within previous 14 days (%)</td><td>28·1 (99/352)</td><td>40 (10/25)</td><td>0·370</td></tr><tr><td>Transfer from other ward (%)</td><td>46·9 (165/352)</td><td>60·0 (15/25)</td><td>0·220</td></tr><tr><td>Pre-existing illness (%)</td><td>34·8 (122/351)</td><td>32 (8/25)</td><td>0·832</td></tr><tr><td>Duration of hospitalization (days)</td><td>7·0 (5·0–13·0)</td><td>21·0 (12·0–30·0)</td><td>0·000</td></tr><tr><td>Outcome other than full recovery (%)</td><td>16·8 (59/352)</td><td>52·0 (13/25)</td><td>0·000</td></tr><tr><td>Deaths</td><td>2·6 (9/352)</td><td>16·0 (4/25)</td><td>0·007</td></tr><tr><td colspan="4">Laboratory tests</td></tr><tr><td> Hemoglobin (g/dl)</td><td>10·7 (9·8–11·5)</td><td>10·3 (9·2–11·5)</td><td>0·318</td></tr><tr><td> Hematocrit (%)</td><td>32·3 (30·1–35·3)</td><td>30·8 (27·4–33·5)</td><td>0·071</td></tr><tr><td> Leukocytes (×1000/μl)</td><td>14·0 (10·7–17·1)</td><td>13·0 (9·6–16·4)</td><td>0·313</td></tr><tr><td> Neutrophils (%)</td><td>49·5 (31·9–61·2)</td><td>32·0 (26·0–44·8)</td><td>0·001</td></tr><tr><td> Lymphocytes (%)</td><td>39·7 (28·1–56·1)</td><td>53·7 (45·7–65·2)</td><td>0·002</td></tr><tr><td> Platelets (×1000/μl)</td><td>311·0 (210·0–425·0)</td><td>268·0 (185·5–412·0)</td><td>0·230</td></tr></table> |
effa74d300286437f14c815db8392b3b9602440497d209cf539f60ea412956a6.png | simple | <table><tr><td></td><td>Recall</td><td>Precision</td><td>F-score</td></tr><tr><td>Any</td><td>79.46</td><td>78.45</td><td>78.95</td></tr><tr><td>Unrelated</td><td>60.26</td><td>70.59</td><td>65.02</td></tr><tr><td>Altered expression</td><td>77.96</td><td>79.90</td><td>78.91</td></tr><tr><td>Genetic variation</td><td>77.76</td><td>82.45</td><td>80.04</td></tr><tr><td>Regulatory modification</td><td>69.17</td><td>73.28</td><td>71.16</td></tr><tr><td>Overall</td><td>76.61</td><td>79.46</td><td>78.00</td></tr></table> |
776a0d2f5055cd13a68598ecb58c4c364b3440f8e5fcafaee2e5e01783c11e3a.png | simple | <table><tr><td></td><td>All patients</td><td>PiCCO</td><td>PAC</td><td><i>p </i>value</td></tr><tr><td>Mean daily FB (ml/day)</td><td>490 (-216, 1,259)</td><td>659 (-128, 1,403)</td><td>350 (-573, 1,064)</td><td>0.017</td></tr><tr><td>MV days</td><td>5 (2, 10)</td><td>6 (2, 10)</td><td>4 (2, 10)</td><td>0.44</td></tr><tr><td>MV-free days in 28 days</td><td>15 (0, 24)</td><td>12 (0, 23)</td><td>21 (0, 25)</td><td>0.045</td></tr><tr><td>ICU days</td><td>6 (3, 14)</td><td>7 (3, 13)</td><td>6 (3, 14)</td><td>0.58</td></tr><tr><td>ICU-free days in 28 days</td><td>11 (0, 22)</td><td>5 (0, 21)</td><td>14 (0, 22)</td><td>0.15</td></tr><tr><td>Hospital days</td><td>19 (9, 38)</td><td>20 (9, 45)</td><td>17 (8, 33)</td><td>0.15</td></tr><tr><td>ICU mortality</td><td>34.7%</td><td>38.5%</td><td>30.0%</td><td>0.11</td></tr><tr><td>Hospital mortality</td><td>42.0%</td><td>45.8%</td><td>36.9%</td><td>0.12</td></tr></table> |
d17693f5b63285c2d029177b7e4ab6e4dbc2db21cb11e69eea92d63719c5cc38.png | complex | <table><tr><td></td><td>Elderly patients</td><td>Non-elderly patients</td><td><i>p</i> value</td></tr><tr><td>Patients (<i>n</i>)</td><td>157 (32.6%)</td><td>325 (67.4%)</td><td rowspan="2"></td></tr><tr><td>Age (years), mean (range)</td><td>79.3 (75–90)</td><td>63.9 (27–74)</td></tr><tr><td>Sex, male/female</td><td>92/65</td><td>197/128</td><td rowspan="2">0.67</td></tr><tr><td>Lesion (<i>n</i>)</td><td>164 (32.7%)</td><td>337 (67.3%)</td></tr><tr><td colspan="4">Tumor location (<i>n</i>)</td></tr><tr><td> Cecum and colon</td><td>112 (68.3%)</td><td>227 (67.4%)</td><td rowspan="2">0.83</td></tr><tr><td> Rectum</td><td>52 (31.7%)</td><td>131 (32.6%)</td></tr><tr><td colspan="4">Tumor size</td></tr><tr><td> Long axis (mm), mean ± SD</td><td>37.0 ± 16.5</td><td>35.2 ± 15.9</td><td>0.26</td></tr><tr><td> Short axis (mm), mean ± SD</td><td>29.7 ± 15.4</td><td>27.7 ± 13.6</td><td>0.23</td></tr><tr><td colspan="4">Morphology (<i>n</i>)</td></tr><tr><td> LST-G</td><td>93 (56.7%)</td><td>173 (51.3%)</td><td rowspan="5">0.68</td></tr><tr><td> LST-NG</td><td>55 (33.5%)</td><td>122 (36.2%)</td></tr><tr><td> Protruded</td><td>14 (8.5%)</td><td>34 (10.1%)</td></tr><tr><td> Depressed</td><td>0 (0.0%)</td><td>2 (0.6%)</td></tr><tr><td> Residual/local recurrence</td><td>2 (1.2%)</td><td>6 (1.8%)</td></tr><tr><td colspan="4">Histological classification (<i>n</i>)</td></tr><tr><td> Adenoma</td><td>52 (31.7%)</td><td>131 (38.9%)</td><td rowspan="6">0.47</td></tr><tr><td> Intramucosal cancer</td><td>89 (54.3%)</td><td>164 (48.7%)</td></tr><tr><td> SM superficial cancer</td><td>11 (6.7%)</td><td>20 (5.9%)</td></tr><tr><td> SM deep cancer</td><td>11 (6.7%)</td><td>19 (5.6%)</td></tr><tr><td> Others</td><td>0 (0.0%)</td><td>2 (0.6%)</td></tr><tr><td> Failure of retrieval</td><td>1 (0.6%)</td><td>1 (0.3%)</td></tr></table> |
6984b125096c3471dbe7fe5e1db0cc9f6cb6c01f62414edd945f2d466935000e.png | complex | <table><tr><td>Key words</td><td colspan="2">Other variations of key words</td></tr><tr><td rowspan="4">NCDs metabolic risk factors plus proximal determinants plus distal determinants plus geographic location</td><td>NCDs metabolic risk factors</td><td>High blood pressure, hypertension, high blood glucose, hyperglycemia, diabetes, high BMI, obesity, overweight, waist circumference, waist-hip ratio</td></tr><tr><td>Proximal determinants</td><td>Determinants, risk, diet, salt intake, tobacco, smoking, alcohol, physical inactivity, lifestyle</td></tr><tr><td>Distal determinants</td><td>Social determinants, education, income, gender, race, caste, ethnicity, socio-economic status, wealth index, income</td></tr><tr><td>South Asia</td><td>Nepal, India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Maldives, Afghanistan</td></tr></table> |
c822e02027766c9a69de359b08f842db7c34639a22958d433ae5025f50279c24.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2"></td><td rowspan="2">Prevalence (%) of PN (n = 300)</td><td colspan="2">Univariate models</td><td colspan="2">Multivariate models</td></tr><tr><td>Odds ratio (OR) (95% CI)</td><td>p-value</td><td>Adjusted odds ratio (aOR) (95% CI)</td><td><i>p-value</i></td></tr><tr><td>Age</td><td></td><td>42 (±9.2)</td><td>1.1 (1.0, 1.1)</td><td><0.001</td><td>1.1 (1.0, 1.1)</td><td><0.001*</td></tr><tr><td>Gender</td><td>Female</td><td>210 (57)</td><td>1.0 (ref)</td><td>0.25</td><td></td><td></td></tr><tr><td></td><td>Male</td><td>87 (63)</td><td>1.3 (0.8, 1.9)</td><td></td><td></td><td></td></tr><tr><td>Education</td><td>None</td><td>73 (65)</td><td>1.0 (ref)</td><td></td><td>1.0 (ref)</td><td></td></tr><tr><td></td><td>Primary</td><td>128 (51)</td><td>0.6 (0.4, 0.9)</td><td>0.01</td><td>0.6 (0.3, 1.0)</td><td>0.04*</td></tr><tr><td></td><td>> = Secondary</td><td>99 (69)</td><td>1.2 (0.7, 2.0)</td><td>0.55</td><td>0.6 (0.3, 1.3)</td><td>0.2</td></tr><tr><td>Occupation</td><td>Public employed</td><td>29 (69)</td><td>1.0 (ref)</td><td></td><td>1.0 (ref)</td><td></td></tr><tr><td></td><td>Peasant/Farmer</td><td>106 (47)</td><td>0.4 (0.2, 0.8)</td><td>0.01</td><td>0.9 (0.3, 2.2)</td><td>0.76</td></tr><tr><td></td><td>Self employed</td><td>56 (63)</td><td>0.8 (0.3, 1.7)</td><td>0.5</td><td>0.3 (0.1, 0.9)</td><td>0.03</td></tr><tr><td></td><td>Unemployed</td><td>109 (72)</td><td>1.1 (0.5, 2.4)</td><td>0.74</td><td>0.6 (0.2, 1.4)</td><td>0.22</td></tr><tr><td>Marital status</td><td>Single</td><td>18 (51)</td><td>1.0 (ref)</td><td></td><td></td><td></td></tr><tr><td></td><td>Married</td><td>112 (48)</td><td>0.9 (0.4, 1.8)</td><td>0.75</td><td></td><td></td></tr><tr><td></td><td>Divorced/Separated</td><td>63 (78)</td><td>3.3 (1., 4)</td><td><0.01</td><td></td><td></td></tr><tr><td></td><td>Window/Widower</td><td>107 (66)</td><td>1. 9 (0.9, 4.)</td><td>0.09</td><td></td><td></td></tr><tr><td>Setting/Residence</td><td>Urban</td><td>200 (78)</td><td>1.0 (ref)</td><td></td><td>1.0 (ref)</td><td></td></tr><tr><td></td><td>Rural</td><td>99 (40)</td><td>0.2 (0.1, 0.3)</td><td><0.001</td><td>0.1 (0.06, 0.3)</td><td><0.001*</td></tr><tr><td>CD4 cell count</td><td><=350</td><td>91 (49)</td><td>1.0 (ref)</td><td></td><td></td><td></td></tr><tr><td></td><td>>350</td><td>209 (59)</td><td>1.0 (0.7, 1.5)</td><td>1.008</td><td></td><td></td></tr><tr><td>Duration since HIV diagnosis</td><td>0 – 3 years ago</td><td>84 (54)</td><td>1.0 (ref)</td><td></td><td>1.0 (ref)</td><td></td></tr><tr><td></td><td>4 – 6 years ago</td><td>96 (51)</td><td>0.9 (0.6, 1.4)</td><td>0.60</td><td>0.6 (0.3,1.1)</td><td>0.08</td></tr><tr><td></td><td>7 and above yrs</td><td>120 (73)</td><td>2.3 (1.5, 3.7)</td><td><0.001</td><td>1.4 (0.7, 3.0)</td><td>0.33</td></tr><tr><td>Current ARV regimen</td><td>Non D4T containing</td><td>247 (61)</td><td>1.0 (ref)</td><td></td><td></td><td></td></tr><tr><td></td><td>D4T containing</td><td>53 (51)</td><td>1.0 (0.4, 1.0)</td><td>0.06</td><td></td><td></td></tr><tr><td>Duration on ARVs (in years)</td><td>0 – 1</td><td>52 (42)</td><td>1.0 (ref)</td><td></td><td>1.0 (ref)</td><td></td></tr><tr><td></td><td>1 – 3</td><td>101 (64)</td><td>2.4 (1.5, 3.8)</td><td><0.001</td><td>2.6 (1.4, 4.8)</td><td>0.001</td></tr><tr><td></td><td>4 – 6</td><td>108 (64)</td><td>2.4 (1.5, 3.9)</td><td><0.001</td><td>2.0 (10, 4.1)</td><td>0.05</td></tr><tr><td></td><td>7 and above</td><td>39 (70)</td><td>3.1 (1.6, 6.1)</td><td>0.001</td><td>2.2 (0.8, 5.9)</td><td>0.1</td></tr><tr><td>ARV regimen changes</td><td>None</td><td>48 (57)</td><td>1.0 (ref)</td><td></td><td></td><td></td></tr><tr><td></td><td>Once</td><td>150 (56)</td><td>0.9 (0.6, 1.5)</td><td>0.80</td><td></td><td></td></tr><tr><td></td><td>Two and more</td><td>92 (68)</td><td>1.6 (1.0, 2.8)</td><td>0.08</td><td></td><td></td></tr><tr><td>ARV started with</td><td>Non D4T containing</td><td>104 (63)</td><td>1.0 (ref)</td><td></td><td></td><td></td></tr><tr><td></td><td>D4T containing</td><td>196 (57)</td><td>0.8 (0.6, 1.2)</td><td>0.27</td><td></td><td></td></tr></table> |
0c50810904a48069bca9570356c51407651867318254219e721e5c25ebca5481.png | simple | <table><tr><td></td><td>Training set</td><td>Development set</td><td>Test set</td><td>Entire corpus</td></tr><tr><td>Abstracts</td><td>3,500</td><td>3,500</td><td>3,000</td><td>10,000</td></tr><tr><td>Nr. characters</td><td>4,883,753</td><td>4,864,558</td><td>4,199,068</td><td>13,947,379</td></tr><tr><td>Nr. tokens</td><td>770,855</td><td>766,331</td><td>662,571</td><td>2,199,757</td></tr><tr><td>Abstracts with SACEM</td><td>2,916</td><td>2,907</td><td>2,478</td><td>8,301</td></tr><tr><td>Nr. mentions</td><td>29,478</td><td>29,526</td><td>25,351</td><td>84,355</td></tr><tr><td>Nr. chemicals</td><td>8,520</td><td>8,677</td><td>7,563</td><td>19,805</td></tr><tr><td>Nr. journals</td><td>193</td><td>188</td><td>188</td><td>203</td></tr><tr><td>TRIVIAL</td><td>8,832</td><td>8,970</td><td>7,808</td><td>25,610</td></tr><tr><td>SYSTEMATIC</td><td>6,656</td><td>6,816</td><td>5,666</td><td>19,138</td></tr><tr><td>ABBREVIATION</td><td>4,538</td><td>4,521</td><td>4059</td><td>13,118</td></tr><tr><td>FORMULA</td><td>4,448</td><td>4,137</td><td>3,443</td><td>12,028</td></tr><tr><td>FAMILY</td><td>4,090</td><td>4,223</td><td>3,622</td><td>11,935</td></tr><tr><td>IDENTIFIER</td><td>672</td><td>639</td><td>513</td><td>1,824</td></tr><tr><td>MULTIPLE</td><td>202</td><td>188</td><td>199</td><td>589</td></tr><tr><td>NO CLASS</td><td>40</td><td>32</td><td>41</td><td>113</td></tr></table> |
ede4ddb46849ddc5d5528053e7b91597ba2045f16b198c5e0b815c1d2b4d3b08.png | simple | <table><tr><td></td><td>FeNO</td><td>CalvNO</td><td>nNO</td></tr><tr><td>Asthma</td><td>Normal/increased</td><td>Normal/increased</td><td>Normal/increased</td></tr><tr><td>COPD</td><td>Normal/increased</td><td>Increased</td><td>NS</td></tr><tr><td>CF</td><td>Normal/decreased</td><td>Contradictory results</td><td>Decreased</td></tr><tr><td>PCD</td><td>Normal/decreased</td><td>Contradictory results</td><td>Decreased</td></tr><tr><td>Allergic rhinitis</td><td>Normal/increased</td><td>Normal</td><td>NS</td></tr><tr><td>BPD</td><td>Normal/decreased</td><td>Decreased</td><td>NS</td></tr><tr><td>HPS</td><td>Decreased</td><td>Increased</td><td>NS</td></tr><tr><td>PAH</td><td>Decreased</td><td>Increased</td><td>NS</td></tr><tr><td>SSc</td><td>Normal/decreased</td><td>Increased</td><td>NS</td></tr><tr><td>Rhinovirus infection</td><td>Increased</td><td>NS</td><td>NS</td></tr><tr><td>Allograft rejection</td><td>Increased</td><td>NS</td><td>NS</td></tr></table> |
453735c26a8f3649441d0d766db325d1919ec6a788e1a33ee2cdcb990dfd2397.png | complex | <table><tr><td>Allele</td><td>DYS635</td><td>DYS456</td><td>DYS458</td><td>DYS391</td><td>DYS392</td><td>DYS390</td><td>DYS393</td><td>DYS438</td><td colspan="4">DYS385a,b</td></tr><tr><td>8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.0185</td><td>10,12</td><td>0.0093</td><td>13,17</td><td>0.0093</td></tr><tr><td>9</td><td></td><td></td><td></td><td>0.0185</td><td></td><td></td><td></td><td></td><td>10,17</td><td>0.0185</td><td>13,18</td><td>0.0926</td></tr><tr><td>10</td><td></td><td></td><td></td><td>0.7407</td><td>0.0093</td><td></td><td></td><td>0.7593</td><td>11,11</td><td>0.0370</td><td>13,19</td><td>0.0278</td></tr><tr><td>11</td><td></td><td></td><td></td><td>0.2315</td><td>0.1481</td><td></td><td></td><td>0.2130</td><td>11,12</td><td>0.0278</td><td>13,20</td><td>0.0093</td></tr><tr><td>12</td><td></td><td></td><td></td><td>0.0093</td><td>0.1481</td><td></td><td>0.5556</td><td>0.0093</td><td>11,13</td><td>0.0093</td><td>13,21</td><td>0.0278</td></tr><tr><td>13</td><td></td><td>0.0093</td><td>0.0093</td><td></td><td>0.3519</td><td></td><td>0.2593</td><td></td><td>11,16</td><td>0.0185</td><td>13,26</td><td>0.0093</td></tr><tr><td>14</td><td></td><td>0.2685</td><td>0.0185</td><td></td><td>0.2685</td><td></td><td>0.1111</td><td></td><td>11,17</td><td>0.0370</td><td>14,17</td><td>0.0185</td></tr><tr><td>15</td><td></td><td>0.4815</td><td>0.1296</td><td></td><td>0.0741</td><td></td><td>0.0741</td><td></td><td>11,18</td><td>0.0093</td><td>14,18</td><td>0.0185</td></tr><tr><td>15</td><td></td><td></td><td>0.0093</td><td></td><td></td><td></td><td></td><td></td><td>11,19</td><td>0.0370</td><td>14,19</td><td>0.0093</td></tr><tr><td>16</td><td></td><td>0.1574</td><td>0.1852</td><td></td><td></td><td></td><td></td><td></td><td>12,12</td><td>0.0370</td><td>14,21</td><td>0.0093</td></tr><tr><td>17</td><td></td><td>0.0741</td><td>0.2778</td><td></td><td></td><td></td><td></td><td></td><td>12,14</td><td>0.0093</td><td>14,22</td><td>0.0093</td></tr><tr><td>18</td><td></td><td>0.0093</td><td>0.2222</td><td></td><td></td><td></td><td></td><td></td><td>12,15</td><td>0.0093</td><td>15,17</td><td>0.0093</td></tr><tr><td>19</td><td>0.1389</td><td></td><td>0.1111</td><td></td><td></td><td></td><td></td><td></td><td>12,16</td><td>0.0741</td><td>15,19</td><td>0.0093</td></tr><tr><td>20</td><td>0.2778</td><td></td><td>0.0185</td><td></td><td></td><td>0.0093</td><td></td><td></td><td>12,17</td><td>0.0185</td><td>15,20</td><td>0.0093</td></tr><tr><td>21</td><td>0.2778</td><td></td><td>0.0093</td><td></td><td></td><td></td><td></td><td></td><td>12,19</td><td>0.0926</td><td>15,22</td><td>0.0093</td></tr><tr><td>22</td><td>0.2037</td><td></td><td>0.0093</td><td></td><td></td><td>0.0093</td><td></td><td></td><td>12,20</td><td>0.0741</td><td>18,19</td><td>0.0093</td></tr><tr><td>23</td><td>0.0556</td><td></td><td></td><td></td><td></td><td>0.5093</td><td></td><td></td><td>13,13</td><td>0.1204</td><td></td><td></td></tr><tr><td>24</td><td>0.0370</td><td></td><td></td><td></td><td></td><td>0.2407</td><td></td><td></td><td>13,14</td><td>0.0370</td><td></td><td></td></tr><tr><td>25</td><td>0.0093</td><td></td><td></td><td></td><td></td><td>0.2222</td><td></td><td></td><td>13,15</td><td>0.0093</td><td></td><td></td></tr><tr><td>26</td><td></td><td></td><td></td><td></td><td></td><td>0.0093</td><td></td><td></td><td>13,16</td><td>0.0278</td><td></td><td></td></tr><tr><td>GD</td><td>0.7876</td><td>0.6719</td><td>0.8165</td><td>0.4010</td><td>0.7617</td><td>0.6390</td><td>0.6120</td><td>0.3813</td><td></td><td>0.9983</td><td></td><td></td></tr></table> |
44e17eafc38342674247b22a1cbd8a5a9d5811ff48e25342155a4c34add9fd8f.png | simple | <table><tr><td>KEGGID</td><td>Pvalue</td><td>Count</td><td>Size</td><td>Term</td></tr><tr><td>4530</td><td>0.011</td><td>3</td><td>11</td><td>Tight junction</td></tr><tr><td>533</td><td>0.046</td><td>1</td><td>1</td><td>Keratan sulfate biosynthesis</td></tr><tr><td>604</td><td>0.046</td><td>1</td><td>1</td><td>Glycosphingolipid biosynthesis - ganglio series</td></tr><tr><td>1031</td><td>0.047</td><td>2</td><td>8</td><td>Glycan structures - biosynthesis 2</td></tr><tr><td>4620</td><td>0.047</td><td>2</td><td>8</td><td>Toll-like receptor signaling pathway</td></tr><tr><td>51</td><td>0.059</td><td>2</td><td>9</td><td>Fructose and mannose metabolism</td></tr><tr><td>4210</td><td>0.059</td><td>2</td><td>9</td><td>Apoptosis</td></tr><tr><td>3010</td><td>0.064</td><td>3</td><td>21</td><td>Ribosome</td></tr><tr><td>52</td><td>0.089</td><td>1</td><td>2</td><td>Galactose metabolism</td></tr><tr><td>512</td><td>0.089</td><td>1</td><td>2</td><td>O-Glycan biosynthesis</td></tr><tr><td>720</td><td>0.089</td><td>1</td><td>2</td><td>Reductive carboxylate cycle (CO2 fixation)</td></tr><tr><td>5213</td><td>0.089</td><td>1</td><td>2</td><td>Endometrial cancer</td></tr><tr><td>5218</td><td>0.089</td><td>1</td><td>2</td><td>Melanoma</td></tr><tr><td>5223</td><td>0.089</td><td>1</td><td>2</td><td>Non-small cell lung cancer</td></tr></table> |
6a1180aace651fe262d7315b71493bd21560d195fc7c639626799951fd99f9cc.png | simple | <table><tr><td>Gene</td><td>Abbreviation</td><td>Teleost accession number</td><td>Transcript in the greater amberjack</td><td><i>In silico</i> group</td><td>DE* male vs female gonads</td><td>Sex determining in</td></tr><tr><td>DM domain gene on the Y chromosome/ doublesex and mab-3-related transcription factor 1a</td><td><i>dmY/dmrt1a</i></td><td><i>Oryzias latipes</i> NM_0 011 04680/ XM_004086451 unplaced scaffold</td><td>maker-jcf7180000931253-snap-gene-0.40-mRNA-1</td><td>SD7</td><td>Up in male gonads</td><td><i>Oryzias latipes</i> [23, 65]</td></tr><tr><td>Gonadal soma-derived factor</td><td><i>gsdf</i></td><td><i>Oryzias latipes</i> NM_0 011 77742 chr.12</td><td>Augustus-masked-jcf7180000916295-processed-gene-0.7-mRNA-1</td><td>SD17</td><td>Up in male gonads</td><td><i>Oryzias</i> l<i>uzonensis</i> [66]</td></tr><tr><td>Y chromosome–specific antimuellerian hormone</td><td><i>amhY</i></td><td><i>Oryzias latipes</i> NM_0 011 04728 chr. 4</td><td>maker-jcf7180000931145-snap-gene-0.73-mRNA-2</td><td>SD4</td><td>Up in male gonads</td><td><i>Odontesthes hatcheri</i> [67] <i>HM153803.1</i></td></tr><tr><td>Antimuellerian hormone receptor 2</td><td><i>amhr2</i></td><td><i>Lates calcarifer</i> KR492510 <i>Oryzias latipes</i> DQ499644.1 chr. 5 or 7</td><td>maker-jcf7180000889430-snap-gene-0.77-mRNA-5</td><td>SD1</td><td>No expression</td><td><i>Takifugu genus</i> [68]</td></tr><tr><td>Sexually dimorphic o the Y chromosome</td><td><i>sdY</i></td><td><i>Salmonidae</i> family</td><td>n/a</td><td>n/a</td><td>n/a</td><td><i>Salmonidae family</i> [69]</td></tr><tr><td>SRY-box containing protein 3Y</td><td><i>sox3Y</i></td><td>Oryzias latipes AJ245396 chr.10</td><td>augustus-masked-jcf7180000920392-processed-gene-0.31-mRNA-1</td><td>SD18</td><td>Up in female gonads</td><td><i>Oryzias dancena</i> [65]</td></tr></table> |
f96f7f206c451227aed44e2c39f8adab4acc519320324a80295677390bf0270d.png | simple | <table><tr><td>Number of women (percentage)</td><td>357</td><td>(92%)</td></tr><tr><td>Median years of age (IQR)</td><td>52</td><td>(8)</td></tr><tr><td>Median years of age diagnosed with a pain disorder (IQR)<sup>a</sup></td><td>30</td><td>(18)</td></tr><tr><td>Median PPI (IQR)</td><td>4</td><td>(3)</td></tr><tr><td>Median number of comorbid pain conditions (IQR)</td><td>3</td><td>(2)</td></tr><tr><td>Median number of current pain medications (IQR)</td><td>3</td><td>(3)</td></tr><tr><td>Median number of past pain medications (IQR)</td><td>6</td><td>(7)</td></tr></table> |
8bb7e0431fba6a985b82ea94e8368c176aaa376913e6c5c6f0810408bb83c00e.png | complex | <table><tr><td colspan="2"></td><td>Nurses</td><td><i>Controls</i></td></tr><tr><td colspan="2"><i>N</i></td><td>32</td><td>30</td></tr><tr><td colspan="2">Age (in years)</td><td>40.3 (11.3)</td><td>40.0 (12.3)</td></tr><tr><td colspan="2">Sex (male/female)</td><td>7/25</td><td>3/27</td></tr><tr><td rowspan="4">Education</td><td>lower secondary school (Hauptschule)</td><td>7</td><td>4</td></tr><tr><td>Intermediate secondary school (Realschule)</td><td>18</td><td>22</td></tr><tr><td>Higher education entrance qualification (Abitur) (finished or enrolled)</td><td>5</td><td>4</td></tr><tr><td>University degree</td><td>2</td><td>0</td></tr></table> |
b2e3c3737cb1e5c9aad731f6cb82e8d5f195e477ba9fd234fd43895e518c6e0c.png | complex | <table><tr><td>Dependent variable</td><td>Fivefolded cross-validated <i>R</i><sup>2</sup> (%)</td><td>Effect size, <i>f</i><sup>2</sup></td></tr><tr><td colspan="3">MUSICIANS ONLY</td></tr><tr><td>Judgment line orientation</td><td>15</td><td>0.18</td></tr><tr><td>Letter-number sequencing</td><td>14</td><td>0.16</td></tr><tr><td>Tower rule violations</td><td>0</td><td>0.00</td></tr><tr><td>Letter fluency</td><td>0</td><td>0.00</td></tr><tr><td>CVLT-II SDFR</td><td>0</td><td>0.00</td></tr><tr><td>Grooved pegboard – dominant hand</td><td>29</td><td>0.21</td></tr><tr><td>Grooved pegboard – non-dominant hand</td><td>28</td><td>0.20</td></tr></table> |
cfa2a42d3db864c4cf6125b70ddfa24cc382bbc6362dbfff34ca6e3c3f268e3b.png | simple | <table><tr><td><i>PT number</i></td><td><i>Global</i></td><td><i>For strengthening exercises</i></td><td><i>For stretching exercises</i></td></tr><tr><td>1</td><td>0.74 (0.58–0.84)</td><td>0.68 (0.38–0.84)</td><td>0.78 (0.57–0.91)</td></tr><tr><td>2</td><td>0.72 (0.57–0.81)</td><td>0.71 (0.43–0.84)</td><td>0.68 (0.46–0.81)</td></tr><tr><td>3</td><td>0.86 (0.76–0.92)</td><td>0.79 (0.57–0.91)</td><td>0.92 (0.86–0.95)</td></tr><tr><td>4</td><td>0.82 (0.73–0.89)</td><td>0.81 (0.71–0.87)</td><td>0.84 (0.67–0.96)</td></tr><tr><td>5</td><td>0.86 (0.73–0.93)</td><td>0.82 (0.48–0.94)</td><td>0.88 (0.73–0.94)</td></tr><tr><td>6</td><td>0.88 (0.79–0.94)</td><td>0.82 (0.56–0.92)</td><td>0.96 (0.91–0.98)</td></tr></table> |
d606f259ff0430c4bcf11d03763ec8dd72523e39ba8a0e9c0f1637ed01e6c8e7.png | complex | <table><tr><td colspan="6">Year</td></tr><tr><td>Variable</td><td>2010</td><td>2011</td><td>2012</td><td>2013</td><td>Total</td></tr><tr><td></td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td colspan="6">Sex</td></tr><tr><td> Female</td><td>41(45)</td><td>26(50)</td><td>83(36.4)</td><td>131(41.8)</td><td>281(41.1)</td></tr><tr><td> Male</td><td>50(55)</td><td>26(50)</td><td>145 (63.6)</td><td>182(58.2)</td><td>403(58.9)</td></tr><tr><td>Total</td><td>91(100)</td><td>52(100)</td><td>228 (100)</td><td>313(100)</td><td>684(100)</td></tr><tr><td colspan="6">Age (Months)</td></tr><tr><td> 0–5</td><td>20(22)</td><td>13 (25)</td><td>66(29)</td><td>82(26)</td><td>181(26)</td></tr><tr><td> 6–11</td><td>28(31)</td><td>16(31)</td><td>74(32)</td><td>112(36)</td><td>230(34)</td></tr><tr><td> 12–17</td><td>19(21)</td><td>11(21)</td><td>49(21)</td><td>57(18)</td><td>136(20)</td></tr><tr><td> 18–23</td><td>12(13)</td><td>7(13)</td><td>18(8)</td><td>31(10)</td><td>68(10)</td></tr><tr><td> > 24</td><td>12(13)</td><td>5(10)</td><td>21(10)</td><td>31(10)</td><td>69(10)</td></tr><tr><td>Total</td><td>91(100)</td><td>52(100)</td><td>228(100)</td><td>313(100)</td><td>684(100)</td></tr><tr><td colspan="6">EIA Result</td></tr><tr><td> Positive</td><td>15(16.4)</td><td>18(34.6)</td><td>59(25.9)</td><td>94(30)</td><td>186(27.1)</td></tr><tr><td> Negative</td><td>76(83.6)</td><td>34(65.4)</td><td>169(74.1)</td><td>219(70)</td><td>498(72.9)</td></tr><tr><td>Total</td><td>91(100)</td><td>52(100)</td><td>228(100)</td><td>313(100)</td><td>684(100)</td></tr></table> |
cd925464015c3077e8bd93508331b389f58460d1d1d61f8893445bf734178eb8.png | complex | <table><tr><td>Welding Positions</td><td>No. of Butt Welds</td><td>Laser Beam Power, W</td><td>Traveling Speed, m/min</td><td>Heat Input, kJ/m</td></tr><tr><td rowspan="2">Vertical up</td><td>U01</td><td>2200</td><td>0.5</td><td>275</td></tr><tr><td>U02</td><td>2500</td><td>1.2</td><td>125</td></tr><tr><td rowspan="2">Vertical down</td><td>D01</td><td>2200</td><td>0.5</td><td>275</td></tr><tr><td>D02</td><td>2500</td><td>1.2</td><td>125</td></tr></table> |
9255e6b662c60aea9a3be198f787cab0c69a04d44f529ca6c1f4d418d37f2a58.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">Organs</td><td rowspan="2"><i>n</i></td><td colspan="2">Elks up to 2 years</td><td rowspan="2"><i>n</i></td><td colspan="2">Elks older than 3 years</td></tr><tr><td>Mean ± SD</td><td>Median</td><td>Mean ± SD</td><td>Median</td></tr><tr><td rowspan="3">Cu</td><td>Liver</td><td>8</td><td>18.61 ± 18.63</td><td>7.02</td><td>27</td><td>24.45 ± 30.03</td><td>10.77</td></tr><tr><td>Kidney</td><td>8</td><td>4.51 ± 2.43</td><td>3.72</td><td>27</td><td>5.13 ± 5.73</td><td>4.01</td></tr><tr><td>Muscle</td><td>8</td><td>2.68 ± 0.57</td><td>2.44</td><td>27</td><td>2.28 ± 0.49</td><td>2.31</td></tr><tr><td rowspan="3">Mo</td><td>Liver</td><td>8</td><td>0.75 ± 0.42</td><td>0.79</td><td>27</td><td>0.97 ± 0.48</td><td>1.00</td></tr><tr><td>Kidney</td><td>8</td><td>0.25 ± 0.33</td><td>0.12</td><td>27</td><td>0.46 ± 0.67</td><td>0.35</td></tr><tr><td>Muscle</td><td>8</td><td>0.07 ± 0.06</td><td>0.05</td><td>27</td><td>0.047 ± 0.02</td><td>0.05</td></tr></table> |
8e2588edfb19978c9404e488c8d35cd8a530ac51ff97e51a377ae940bdc63ec8.png | complex | <table><tr><td> </td><td colspan="6">Voyage</td></tr><tr><td> </td><td colspan="2">1</td><td colspan="2">2</td><td colspan="2">3</td></tr><tr><td>Measure</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>Indoor cabin temp (°C)</td><td>20.97</td><td>1.1</td><td>20.83</td><td>0.9</td><td>21.05</td><td>1.7</td></tr><tr><td>Outdoor temp (°C)</td><td>6.19</td><td>3.4</td><td>6.13</td><td>2.1</td><td>6.10</td><td>1.9</td></tr><tr><td>Expedition length (h)</td><td>3.29</td><td>0.7</td><td>3.12</td><td>0.8</td><td>3.08</td><td>0.7</td></tr><tr><td>Wind velocity (km/h)</td><td>26.36</td><td>13.3</td><td>12.73</td><td>7.9</td><td>18.52</td><td>13.0</td></tr><tr><td>Wind chill (°C)</td><td>1.92</td><td>5.55</td><td>3.50</td><td>3.08</td><td>2.63</td><td>0.94</td></tr></table> |
9b369c7006e7c35eba58ada59155a685e8b7c774690b0a115fedc83c909f9427.png | simple | <table><tr><td>Category</td><td>Term</td><td>Count</td><td><i>P</i>-value</td><td>Benjamini</td></tr><tr><td>KEGG_PATHWAY</td><td>Cytokine-cytokine receptor interaction</td><td>24</td><td>9.00E-07</td><td>1.30E-04</td></tr><tr><td>GOTERM_BP_FAT</td><td>Immune response</td><td>18</td><td>1.90E-03</td><td>2.50E-01</td></tr><tr><td>GOTERM_CC_FAT</td><td>Extracellular region part</td><td>15</td><td>1.60E-02</td><td>6.30E-01</td></tr><tr><td>GOTERM_MF_FAT</td><td>Cytokine activity</td><td>14</td><td>1.80E-03</td><td>1.90E-01</td></tr><tr><td>GOTERM_CC_FAT</td><td>Extracellular space</td><td>14</td><td>2.10E-02</td><td>4.90E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Natural killer cell mediated cytotoxicity</td><td>13</td><td>8.10E-04</td><td>5.50E-02</td></tr><tr><td>KEGG_PATHWAY</td><td>Chemokine signaling pathway</td><td>13</td><td>3.20E-02</td><td>2.90E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Defense response</td><td>12</td><td>1.40E-02</td><td>4.60E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Jak-STAT signaling pathway</td><td>12</td><td>1.80E-02</td><td>2.00E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>T cell receptor signaling pathway</td><td>10</td><td>1.50E-02</td><td>2.10E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Hematopoietic cell lineage</td><td>9</td><td>1.10E-02</td><td>1.80E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Toll-like receptor signaling pathway</td><td>9</td><td>2.30E-02</td><td>2.40E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>NOD-like receptor signaling pathway</td><td>8</td><td>5.50E-03</td><td>1.40E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Allograft rejection</td><td>8</td><td>7.40E-03</td><td>1.60E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Response to wounding</td><td>8</td><td>1.30E-02</td><td>5.10E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Fc epsilon RI signaling pathway</td><td>8</td><td>1.70E-02</td><td>2.10E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Asthma</td><td>7</td><td>2.00E-03</td><td>6.80E-02</td></tr><tr><td>GOTERM_BP_FAT</td><td>Inflammatory response</td><td>7</td><td>7.90E-03</td><td>3.90E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Cytosolic DNA-sensing pathway</td><td>7</td><td>8.20E-03</td><td>1.50E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Autoimmune thyroid disease</td><td>7</td><td>5.70E-02</td><td>4.20E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Chemotaxis</td><td>6</td><td>1.40E-02</td><td>4.20E-01</td></tr><tr><td>GOTERM_MF_FAT</td><td>Cytokine binding</td><td>6</td><td>3.40E-02</td><td>8.60E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Locomotors behavior</td><td>6</td><td>3.40E-02</td><td>7.10E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Graft-versus-host disease</td><td>6</td><td>4.30E-02</td><td>3.60E-01</td></tr><tr><td>INTERPRO</td><td>Immunoglobulin</td><td>6</td><td>4.50E-02</td><td>9.00E-01</td></tr><tr><td>KEGG_PATHWAY</td><td>Type I diabetes mellitus</td><td>6</td><td>6.90E-02</td><td>4.70E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Behavior</td><td>6</td><td>7.90E-02</td><td>9.20E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Cell migration</td><td>5</td><td>1.80E-03</td><td>4.30E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Cell motility</td><td>5</td><td>3.30E-03</td><td>2.90E-01</td></tr><tr><td>INTERPRO</td><td>Small chemokine, C-C group, conserved site</td><td>5</td><td>5.50E-02</td><td>8.80E-01</td></tr><tr><td>GOTERM_BP_FAT</td><td>Leukocyte migration</td><td>4</td><td>6.40E-03</td><td>4.00E-01</td></tr><tr><td>INTERPRO</td><td>Chemokine receptor</td><td>4</td><td>6.40E-02</td><td>8.70E-01</td></tr><tr><td>GOTERM_MF_FAT</td><td>C-C chemokine receptor activity</td><td>4</td><td>7.20E-02</td><td>9.40E-01</td></tr><tr><td>GOTERM_MF_FAT</td><td>C-C chemokine binding</td><td>4</td><td>7.20E-02</td><td>9.40E-01</td></tr><tr><td>GOTERM_MF_FAT</td><td>Chemokine receptor activity</td><td>4</td><td>9.50E-02</td><td>9.40E-01</td></tr></table> |
8c49f287ce51a8ab669acc75ff91dc93fa5b45fcfc816b7dfa5a50a03d472326.png | simple | <table><tr><td>Time (min)</td><td>% Eluent A (0.1% TFA in <sup>d</sup>H<sub>2</sub>O)</td><td>% Eluent B (MeOH)</td><td>Flow Rate (mL/min)</td></tr><tr><td>0</td><td>15</td><td>85</td><td>1.5</td></tr><tr><td>6</td><td>0</td><td>100</td><td>1.5</td></tr><tr><td>25</td><td>0</td><td>100</td><td>1.5</td></tr><tr><td>26</td><td>15</td><td>85</td><td>1.5</td></tr><tr><td>35</td><td>15</td><td>85</td><td>1.5</td></tr></table> |
92defea45595628c423c6b33816e6275848fa76b18bfd7696c4018aad473cb69.png | complex | <table><tr><td rowspan="2" colspan="2">Variable</td><td colspan="2">PCS</td><td colspan="2">MCS</td><td colspan="2">KDCS</td></tr><tr><td>Score</td><td><i>p</i>-value</td><td>Score</td><td><i>p</i>-value</td><td>Score</td><td><i>p</i>-value</td></tr><tr><td rowspan="2">Age</td><td><45 years (<i>n</i> = 11)</td><td>49.8</td><td rowspan="2">0.89</td><td>58.3</td><td rowspan="2">0.55</td><td>62.9</td><td rowspan="2">0.08</td></tr><tr><td>>45 years (<i>n</i> = 11)</td><td>51.1</td><td>64.4</td><td>72.9</td></tr><tr><td rowspan="2">Sex</td><td>Male (<i>n</i> = 13)</td><td>54.1</td><td rowspan="2">0.38</td><td>64.0</td><td rowspan="2">0.52</td><td>68.1</td><td rowspan="2">0.93</td></tr><tr><td>Female (<i>n</i> = 9)</td><td>45.2</td><td>57.4</td><td>67.6</td></tr><tr><td rowspan="2">Marital status</td><td>Married (<i>n</i> = 12)</td><td>56.2</td><td rowspan="2">0.20</td><td>68.3</td><td rowspan="2">0.12</td><td>70.9</td><td rowspan="2">0.25</td></tr><tr><td>Not married (<i>n</i> = 10)</td><td>43.6</td><td>52.9</td><td>64.3</td></tr><tr><td rowspan="2">Education status</td><td>Secondary or below (<i>n</i> = 9)</td><td>47.1</td><td rowspan="2">0.58</td><td>63.4</td><td rowspan="2">0.73</td><td>65.5</td><td rowspan="2">0.52</td></tr><tr><td>Above secondary (<i>n</i> = 13)</td><td>52.8</td><td>60.0</td><td>69.4</td></tr><tr><td rowspan="2">Employment status</td><td>Employed (<i>n</i> = 11)</td><td>51.9</td><td rowspan="2">0.78</td><td>66.6</td><td rowspan="2">0.29</td><td>70.4</td><td rowspan="2">0.39</td></tr><tr><td>Unemployed (<i>n</i> = 11)</td><td>49.0</td><td>56.0</td><td>65.4</td></tr><tr><td rowspan="2">Dialysis vintage</td><td><12 months (<i>n</i> = 10)</td><td>49.1</td><td rowspan="2">0.81</td><td>62.6</td><td rowspan="2">0.82</td><td>70.2</td><td rowspan="2">0.39</td></tr><tr><td>>12 months (<i>n</i> = 12)</td><td>51.6</td><td>60.3</td><td>66.0</td></tr><tr><td rowspan="2">Yearly total household income</td><td><$4000 (<i>n</i> = 16)</td><td>43.3</td><td rowspan="2">0.30</td><td>51.2</td><td rowspan="2">0.04</td><td>67.8</td><td rowspan="2">0.99</td></tr><tr><td>>$4000 (<i>n</i> = 6)</td><td>56.1</td><td>75.2</td><td>67.9</td></tr></table> |
390ea9d981372050d854968fabc26037ce9856819b7125772fe1863edbe6a10c.png | complex | <table><tr><td>Characteristics</td><td colspan="2">OCP-patch (<i>N</i> = 30)</td><td colspan="2">LTS-2 patch (<i>N</i> = 30)</td></tr><tr><td>Definition of reaction</td><td>At 24 h</td><td>At 30 h</td><td>At 24 h</td><td>At 30 h</td></tr><tr><td> None</td><td>3 (10.0)</td><td>2 (6.7)</td><td>5 (16.7)</td><td>0</td></tr><tr><td>Oedema under the patch (any score)</td><td>NA</td><td>NA</td><td>25 (83.3)</td><td>30 (100)</td></tr><tr><td> 100 % of area oedematous (score 3)</td><td>NA</td><td>NA</td><td>17 (56.7)</td><td>27 (90.0)</td></tr><tr><td>> 50 % of area oedematous (score 2)</td><td>NA</td><td>NA</td><td>4 (13.3)</td><td>3 (10.0)</td></tr><tr><td>< 50 % of area oedematous (score 1)</td><td>NA</td><td>NA</td><td>4 (13.3)</td><td>0</td></tr><tr><td> 0 % of area oedematous (score 0)</td><td>NA</td><td>NA</td><td>5 (15.7)</td><td>0</td></tr><tr><td> All reactions</td><td>27 (90.0)</td><td>28 (93.3)</td><td>25 (83.3)</td><td>30 (100)</td></tr><tr><td>Very easily visible reaction</td><td>18 (60.0)</td><td>24 (80.0)</td><td>22 (73.</td><td>19 (63.3)</td></tr><tr><td>Easily visible reaction</td><td>2 (6.7)</td><td>3 (10.0)</td><td>0</td><td>1 (3.3)</td></tr><tr><td>Attentive visual inspection required</td><td>7 (23.3)</td><td>1 (3.3)</td><td>3 (10.0)</td><td>10 (33.3)</td></tr><tr><td>Character of papules</td><td></td><td></td><td></td><td></td></tr><tr><td> None</td><td>3 (10.0)</td><td>2 (6.7)</td><td>5 (16.7)</td><td>0</td></tr><tr><td> Vague</td><td>4 (13.3)</td><td>1 (3.3)</td><td>3 (10.0)</td><td>0</td></tr><tr><td> Pinheads</td><td>16 (53.3)</td><td>16 (53.3)</td><td>0</td><td>0</td></tr><tr><td> Pinpoints</td><td>7 (23.3)</td><td>11 (36.7)</td><td>19 (63.3)</td><td>29 (96.7)</td></tr><tr><td> Urticariform</td><td>0</td><td>0</td><td>3 (10.0)</td><td>1 (3.3)</td></tr><tr><td>Extension beyond patch area</td><td>2 (6.7)</td><td>8 (26.7)</td><td>0</td><td>0</td></tr></table> |
ca58de56b913c3bdc689bc12cf7e44a9e639a35e4ccac9c811d414941b92a243.png | simple | <table><tr><td>Studies</td><td>Reported outcomes</td><td>Follow up period</td><td>Bias grade</td></tr><tr><td>Brar2008</td><td>Death, MI</td><td>9.7 months</td><td>-</td></tr><tr><td>I-LOVE IT 2</td><td>NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding</td><td>12 and 18 months</td><td>B</td></tr><tr><td>ISAR-SAFE</td><td>Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding</td><td>9 months</td><td>B</td></tr><tr><td>Tarantini2016</td><td>Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization</td><td>1 year</td><td>-</td></tr><tr><td>ARCTIC</td><td>Primary endpoints, Death, MI, ST, stroke, revascularization</td><td>17 months</td><td>B</td></tr><tr><td>OPTIMIZE</td><td>NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding</td><td>1 year</td><td>B</td></tr><tr><td>RESET</td><td>Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke</td><td>1 year</td><td>B</td></tr><tr><td>EXCELLENT</td><td>Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding</td><td>1 year</td><td>B</td></tr><tr><td>PEGASUS</td><td>Death, MI, stroke, TIMI major and minor bleeding</td><td>3 years</td><td>B</td></tr><tr><td>DAPT</td><td>ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5</td><td>12 to 30 months</td><td>B</td></tr><tr><td>Sardella2011</td><td>Death, MI, stroke, TIMI minor bleeding, revascularization</td><td>2 years</td><td>-</td></tr><tr><td>PRODIGY</td><td>Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding</td><td>2 years</td><td>B</td></tr><tr><td>Thukkani2015</td><td>Death, MI, Stroke</td><td>4 years</td><td>-</td></tr><tr><td>ENDEAVOR</td><td>Death, MI, ST (definite and probable), stroke, major bleeding</td><td>2 years</td><td>B</td></tr><tr><td>ITALIC</td><td>Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding</td><td>1 year</td><td>B</td></tr></table> |
81a78c7410b3b843470adf34e5ab52d39eb292a5ccfd23d166f69fdc4a9ec2a7.png | complex | <table><tr><td>Variable</td><td colspan="2">Univariate</td><td colspan="2">Multivariate</td><td colspan="2">Covariate height</td><td colspan="2">Covariate gender</td></tr><tr><td></td><td><i>B</i> (95% CI)</td><td><i>P</i> value</td><td><i>B</i> (95% CI)</td><td><i>P</i> value</td><td><i>B</i> (95% CI)</td><td><i>P</i> value</td><td><i>B</i> (95% CI)</td><td><i>P</i> value</td></tr><tr><td>Age</td><td>-0.07 (-0.2; 0.1)</td><td>0.417</td><td></td><td></td><td>0.06 (-0.1; 0.2)</td><td>0.369</td><td>-0.08 (-0.2; 0.06)</td><td>0.258</td></tr><tr><td>Gender</td><td>6.93 (4.8; 9.0)</td><td><0.001</td><td>4.24 (-0.8; 9.3)</td><td>0.098</td><td>3.33 (0.9; 5.7)</td><td>0.006</td><td></td><td></td></tr><tr><td>BMI</td><td>-0.14 (-0.4; 0.1)</td><td>0.258</td><td></td><td></td><td>-0.05 (-0.2; 0.1)</td><td>0.560</td><td>-0.06 (-0.2; 0.1)</td><td>0.549</td></tr><tr><td>Waist-to-hip ratio</td><td>19.8 (5.9; 33.7)</td><td>0.006</td><td>-6.32 (-20.4; 7.7)</td><td>0.373</td><td>4.72 (-6.7; 16.1)</td><td>0.412</td><td>-9.5 (-24.7; 5.9)</td><td>0.222</td></tr><tr><td>Waist circumference</td><td>0.04 (-0.06; 0.1)</td><td>0.391</td><td></td><td></td><td>0.003 (-0.1; 0.1)</td><td>0.932</td><td>-0.02 (-0.1; 0.06)</td><td>0.682</td></tr><tr><td>Fat percentage</td><td>-0.29 (-0.4; -0.2)</td><td><0.001</td><td>0.01 (-0.3; 0.3)</td><td>0.943</td><td>-0.13 (-0.3; -0.1)</td><td>0.024</td><td>0.02 (-0.2; 0.2)</td><td>0.824</td></tr><tr><td>Height</td><td>0.41 (0.3; 0.5)</td><td><0.001</td><td>0.31 (0.2; 0.4)</td><td><0.001</td><td></td><td></td><td>0.29 (0.2; 0.4)</td><td><0.001</td></tr><tr><td>Weight</td><td>0.08 (0.01; 0.2)</td><td>0.023</td><td>-0.02 (-0.1; 0.1)</td><td>0.773</td><td>-0.02 (-0.1; 0.1)</td><td>0.475</td><td>0.04 (-0.02; 0.1)</td><td>0.207</td></tr><tr><td>KL score</td><td>0.28 (-0.9; 1.5)</td><td>0.648</td><td></td><td></td><td>-0.29 (-1.2; 0.6)</td><td>0.523</td><td>-0.5 (-1.5; 0.5)</td><td>0.291</td></tr></table> |
8aafca62f429d6a0e39f2613a1da3dfbcf7fb65c54cdaca1c03ddfb64ebbb2f9.png | simple | <table><tr><td></td><td>User-initiated (n = 17)</td><td>Not user-initiated (n = 3)</td></tr><tr><td>User investigator</td><td>14</td><td>–</td></tr><tr><td>External user involved since formulation</td><td>2</td><td>1</td></tr><tr><td>External user involved only in interpretation</td><td>1</td><td>2</td></tr></table> |
d0a82cd7823f8482577e9b052a2b136938f70de68037a45b70461f06e2318765.png | complex | <table><tr><td></td><td>Sole C source<sup>a</sup></td><td colspan="4">Glucosinolate decomposition in horseradish extract Residual amount after 16d (%)<sup>b</sup></td><td colspan="4">Decomposition rate in horseradish extract(mM d<sup>-1</sup>)</td><td colspan="2">IC<sub>50</sub> liquid culture(mM)</td></tr><tr><td>ID</td><td>SGN</td><td>SGN</td><td>GIB</td><td>GLN</td><td>GBR</td><td>SGN</td><td>GIB</td><td>GLN</td><td>GBR</td><td>AITC</td><td>PEITC</td></tr><tr><td><i>E1</i></td><td>+</td><td>0.2 ± 0%</td><td>3.7 ± 0.9%</td><td>0 ± 0%</td><td>17 ± 3.1%</td><td>1.125</td><td>0.006</td><td>0.057</td><td>0.005</td><td>0.2834</td><td>0.0903</td></tr><tr><td><i>E2</i></td><td>+</td><td>0.3 ± 0%</td><td>25.6 ± 1.9%</td><td>0.4 ± 0.1%</td><td>28.1 ± 1.6%</td><td>1.476</td><td>0.002</td><td>0.033</td><td>0.004</td><td>0.2590</td><td>0.1004</td></tr><tr><td><i>E3</i></td><td>+</td><td>3.6 ± 0.8%</td><td>7.4 ± 0.9%</td><td>0.5 ± 0.2%</td><td>6.5 ± 1%</td><td>0.606</td><td>0.003</td><td>0.030</td><td>0.008</td><td>0.1925</td><td>0.0907</td></tr><tr><td><i>E4</i></td><td>+</td><td>0.3 ± 0%</td><td>36.3 ± 12.2%</td><td>0.4 ± 0.3%</td><td>33.9 ± 11.7%</td><td>0.734</td><td>0.003</td><td>0.036</td><td>0.006</td><td>0.1096</td><td>0.0288</td></tr><tr><td><i>E5</i></td><td></td><td>16 ± 18.9%</td><td>85 ± 10.3%</td><td>50.5 ± 14.8%</td><td>71.6 ± 8.1%</td><td>0.624</td><td>0.001</td><td>0.018</td><td>0.003</td><td>0.0920</td><td>0.0404</td></tr><tr><td><i>E6</i></td><td></td><td>0.2 ± 0.1%</td><td>42.5 ± 6.1%</td><td>3.3 ± 1.4%</td><td>26.6 ± 4.6%</td><td>0.783</td><td>0.001</td><td>0.032</td><td>0.006</td><td>0.0764</td><td>0.0328</td></tr><tr><td><i>E7</i></td><td></td><td>110.9 ± 4.9%</td><td>103.5 ± 4.4%</td><td>108.1 ± 2.3%</td><td>92.5 ± 10.1%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.2565</td><td>0.0257</td></tr><tr><td><i>S1</i></td><td>+</td><td>0.1 ± 0%</td><td>5.1 ± 0.2%</td><td>0 ± 0%</td><td>65.3 ± 3.7%</td><td>3.037</td><td>0.007</td><td>0.214</td><td>0.008</td><td>0.1084</td><td>0.1511</td></tr><tr><td><i>S2</i></td><td>+</td><td>0.1 ± 0%</td><td>0 ± 0%</td><td>0 ± 0%</td><td>0 ± 0%</td><td>2.111</td><td>0.015</td><td>0.148</td><td>0.030</td><td>0.0743</td><td>0.0266</td></tr><tr><td><i>S3</i></td><td>+</td><td>85.2 ± 4.9%</td><td>75 ± 1.9%</td><td>74.8 ± 0.6%</td><td>83.9 ± 1%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.2639</td><td>0.0700</td></tr><tr><td><i>S4</i></td><td></td><td>58.7 ± 5.7%</td><td>72 ± 5%</td><td>33.4 ± 5.7%</td><td>47.3 ± 4.7%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.0338</td><td>0.0246</td></tr><tr><td><i>S5</i></td><td></td><td>87.5 ± 18.2%</td><td>101.4 ± 4.6%</td><td>106.7 ± 3.8%</td><td>98.7 ± 2%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.1251</td><td>0.0176</td></tr><tr><td><i>S6</i></td><td></td><td>67.3 ± 12.1%</td><td>61.8 ± 9.4%</td><td>67.4 ± 14.4%</td><td>63.2 ± 10.4%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.0277</td><td>0.0187</td></tr><tr><td><i>S7</i></td><td></td><td>105.2 ± 4.9%</td><td>90.3 ± 3.4%</td><td>95.7 ± 3.6%</td><td>89.8 ± 2.9%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.0930</td><td>0.0738</td></tr><tr><td><i>S8</i></td><td></td><td>100.8 ± 2.5%</td><td>88 ± 4.8%</td><td>87.9 ± 4%</td><td>92.2 ± 3.5%</td><td>-</td><td>-</td><td>-</td><td>-</td><td>0.0867</td><td>0.0149</td></tr><tr><td><i>S9</i></td><td></td><td>0.3 ± 0.2%</td><td>0.1 ± 0.2%</td><td>0.2 ± 0.1%</td><td>0.4 ± 0.1%</td><td>2.982</td><td>0.012</td><td>0.206</td><td>0.018</td><td>0.0221</td><td>0.0553</td></tr><tr><td><i>S10</i></td><td></td><td>0.1 ± 0.1%</td><td>0.1 ± 0.1%</td><td>0.1 ± 0%</td><td>0.2 ± 0%</td><td>2.669</td><td>0.021</td><td>0.178</td><td>0.032</td><td>0.1954</td><td>0.1393</td></tr></table> |
459af3e20a73ed186a64dfd02104267c6201b89993a422b4363b0d43d95b6750.png | complex | <table><tr><td rowspan="2">Markers</td><td colspan="3">Staining intensity</td></tr><tr><td>LNCaP</td><td>Spheres</td><td>Neuroendocrine cells</td></tr><tr><td>Pancytokeratin</td><td>+/−</td><td>-</td><td>+++</td></tr><tr><td>Neuro-specific enolase</td><td>+/−</td><td>−</td><td>+++</td></tr><tr><td>Serotonin</td><td>−</td><td>−</td><td>+</td></tr></table> |
5879d74400fff2a0fee1abde7295eb2e56670744e7ff1627ba2a63e62281075a.png | complex | <table><tr><td></td><td colspan="2">certified CAM</td><td colspan="2">noncertified CAM</td><td colspan="2">COM</td></tr><tr><td></td><td>mean</td><td>median</td><td>mean</td><td>median</td><td>mean</td><td>median</td></tr><tr><td>Number of patients per year</td><td>652</td><td>537</td><td>955</td><td>899</td><td>987</td><td>906</td></tr><tr><td>Number of consultations per year</td><td>2797</td><td>2440</td><td>3811</td><td>3726</td><td>3918</td><td>3783</td></tr><tr><td>- Disease related</td><td>2746</td><td>2421</td><td>3694</td><td>3621</td><td>3822</td><td>3731</td></tr><tr><td>- Accident related</td><td>40</td><td>14</td><td>100</td><td>76</td><td>82</td><td>46</td></tr><tr><td>- Other (maternity, unclassified)</td><td>12</td><td>2</td><td>17</td><td>3</td><td>13</td><td>2</td></tr><tr><td>- Number of home visits</td><td>79</td><td>30</td><td>268</td><td>181</td><td>304</td><td>211</td></tr><tr><td>Number of consultations per patient and year</td><td>4.6</td><td>4.2</td><td>4.1</td><td>3.9</td><td>4.2</td><td>4.0</td></tr></table> |
de88650f784767654f740460224f8791c3fac292a76f58c6a8b555d515d03563.png | simple | <table><tr><td></td><td>EEG normal patients = 53(%)</td><td>EEG abnormal patients = 17(%)</td></tr><tr><td>palpitations, pounding heart, or accelerated heart rate</td><td>44 (83.0)</td><td>13 (76.5)</td></tr><tr><td>sweating</td><td>11 (20.8)</td><td>5 (29.4)</td></tr><tr><td>trembling or shaking</td><td>16 (30.2)</td><td>5 (29.4)</td></tr><tr><td>sensations of shortness of breath or smothering</td><td>40 (75.5)</td><td>13 (76.5)</td></tr><tr><td>feeling of choking</td><td>13 (24.5)</td><td>4 (23.5)</td></tr><tr><td>chest pain or discomfort</td><td>22 (41.5)</td><td>7 (41.2)</td></tr><tr><td>nausea or abdominal distress</td><td>20 (37.7)</td><td>14 (82.4)</td></tr><tr><td>feeling dizzy, unsteady, lightheaded, or faint</td><td>38 (71.7)</td><td>15 (88.2)</td></tr><tr><td>derealization or depersonalization</td><td>4 (7.5)</td><td>8 (47.1)</td></tr><tr><td>fear of losing control or going crazy</td><td>23 (43.4)</td><td>11 (64.7)</td></tr><tr><td>fear of dying</td><td>16 (30.2)</td><td>5 (29.4)</td></tr><tr><td>paresthesias</td><td>23 (43.4)</td><td>11 (64.7)</td></tr><tr><td>chills or hot flushes</td><td>11 (20.8)</td><td>7 (41.2)</td></tr><tr><td>age</td><td>34.6 ± 9.3</td><td>33.9 ± 9.8</td></tr><tr><td>sex</td><td>M:17F:36</td><td>M: 3F:14</td></tr></table> |
b437aa1cbb4de1c618f46cd438b08b3db303afaff4a9452232dee00d3233fba7.png | simple | <table><tr><td>Costs per patient in different situation in CHF</td><td>CMR strategy</td><td>“hypothetical” CXA strategy</td></tr><tr><td>All tests performed as outpatient procedures in Switzerland</td><td>1,984</td><td>2,580</td></tr><tr><td>CXA performed as an inpatient procedure in Switzerland</td><td>2,408</td><td>4,638</td></tr></table> |
ce6d01ae0973473cd8314cd28323b2535b8b0481f580c51ae468c9225d561682.png | simple | <table><tr><td>Sensor</td><td>Targeted Gases</td><td>Smell Description</td></tr><tr><td>TGS 880</td><td>volatile vapors from food</td><td>food (while cooking)</td></tr><tr><td>TGS 825</td><td>hydrogen sulfide</td><td>rotten egg, sulfurous smells</td></tr><tr><td>TGS 826</td><td>ammonia</td><td>old rotten urine and fish (sharp, penetrating, and irritating smell)</td></tr><tr><td>TGS 822</td><td>alcohol, xylene, toluene, other VOC</td><td>aromatic solvents, wood fermentation, alcoholic beverages</td></tr><tr><td>TGS 2610</td><td>general hydrocarbons</td><td>smell of ripening fruits</td></tr><tr><td>TGS 2602</td><td>ammonia, hydrogen sulfide,ethanol, toluene</td><td>a wide range of smell: from rotten fish to wood fermentattion</td></tr></table> |
c1280e044d183ed076bda2f4629bfa0dfd6dce1ae748443673f66da0cf9e39dd.png | complex | <table><tr><td></td><td></td><td colspan="2">Haplo2Ped</td><td colspan="2">Merlin</td><td></td></tr><tr><td>Chr</td><td>Expected region<sup>a</sup>(bp)</td><td>Detected region (bp)</td><td>LOD score</td><td>Detected region (bp)</td><td>LOD score</td><td>SNPLINK<sup>b</sup></td></tr><tr><td>1</td><td>216,655,820-217,662,693</td><td>216,631,505-217,703,573</td><td>3.010</td><td>216,907,787-217,662,692</td><td>1.773</td><td>217,005,036-217,668,715</td></tr><tr><td>5</td><td>38,764,018-41,787,459</td><td>38,631,518-42,305,421</td><td>3.010</td><td>38,854,039-41,712,049</td><td>1.777</td><td>38,886,647-42,163,690</td></tr><tr><td>9</td><td>27,316,060-31,341,194</td><td>27,143,875-31,616,167</td><td>3.010</td><td>27,319,623-31,394,530</td><td>1.777</td><td>27,306,972-31,369,980</td></tr><tr><td>13</td><td>96,346,535-101,352,382</td><td>96,316,072101,404,566</td><td>3.010</td><td>96,328,971-101,304,534</td><td>1.778</td><td>96,836,579-101,356,932</td></tr><tr><td>17</td><td>50,661,600-54,645,983</td><td>50,621,012-54,818,763</td><td>3.010</td><td>50,690,828-58,850,202</td><td>1.804</td><td>50,661,601-54,726,213</td></tr><tr><td>21</td><td>21,812,513-26,812,202</td><td>21,781,794-27,090,473</td><td>3.010</td><td>21,833,903-26,812,201</td><td>1.778</td><td>21,812,514-26,818,797</td></tr><tr><td>1</td><td>/</td><td>/</td><td>/</td><td>55,489,086-62,400,262</td><td>1.778</td><td>/</td></tr><tr><td>5</td><td>/</td><td>/</td><td>/</td><td>10,529,760- 11,796,160</td><td>1.778</td><td>/</td></tr><tr><td>9</td><td>/</td><td>/</td><td>/</td><td>73,498,210- 80,047,165</td><td>1.778</td><td>/</td></tr></table> |
163eeedc88e6fcf434458356250a300703605399fe06dc44731b63c212458947.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">5-HT (ng/mL)</td><td colspan="2">NA (ng/mL)</td><td colspan="2"><i>β</i>-EP (ng/mL)</td></tr><tr><td>Brain tissue</td><td>Plasma </td><td>Brain tissue</td><td>Plasma</td><td>Brain tissue </td><td>Plasma</td></tr><tr><td>Normal group</td><td>144.39 ± 30.36</td><td>467.71 ± 86.01</td><td>3.92 ± 0.72</td><td>15.23 ± 2.66</td><td>0.28 ± 0.10</td><td>2.57 ± 0.45</td></tr><tr><td>Model group</td><td>259.38 ± 74.48<sup>#</sup></td><td>549.9 ± 90.1<sup>#</sup></td><td>4.8 ± 1.3<sup>#</sup></td><td>18.5 ± 1.9<sup>#</sup></td><td>0.15 ± 0.08<sup>#</sup></td><td>3.47 ± 1.68<sup>#</sup></td></tr><tr><td>SFZYD group (5.4 g kg<sup>−1</sup>)</td><td>183.49 ± 89.99*</td><td>492.79 ± 72.14*</td><td>4.33 ± 1.46</td><td>16.95 ± 5.11*</td><td>0.24 ± 0.09*</td><td>2.38 ± 1.42*</td></tr><tr><td>SFZYD group (10.8 g kg<sup>−1</sup>)</td><td>153.56 ± 76.32**</td><td>458.24 ± 81.56**</td><td>3.85 ± 1.45*</td><td>15.87 ± 4.36**</td><td>0.34 ± 0.12*</td><td>2.56 ± 1.89*</td></tr></table> |
0f5641ee76026eb455fcac619842a8ca9abec6ff2d64e40338f5369b2f56d43f.png | simple | <table><tr><td>Variables</td><td>B</td><td>SE</td><td>Sig.</td><td>AOR</td><td>95.0 % C.I. for Exp (B)</td></tr><tr><td>Insufficient family time</td><td>.760</td><td>0.338</td><td><i>.025</i></td><td>2.138</td><td>1.102, 4.148</td></tr><tr><td>Unsatisfactory doctor behaviour</td><td>.322</td><td>0.375</td><td>.391</td><td>1.380</td><td>0.662, 2.878</td></tr><tr><td>Unsatisfactory manager behaviour</td><td>.692</td><td>0.343</td><td><i>.044</i></td><td>1.999</td><td>1.020, 3.915</td></tr><tr><td>No sales achievement award</td><td>.738</td><td>0.414</td><td>.075</td><td>2.092</td><td>0.929, 4.711</td></tr><tr><td>No annual sales conference</td><td>.412</td><td>0.427</td><td>.335</td><td>1.509</td><td>0.653, 3.485</td></tr><tr><td>Monthly income less than 36,000 PKR</td><td>.604</td><td>0.379</td><td>.111</td><td>1.829</td><td>0.871, 3.842</td></tr></table> |
b227c0fa2f82081c4079df9eecc5fcc0369597b55fc8e433cfabc4ee364a7462.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">PinX1</td></tr><tr><td>Positive</td><td>Negative</td><td><i>P</i></td></tr><tr><td><i>Sex</i></td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>34</td><td>74</td><td> </td></tr><tr><td>Female</td><td>7</td><td>43</td><td>0.020</td></tr><tr><td><i>Age</i></td><td> </td><td> </td><td> </td></tr><tr><td><60 years</td><td>19</td><td>52</td><td> </td></tr><tr><td>≥60 years</td><td>22</td><td>65</td><td>0.834</td></tr><tr><td><i>Smoking status</i></td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>34</td><td>76</td><td> </td></tr><tr><td>No</td><td>7</td><td>41</td><td>0.034</td></tr><tr><td><i>Histology</i></td><td> </td><td> </td><td> </td></tr><tr><td>Squamous</td><td>36</td><td>65</td><td> </td></tr><tr><td>Adenocarcinoma</td><td>5</td><td>52</td><td>0.000</td></tr><tr><td><i>Lesion</i></td><td> </td><td> </td><td> </td></tr><tr><td>Peripheral</td><td>28</td><td>83</td><td> </td></tr><tr><td>Central</td><td>13</td><td>34</td><td>0.750</td></tr><tr><td><i>Tumour location</i></td><td> </td><td> </td><td> </td></tr><tr><td>Left</td><td>17</td><td>48</td><td> </td></tr><tr><td>Right</td><td>24</td><td>69</td><td>0.961</td></tr><tr><td><i>Resection type</i></td><td> </td><td> </td><td> </td></tr><tr><td>Lobectomy</td><td>35</td><td>95</td><td> </td></tr><tr><td>Pneumonectomy</td><td>3</td><td>19</td><td> </td></tr><tr><td>Other</td><td>3</td><td>3</td><td>0.163</td></tr><tr><td><i>Metastasis</i></td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>15</td><td>67</td><td> </td></tr><tr><td>No</td><td>26</td><td>50</td><td>0.023</td></tr><tr><td><i>T stage</i></td><td> </td><td> </td><td> </td></tr><tr><td>T1</td><td>6</td><td>41</td><td> </td></tr><tr><td>T2 + T3</td><td>35</td><td>76</td><td>0.013</td></tr><tr><td><i>N stage</i></td><td> </td><td> </td><td> </td></tr><tr><td>N0</td><td>46</td><td>24</td><td> </td></tr><tr><td>N1 + N2</td><td>17</td><td>71</td><td>0.033</td></tr><tr><td><i>TNM stage</i></td><td> </td><td> </td><td> </td></tr><tr><td>I</td><td>13</td><td>31</td><td> </td></tr><tr><td>II</td><td>17</td><td>32</td><td> </td></tr><tr><td>III</td><td>11</td><td>54</td><td>0.082</td></tr></table> |
cc800ef143a7d45c6c92eee545b521988b3267a136c477e31686e86d81cbc25b.png | simple | <table><tr><td></td><td>2010</td><td>2011</td><td>2012</td><td>2013</td></tr><tr><td>Birth attendant, N (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Physician</td><td>1,241 (32.1)</td><td>1,547 (37.8)</td><td>1,851 (45.4)</td><td>2,416 (52.9)</td></tr><tr><td>Nurse/Midwife/HW</td><td>39 (1.0)</td><td>96 (2.3)</td><td>89 (2.2)</td><td>95 (2.1)</td></tr><tr><td>TBA</td><td>2,575 (66.6)</td><td>2,433 (59.5)</td><td>2,121 (52.1)</td><td>2,028 (44.4)</td></tr><tr><td>Family/Other</td><td>14 (0.4)</td><td>12 (0.3)</td><td>12 (0.3)</td><td>31 (0.7)</td></tr><tr><td>Delivery location, N (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Hospital</td><td>1,162 (30.0)</td><td>1,570 (38.4)</td><td>1,814 (44.5)</td><td>2,297 (50.3)</td></tr><tr><td>Clinic</td><td>104 (2.7)</td><td>56 (1.4)</td><td>121 (3.0)</td><td>215 (4.7)</td></tr><tr><td>Home/Other</td><td>2,603 (67.3)</td><td>2,462 (60.2)</td><td>2,138 (52.5)</td><td>2,058 (45.0)</td></tr><tr><td>Delivery mode, N (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Vaginal</td><td>3,350 (86.6)</td><td>3,402 (83.2)</td><td>3,251 (79.8)</td><td>3,461 (75.7)</td></tr><tr><td>Vaginal assisted</td><td>4 (0.1)</td><td>4 (0.1)</td><td>12 (0.3)</td><td>0 (0.0)</td></tr><tr><td>C-section</td><td>515 (13.3)</td><td>682 (16.7)</td><td>809 (19.9)</td><td>1,109 (24.3)</td></tr><tr><td>Maternal antibiotics, N (%)</td><td>405 (12.6)</td><td>675 (17.0)</td><td>950 (24.2)</td><td>1,373 (30.7)</td></tr><tr><td>Oxytocics, N (%)</td><td>602 (18.7)</td><td>1,014 (25.5)</td><td>1,155 (29.5)</td><td>1,779 (40.0)</td></tr><tr><td>Blood transfusion, N (%)</td><td>6 (0.2)</td><td>9 (0.2)</td><td>11 (0.3)</td><td>29 (0.7)</td></tr><tr><td>Clean razor</td><td></td><td></td><td></td><td></td></tr><tr><td>Fetal heart rate taken, N (%)</td><td>1,381 (35.7)</td><td>1,933 (47.3)</td><td>3,340 (82.0)</td><td>3,811 (83.4)</td></tr><tr><td>BA gloves used, N (%)</td><td>3,750 (98.4)</td><td>4,043 (99.3)</td><td>4,011 (99.2)</td><td>4,503 (99.2)</td></tr><tr><td>Bag and mask resuscitation, N (%)</td><td>28 (0.7)</td><td>23 (0.6)</td><td>29 (0.7)</td><td>76 (1.7)</td></tr><tr><td>Breastfeed <1 hr after delivery, N (%)</td><td>2,729 (83.6)</td><td>3,346 (81.9)</td><td>3,200 (78.5)</td><td>3,072 (67.1)</td></tr></table> |
c0eabd9ad46508ce6666bc7ff7598957651a35c43bb4a712cbca0805f320e778.png | complex | <table><tr><td>Toxicity</td><td colspan="6">Grade</td></tr><tr><td></td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>≥Grade 3 (%)</td></tr><tr><td>Leukopenia</td><td>26</td><td>16</td><td>17</td><td>3</td><td>0</td><td>5</td></tr><tr><td>Neutropenia</td><td>32</td><td>14</td><td>11</td><td>5</td><td>0</td><td>8</td></tr><tr><td>Anemia</td><td>28</td><td>31</td><td>3</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Thrombocytopenia</td><td>33</td><td>27</td><td>2</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Mucositis</td><td>1</td><td>15</td><td>45</td><td>1</td><td>0</td><td>2</td></tr><tr><td>Dermatitis</td><td>1</td><td>58</td><td>2</td><td>1</td><td>0</td><td>2</td></tr><tr><td>Hoarseness</td><td>45</td><td>12</td><td>4</td><td>1</td><td>0</td><td>2</td></tr></table> |
54ac50f4d11ed300d98c9603590bea57828d041242ebb56bc0170cdd99173d89.png | complex | <table><tr><td>Groups</td><td colspan="2">Number of patients</td><td colspan="2">Age, y (Mean ± SD)</td></tr><tr><td rowspan="2">PEX</td><td rowspan="2">39</td><td>F—18</td><td rowspan="2">76.49 ± 6.54</td><td>F—79.44 ± 5.24</td></tr><tr><td>M—21</td><td>M—73.95 ± 6.59</td></tr><tr><td rowspan="2">PEXG</td><td rowspan="2">37</td><td>F—18</td><td rowspan="2">78.22 ± 7.58</td><td>F—77.06 ± 6.58</td></tr><tr><td>M—19</td><td>M—79.32 ± 8.45</td></tr><tr><td rowspan="2">CNT</td><td rowspan="2">46</td><td>F—21</td><td rowspan="2">76.65 ± 7.26</td><td>F—79.67 ± 7.14</td></tr><tr><td>M—25</td><td>M—74.12 ± 7.20</td></tr></table> |
90a31180734c8c8c5084121d9b335f320b436b6f01557614fb633928ce08e996.png | complex | <table><tr><td>Study</td><td>Subgroups by MP status</td><td>Exposure categories (<i>n</i>)</td><td>Oldest/Youngest age category</td><td colspan="2">RR (95% CI) for oldest vs. youngest age category</td></tr><tr><td></td><td></td><td></td><td></td><td>ER<sup>+</sup>PR<sup>+</sup></td><td>ER<sup>-</sup>PR<sup>-</sup></td></tr><tr><td colspan="6">Cohort studies</td></tr><tr><td>[9]</td><td>Post-MP</td><td>2</td><td>≥13/<13</td><td>0.69 (0.56–0.85)</td><td>1.07 (0.67–1.71)</td></tr><tr><td>[10]</td><td>All women</td><td>2</td><td>15/11</td><td>0.68 (0.62–0.73)</td><td>0.78 (0.68–0.89)</td></tr><tr><td colspan="4">Summary RRs for cohort studies</td><td>0.68 (0.59–0.79)</td><td>0.80 (0.69–0.93)</td></tr><tr><td colspan="6">Population-based case-control studies</td></tr><tr><td>[11]</td><td>All women</td><td>2</td><td>≥12/<12</td><td>0.67 (0.50–0.91)</td><td>0.91 (0.67–1.43)</td></tr><tr><td></td><td>Pre-MP</td><td>2</td><td>≥12/<12</td><td>0.67 (0.4–1.0)</td><td>1.11 (0.67–1.67)</td></tr><tr><td></td><td>Post-MP</td><td>2</td><td>≥12/<12</td><td>0.63 (0.42–1.0)</td><td>0.77 (0.45–1.43)</td></tr><tr><td>[12]</td><td>Young</td><td>2</td><td>≥13/<13</td><td>0.77 (0.63–0.94)</td><td>0.78 (0.61–1.00)</td></tr><tr><td>[13]</td><td>All women</td><td>4</td><td>≥14/<12</td><td>0.72 (0.52–0.99)</td><td>0.99 (0.63–1.53)</td></tr><tr><td></td><td>Pre-MP</td><td>4</td><td>≥14/<12</td><td>0.49 (0.31–0.76)</td><td>1.12 (0.62–2.03)</td></tr><tr><td></td><td>Post-MP</td><td>4</td><td>≥14/<12</td><td>0.84 (0.64–1.10)</td><td>0.94 (0.64–1.37)</td></tr><tr><td>[14]</td><td>Young</td><td></td><td>≥13/<13</td><td>0.8 (0.6–1.1)</td><td>0.6 (0.4–0.9)</td></tr><tr><td>[8]</td><td>Young</td><td>4</td><td>≥14/<12</td><td>0.60 (0.42–0.86)</td><td>0.59 (0.38–0.92)</td></tr><tr><td colspan="4">Summary RRs for population-based case-control studies</td><td>0.73 (0.59–0.89)</td><td>0.77 (0.63–0.94)</td></tr><tr><td colspan="6">Hospital-based case-control studies</td></tr><tr><td>[15]</td><td>All women</td><td>Per 2 years↑</td><td>2 years' increase</td><td>0.83 (0.68–1.01)</td><td>1.11 (0.91–1.36)</td></tr><tr><td>16</td><td>All women</td><td>3</td><td>≥14/<12</td><td>1.0 (0.53–-2.00)</td><td>1.43 (0.71–2.50)</td></tr><tr><td colspan="4">Summary RRs for hospital-based case-control studies</td><td>0.84 (0.64–1.10)</td><td>1.14 (0.87–1.49)</td></tr><tr><td>Summary RRs by MP status</td><td>Pre-MP/Young</td><td></td><td></td><td>0.71 (0.57–0.88)</td><td>0.77 (0.62–0.95)</td></tr><tr><td></td><td>Post-MP</td><td></td><td></td><td>0.74 (0.54–1.01)</td><td>0.95 (0.70–1.30)</td></tr><tr><td colspan="4">Summary RRs for all studies</td><td>0.72 (0.64–0.80)</td><td>0.84 (0.75–0.94)</td></tr><tr><td colspan="4"><i>P </i>for homogeneity between ER<sup>+</sup>PR<sup>+ </sup>and ER<sup>-</sup>PR<sup>- </sup>cancer</td><td colspan="2"><i>p </i>= <i>0.006</i></td></tr></table> |
87873dde909ad18a54dc1be97b108f6f2071bf0414f6541d851a6dd8a6ac9379.png | simple | <table><tr><td>Test substance</td><td>Tomato extract in squalane</td><td>Tomato extract in hydrogenated polydecene</td><td><i>Dunaliella</i> extract in hydrogenated polydecene</td></tr><tr><td>Reactions noted</td><td>None</td><td>None</td><td>None</td></tr><tr><td># reactive subjects (%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td>MDIS</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Conclusion</td><td>Very good skin compatibility/nonirritant</td><td>Very good skin compatibility/nonirritant</td><td>Very good skin compatibility/nonirritant</td></tr></table> |
ce128344d35e425ba160bb6bb32e6639bd0992a0ad84aa8c4ed3d8d248df9739.png | complex | <table><tr><td>Antibiotic</td><td colspan="2">Proportion susceptible (%)</td></tr><tr><td> </td><td>MSSA (n = 80)</td><td>MRSA (n = 6)</td></tr><tr><td>Cefoxitin</td><td>100</td><td>0</td></tr><tr><td>Benzylpenicillin</td><td>26</td><td>0</td></tr><tr><td>Co-trimoxazole</td><td>60</td><td>0</td></tr><tr><td>Tetracycline</td><td>85</td><td>0</td></tr><tr><td>Gentamicin</td><td>99</td><td>0</td></tr><tr><td>Ciprofloxacin</td><td>100</td><td>0</td></tr><tr><td>Erythromicin/Clindamycin</td><td>99</td><td>17</td></tr><tr><td>Rifampicin</td><td>99</td><td>83</td></tr><tr><td>Chloramphenicol</td><td>100</td><td>100</td></tr><tr><td>Vancomycin</td><td>100</td><td>100</td></tr><tr><td>Mupirocin</td><td>100</td><td>100</td></tr></table> |
480fc69c231ce1047b70be246c51c4d3ec953c67ecd648087d130a5e0e826c81.png | simple | <table><tr><td>Polymer Type</td><td>LOD</td><td>Response Time/Recovery Time</td><td>Transducing Mechanism</td><td>Ref.</td></tr><tr><td>PPy nanoparticles</td><td>5 ppm</td><td>Less than 1 s/2 s</td><td>Chemiresistive</td><td>[58]</td></tr><tr><td>Multidimensional PPy nanotubes</td><td>0.01 ppm</td><td>Less than 1 s/55–60 s</td><td>Chemiresistive</td><td>[113]</td></tr><tr><td>Single PPy nanowire</td><td>40 ppm</td><td>15–10 min (for 40–300 ppm)/15 min for 40 ppm</td><td>Chemiresistive</td><td>[36]</td></tr><tr><td>PPy nanowires</td><td>1.5 ppm</td><td>60 s for 73 ppm/prolonged with increasing of con. (1.5–73 ppm)</td><td>Chemiresistive</td><td>[18]</td></tr><tr><td>Single crystal PPy nanotube</td><td>0.00005 ppm</td><td>~16 s/~16 s for 1 ppm</td><td>Chemiresistive</td><td>[114]</td></tr><tr><td>PPy nanoribbons</td><td>0.5 ppm</td><td>~8 min/3 min</td><td>Chemiresistive</td><td>[62]</td></tr><tr><td>PPy nanotubes PPy/Ag–AgCl composite Nanotubes</td><td>–</td><td>>1000 s for 100 ppm/−150 s for 100 ppm/500 s</td><td>Chemiresistive</td><td>[115]</td></tr><tr><td>PPy/ZnO nanocomposite PPy/SnO<sub>2</sub> nanocomposite</td><td>10 ppm</td><td>~100 s for 24 ppm/100 s ~50 s for 24 ppm/250 s for first 3 cycles</td><td>Chemiresistive</td><td>[13]</td></tr><tr><td>PPy/graphene nanocomposite decorated with TiO<sub>2</sub> nanoparticles</td><td>1 ppm</td><td>~36 s/~16 s for 50 ppm</td><td>Chemiresistive</td><td>[116]</td></tr><tr><td>Au/PPy nanopeapods</td><td>0.007 ppm<sub>v</sub></td><td>~15 min for 5 ppm<sub>v</sub>/did not reach R<sub>o</sub> value</td><td>Chemiresistive</td><td>[117]</td></tr></table> |
b0100cd964f5c56840a0f9a54fe6b6ff953a7302a1d866bd3dd2aefa92df8631.png | simple | <table><tr><td>Variable</td><td>HIV-1-seronegative psoriasis</td><td>HIV-1-related psoriasis</td><td>References</td></tr><tr><td>Frequency</td><td>1-3%</td><td>Similar to HIV-seronegative population</td><td>[54,55]</td></tr><tr><td>Severity</td><td>Mild-moderate</td><td>Moderate-severe</td><td>[62]</td></tr><tr><td>Clinical features</td><td>Erythematous plaques usually circumscribed to elbows-knees (psoriasis vulgaris)</td><td>More extensive lesionsIncreased presence of acral lesions and inverse psoriasis</td><td>[4,55]</td></tr><tr><td>Histhopatological features</td><td>Hyperproliferation and hyperkeratosis, lymphocytic infiltrate and absence of granular layer</td><td>Same</td><td>[55]</td></tr><tr><td>Presence of psoriatic arthritis</td><td>5-20%</td><td>23%-50%</td><td>[54,55]</td></tr><tr><td>Mean age of presentation</td><td>>30 years</td><td>=30 years</td><td>[63]</td></tr><tr><td>Family history</td><td>Frequent</td><td>Variable</td><td>[64]</td></tr><tr><td>Presence of HLA-Cw*0602</td><td>25%</td><td>79%</td><td>[64]</td></tr><tr><td>Presence of Reiter's Syndrome</td><td>Rare</td><td>Frequent</td><td>[54]</td></tr><tr><td>Development of erythroderma</td><td>+/+++</td><td>++/+++</td><td>[65]</td></tr><tr><td>Response to conventional treatment (topical steroids, Vitamin D analogues, phototherapy)</td><td>Variable</td><td>Variable-poor</td><td>[63,66]</td></tr><tr><td>Response to zidovudine/HAART</td><td>+/+++</td><td>++/+++</td><td>[67,68]</td></tr></table> |
bd68894349e1251d1922305a293510be9fe3e50fe467603a026af5cb01c1ef41.png | complex | <table><tr><td colspan="2">Characteristic</td><td colspan="4">Region</td><td>Overall</td></tr><tr><td> </td><td> </td><td>Southern</td><td>Highlands</td><td>Momase</td><td>Islands</td><td> </td></tr><tr><td colspan="2">Female n (%)</td><td>64 (51)</td><td>50 (46)</td><td>56 (46)</td><td>51 (47)</td><td>221 (47)</td></tr><tr><td>Age n (%)</td><td>0–4 yrs</td><td>60 (48)</td><td>48 (46)</td><td>58 (48)</td><td>49 (45)</td><td>215 (47)</td></tr><tr><td> </td><td>5–15 yrs</td><td>31 (24)</td><td>14 (14)</td><td>30 (25)</td><td>35 (33)</td><td>110 (24)</td></tr><tr><td> </td><td>16+ yrs</td><td>35 (28)</td><td>41 (40)</td><td>32 (27)</td><td>24 (22)</td><td>132 (29)</td></tr></table> |
cc7e7bb77725523efc9a0c1f2d20134a765065e09757563ee06345aa3a1b2b8e.png | simple | <table><tr><td>Group</td><td>Hoffman cluster</td><td>Species, subspecies, or complex</td><td>Type strain</td><td>Accession no.</td><td>No. of strains</td></tr><tr><td>A</td><td>VI</td><td><i>E. xiangfangensis</i></td><td>LMG 27195<sup>a</sup></td><td>NZ_CP017183.1</td><td>3</td></tr><tr><td>B</td><td>VIII</td><td><i>E. hormaechei</i> subsp. <i>steigerwaltii</i></td><td>DSM 16691<sup>a</sup></td><td>NZ_CP017179.1</td><td>83</td></tr><tr><td>C</td><td>VI</td><td><i>E. hormaechei</i> subsp. <i>oharae</i></td><td>DSM 16687<sup>a</sup></td><td>NZ_CP017180.1</td><td>104</td></tr><tr><td>D</td><td>III</td><td><i>E. hormaechei</i></td><td>DSM 14563<sup>a</sup></td><td>NZ_CP017186.1</td><td>30</td></tr><tr><td>E</td><td>VII</td><td><i>E. hormaechei</i> subsp. <i>hormaechei</i></td><td>ATCC 49162</td><td>GCA_000213995.1</td><td>5</td></tr><tr><td>F</td><td></td><td><i>E. mori</i></td><td>LMG 25706</td><td>AEXB00000000</td><td>1</td></tr><tr><td>G</td><td>XI</td><td><i>E. cloacae</i> subsp. <i>cloacae</i></td><td>ATCC 13047</td><td>NC_014121.1</td><td>11</td></tr><tr><td>H</td><td>XII</td><td><i>E. cloacae</i> subsp. <i>dissolvens</i></td><td></td><td></td><td>4</td></tr><tr><td>I</td><td>V</td><td><i>E. ludwigii</i></td><td>EN-119</td><td>CP017279.1</td><td>11</td></tr><tr><td>J</td><td>I</td><td><i>E. asburiae</i></td><td>ATCC 35953</td><td>NZ_CP011863.1</td><td>30</td></tr><tr><td>K</td><td></td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>6</td></tr><tr><td>L</td><td></td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>7</td></tr><tr><td>M</td><td>IV</td><td><i>E. cloacae</i> complex</td><td>DSM 16690<sup>a</sup></td><td>NZ_CP017184.1</td><td>31</td></tr><tr><td>N</td><td></td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>3</td></tr><tr><td>O</td><td></td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>1</td></tr><tr><td>P</td><td></td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>4</td></tr><tr><td>Q</td><td>II</td><td><i>E. kobei</i></td><td>DSM 13645<sup>a</sup></td><td>NZ_CP017181.1</td><td>31</td></tr><tr><td>R</td><td>IX</td><td><i>E. cloacae</i> complex</td><td></td><td></td><td>14</td></tr></table> |
deaa8e348011dbd4018aa567c9bb1eb5c361d8644db74927d5e27f9ab26c6cd1.png | complex | <table><tr><td rowspan="3"></td><td colspan="2">GDM 2007–2008</td><td colspan="2">No GDM 2007–2008</td><td rowspan="3">p value</td></tr><tr><td colspan="2">(n = 62,958)</td><td colspan="2">(n = 1,452,429)</td></tr><tr><td>Size</td><td>(%)</td><td>Size</td><td>(%)</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td> <20</td><td>520</td><td>0.83</td><td>42,313</td><td>2.91</td><td></td></tr><tr><td> 20–29</td><td>21,471</td><td>34.10</td><td>706,688</td><td>48.66</td><td></td></tr><tr><td> 30–39</td><td>35,922</td><td>57.06</td><td>656,693</td><td>45.21</td><td></td></tr><tr><td> ≥40</td><td>5045</td><td>8.01</td><td>46,735</td><td>3.22</td><td></td></tr><tr><td>Obesity</td><td>8122</td><td>12.90</td><td>56,142</td><td>3.87</td><td><0.0001</td></tr><tr><td>Subsequent diabetes</td><td>1266</td><td>2.01</td><td>1674</td><td>0.12</td><td><0.0001</td></tr><tr><td>Hypertensive disorders during pregnancy</td><td>4834</td><td>7.68</td><td>42,012</td><td>2.89</td><td><0.0001</td></tr><tr><td>Angina pectoris</td><td>64</td><td>0.10</td><td>570</td><td>0.04</td><td><0.0001</td></tr><tr><td colspan="6">Myocardial infarction</td></tr><tr><td> Acute myocardial infarction</td><td>26</td><td>0.04</td><td>257</td><td>0.02</td><td><0.0001</td></tr><tr><td> Repeated myocardial infarction</td><td>0</td><td>0</td><td>2</td><td>0</td><td>1</td></tr><tr><td> Complications of acute myocardial infarction</td><td>0</td><td>0</td><td>11</td><td>0</td><td>1</td></tr><tr><td colspan="6">Stroke</td></tr><tr><td> Ischemic stroke</td><td>71</td><td>0.11</td><td>1181</td><td>0.09</td><td><0.05</td></tr><tr><td> Vascular syndromes of brain in cerebrovascular diseases</td><td>9</td><td>0.01</td><td>160</td><td>0.01</td><td>0.34</td></tr><tr><td> Transient cerebral ischemic attacks</td><td>59</td><td>0.09</td><td>1219</td><td>0.08</td><td>0.06</td></tr><tr><td>Hypertensives diseases</td><td>1566</td><td>2.49</td><td>10,586</td><td>0.73</td><td><.0001</td></tr><tr><td>Therapeutic measures<sup>a</sup></td><td>32</td><td>0.05</td><td>236</td><td>0.02</td><td><.0001</td></tr></table> |
5dc2b9d89bc614985b245ae403e7617f8ebb34de2c79841b7b23e9ece41bbf96.png | complex | <table><tr><td>Variables</td><td>Patients number</td><td>%</td></tr><tr><td>Age (mean ± SD) days</td><td colspan="2">6.7 ± 2.3</td></tr><tr><td>Body weight (mean ± SD) kg</td><td colspan="2">3.4 ± 0.3</td></tr><tr><td colspan="3">Gender</td></tr><tr><td> Male</td><td>13</td><td>68.4</td></tr><tr><td> Female</td><td>6</td><td>31.6</td></tr><tr><td colspan="3">Diagnosis</td></tr><tr><td> TGA with VSD</td><td>2</td><td>10.5</td></tr><tr><td> Taussig–Bing</td><td>17</td><td>89.5</td></tr><tr><td colspan="3">Arch anomaly</td></tr><tr><td> Coarctation of aorta</td><td>13</td><td>68.4</td></tr><tr><td> Interruption</td><td>6</td><td>31.6</td></tr><tr><td> Type A</td><td>2</td><td>10.5</td></tr><tr><td> Type B</td><td>4</td><td>21.1</td></tr><tr><td colspan="3">Coronary artery pattern</td></tr><tr><td> 1L,Cx; 2R</td><td>8</td><td>42.1</td></tr><tr><td> 1L; 2Cx,R</td><td>2 (1RP)</td><td>10.5</td></tr><tr><td> 1R; 2L,Cx</td><td>3 (2RP)</td><td>15.8</td></tr><tr><td> 1R,L; 2Cx</td><td>1 (RP)</td><td>5.3</td></tr><tr><td> 2L,Cx,R</td><td>1 (IM)</td><td>5.3</td></tr><tr><td> 2L,Cx; 2R</td><td>3 (1RP, 1IM)</td><td>15.8</td></tr><tr><td> 2R; 2L,Cx</td><td>1 (RP)</td><td>5.3</td></tr><tr><td colspan="3">Relation of gas</td></tr><tr><td> Anteroposterior</td><td>4</td><td>21.1</td></tr><tr><td> Side by side</td><td>15</td><td>78.9</td></tr><tr><td>PGE1</td><td>19</td><td>100</td></tr><tr><td>Mechanical ventilation</td><td>3</td><td>15.8</td></tr></table> |
af38c4b96abf1ee8fea24c6f3251462f4ec5236e9258e011b4fed4e0e7224131.png | complex | <table><tr><td></td><td></td><td>Odds ratio</td><td colspan="2">95 % confidence intervals</td></tr><tr><td></td><td></td><td></td><td>Lower</td><td>Upper</td></tr><tr><td>Tobacco</td><td>Follow-up vs. Baseline</td><td>1.020</td><td>0.223</td><td>4.661</td></tr><tr><td>Nutrition</td><td>Follow-up vs. Baseline</td><td>1.555</td><td>0.814</td><td>2.972</td></tr><tr><td>Physical activity</td><td>Follow-up vs. Baseline</td><td>0.946</td><td>0.476</td><td>1.879</td></tr><tr><td>Screening</td><td>Follow-up vs. Baseline</td><td>2.788*</td><td>1.166</td><td>6.663</td></tr><tr><td>Clinical trials</td><td>Follow-up vs. Baseline</td><td>3.118*</td><td>1.372</td><td>7.083</td></tr></table> |
53529ac023b1ee483f3c74ed9b87a3a53d950c010c03766174617674b28f75e1.png | complex | <table><tr><td>Populations and risk factors</td><td colspan="2">ET-1 (nM/L)</td><td><i>p</i></td></tr><tr><td rowspan="2">Gender</td><td>Men (n = 121)</td><td>17.4 ± 4.6</td><td rowspan="2"><0.00001</td></tr><tr><td>Women (n = 36)</td><td>7.8 ± 2.3</td></tr><tr><td rowspan="2">Hypertension</td><td>Yes (n = 138)</td><td>16.4 ± 3.3</td><td rowspan="2"><0.00001</td></tr><tr><td>No (n = 19)</td><td>6.6 ± 1.9</td></tr><tr><td rowspan="2">Diabetes</td><td>Yes (n = 101)</td><td>15 ± 5.1</td><td rowspan="2">NS</td></tr><tr><td>No (n = 56)</td><td>15.6 ± 3.8</td></tr><tr><td rowspan="2">Tobacco</td><td>Yes (n = 98)</td><td>11.6 ± 3</td><td rowspan="2"><0.00001</td></tr><tr><td>No (n = 59)</td><td>21.2 ± 6.1</td></tr><tr><td rowspan="2">Personal cardiovascular antecedents</td><td>Yes (n = 104)</td><td>15.3 ± 4.4</td><td rowspan="2">NS</td></tr><tr><td>No (n = 53)</td><td>15 ± 2.8</td></tr><tr><td rowspan="2">Obesity</td><td>Yes (n = 82)</td><td>12.2 ± 5.3</td><td rowspan="2"><0.001</td></tr><tr><td>No (n = 75)</td><td>18.2 ± 4</td></tr><tr><td rowspan="2">Dyslipidemia</td><td>Yes (n = 63)</td><td>11.8 ± 1.6</td><td rowspan="2"><0.00001</td></tr><tr><td>No (n = 94)</td><td>17 .5 ± 4.6</td></tr><tr><td rowspan="2">Alcohol</td><td>Yes (n = 52)</td><td>16 ± 4.1</td><td rowspan="2">NS</td></tr><tr><td>No (n = 105)</td><td>14.8 ± 3.8</td></tr><tr><td rowspan="2">Sedentarity</td><td>Yes (n = 67)</td><td>15.7 ± 3.7</td><td rowspan="2">NS</td></tr><tr><td>No (n = 90)</td><td>14.9 ± 2.4</td></tr></table> |
d1a582c03e2e17d3caaff01332c6f63c93f7bd1fbbecc7e59e11ea452481d351.png | simple | <table><tr><td>Diet composition</td><td>20% animal protein</td><td>10% animal pro+tein</td><td>20% plant protein</td><td>10% plant protein</td></tr><tr><td>Total energy value (kcal/g)</td><td>3.7</td><td>3.7</td><td>3.7</td><td>3.7</td></tr><tr><td>Carbohydrate (%Kcal)</td><td>62.93</td><td>73.23</td><td>63.15</td><td>73.06</td></tr><tr><td>Fat (%kcal)</td><td>16.97</td><td>16.97</td><td>16.87</td><td>16.74</td></tr><tr><td>Protein (%Kcal)</td><td>20.11</td><td>10.04</td><td>19.98</td><td>10.20</td></tr><tr><td>Leucine (g/kg)</td><td>18.7</td><td>9.4</td><td>21.2</td><td>10.6</td></tr><tr><td>Isoleucine (g/kg)</td><td>10.1</td><td>5.0</td><td>7.9</td><td>4.0</td></tr><tr><td>Lysine (g/kg)</td><td>15.7</td><td>7.9</td><td>3.9</td><td>1.9</td></tr><tr><td>Methionine (g/kg)</td><td>4.9</td><td>2.4</td><td>4.1</td><td>2.1</td></tr><tr><td>Cysteine (g/kg)</td><td>2.0</td><td>1.0</td><td>3.0</td><td>1.5</td></tr><tr><td>Arginine (g/kg)</td><td>6.7</td><td>3.3</td><td>7.8</td><td>3.9</td></tr><tr><td>Phenylalanine (g/kg)</td><td>8.8</td><td>4.4</td><td>10.4</td><td>5.2</td></tr><tr><td>Tyrosine (g/kg)</td><td>9.2</td><td>4.6</td><td>5.0</td><td>2.5</td></tr><tr><td>Histidine (g/kg)</td><td>4.9</td><td>2.4</td><td>4.2</td><td>2.1</td></tr><tr><td>Threonine (g/kg)</td><td>8.4</td><td>4.2</td><td>5.5</td><td>2.7</td></tr><tr><td>Tryptophan (g/kg)</td><td>2.5</td><td>1.2</td><td>1.6</td><td>0.8</td></tr><tr><td>Valine (g/kg)</td><td>11.8</td><td>5.9</td><td>8.7</td><td>4.3</td></tr><tr><td>Wheat gluten (g/kg)</td><td>―</td><td>―</td><td>110</td><td>55</td></tr><tr><td>Corn gluten (60%) (g/kg)</td><td>―</td><td>―</td><td>136</td><td>68</td></tr><tr><td>Isolated soy protein (g/kg)</td><td>―</td><td>―</td><td>22</td><td>11</td></tr><tr><td>Casein (g/kg)</td><td>170</td><td>85</td><td>―</td><td>―</td></tr><tr><td>Lactalbumin (g/kg)</td><td>44</td><td>22</td><td>―</td><td>―</td></tr><tr><td>Corn starch (g/kg)</td><td>380.1</td><td>486.3</td><td>325.4</td><td>459</td></tr><tr><td>Maltodextrin (g/kg)Sucrose (g/kg)</td><td>100150</td><td>100150</td><td>100150</td><td>100150</td></tr><tr><td>Corn oil (g/kg)</td><td>32</td><td>32</td><td>32</td><td>32</td></tr><tr><td>Olive oil (g/kg)</td><td>32</td><td>32</td><td>32</td><td>32</td></tr><tr><td>Cellulose (g/kg)</td><td>50</td><td>50</td><td>50</td><td>50</td></tr><tr><td>Mineral Mix, w/o Ca & P</td><td>13.14</td><td>13.14</td><td>13.14</td><td>13.14</td></tr><tr><td>Calcium phosphate (g/kg)</td><td>8</td><td>10.8</td><td>12</td><td>12.6</td></tr><tr><td>Calcium carbonate (g/kg)</td><td>10.3</td><td>8.3</td><td>7.0</td><td>6.8</td></tr><tr><td>Vitamin Mix, Tekland (g/kg)</td><td>10</td><td>10</td><td>10</td><td>10</td></tr></table> |
d9b70091e7d1930ad1b05cfd6203d691b432a2ef33bd3657a9de13556a0f67e7.png | simple | <table><tr><td> </td><td> </td><td><i><underline>Mean (SD)</underline></i></td></tr><tr><td>Age</td><td>(Year)</td><td>43.91 (15.4)</td></tr><tr><td>Pain intensity<sup>*</sup></td><td>(0–10)</td><td>4.11 (1.9)</td></tr><tr><td>Physical disability<sup>**</sup></td><td>(0–24)</td><td>8.78 (5.3)</td></tr><tr><td>Depression<sup>***</sup></td><td>(0–42)</td><td>8.75 (9.9)</td></tr><tr><td>Anxiety<sup>≠</sup></td><td>(0–42)</td><td>6.55 (8.4)</td></tr><tr><td>Stress<sup>±</sup></td><td>(0–42)</td><td>13.08 (9.8)</td></tr><tr><td>Fatigue<sup>†</sup></td><td>(1–63)</td><td>32.49 (12.3)</td></tr><tr><td>Pittsburgh questionnaire<sup>#</sup></td><td>(0 – 21)</td><td>7.92 (3.8)</td></tr><tr><td>Insomnia index<sup>$</sup></td><td>(0 – 28)</td><td>11.25 (6.4)</td></tr><tr><td>Epworth scale<sup>¥</sup></td><td>(0 – 24)</td><td>7.26 (5.2)</td></tr><tr><td>Body mass index</td><td>(Kg/m<sup>2</sup>)</td><td>25.73 (4.9)</td></tr><tr><td> </td><td> </td><td><i><underline>N (%)</underline></i></td></tr><tr><td>Pain duration</td><td>Acute</td><td>32 (41%)</td></tr><tr><td> </td><td>Chronic</td><td>47 (59%)</td></tr><tr><td>Roland item<sup>£</sup></td><td>(Yes)</td><td>46 (58%)</td></tr><tr><td>Seeking care</td><td>(Yes)</td><td>58 (73%)</td></tr><tr><td>Taking pain medication</td><td>(Yes)</td><td>35 (44%)</td></tr><tr><td>Gender</td><td>(Female)</td><td>40 (51%)</td></tr><tr><td>Level of education</td><td>(University degree)</td><td>35 (44%)</td></tr><tr><td>Smoking status</td><td>(Not)</td><td>74 (94%)</td></tr><tr><td>Work status</td><td>Full-time</td><td>48 (61%)</td></tr><tr><td> </td><td>Part-time</td><td>14 (18%)</td></tr><tr><td> </td><td>Not working</td><td>4 (5%)</td></tr><tr><td> </td><td>Retired</td><td>13 (16%)</td></tr><tr><td>Marital status</td><td>Married or defacto</td><td>39 (49%)</td></tr><tr><td> </td><td>Separated</td><td>8 (10%)</td></tr><tr><td> </td><td>Single</td><td>32 (41%)</td></tr></table> |
b11a924172c22e8d19f8f9acc1df01d461122a810a7d5897102795767b34d61e.png | complex | <table><tr><td></td><td colspan="2">Full sample (n = 14,798)</td><td colspan="2">Restricted analytic sample (n = 11,733)</td></tr><tr><td></td><td><i>percent</i></td><td><i>std error</i></td><td><i>percent</i></td><td><i>std error</i></td></tr><tr><td><i>Age</i></td><td></td><td></td><td></td><td></td></tr><tr><td>18–24</td><td>17</td><td>0.6</td><td>18</td><td>0.6</td></tr><tr><td>26–44</td><td>53</td><td>0.9</td><td>55</td><td>1.0</td></tr><tr><td>45–64</td><td>30</td><td>0.8</td><td>28</td><td>0.9</td></tr><tr><td><i>Gender</i></td><td></td><td></td><td></td><td></td></tr><tr><td>Men</td><td>49</td><td>0.4</td><td>49</td><td>0.5</td></tr><tr><td>Women</td><td>51</td><td>0.4</td><td>51</td><td>0.5</td></tr><tr><td><i>Race/ethnicity</i></td><td></td><td></td><td></td><td></td></tr><tr><td>White</td><td>74</td><td>1</td><td>75</td><td>1</td></tr><tr><td>Black</td><td>12</td><td>0.6</td><td>11</td><td>0.6</td></tr><tr><td>Mexican-American</td><td>6</td><td>0.5</td><td>6</td><td>0.5</td></tr><tr><td>Other</td><td>8</td><td>0.9</td><td>8</td><td>1</td></tr><tr><td><i>Marital status</i></td><td></td><td></td><td></td><td></td></tr><tr><td>married/living as</td><td>64</td><td>0.9</td><td>64</td><td>0.9</td></tr><tr><td>not married/not living as</td><td>36</td><td>0.9</td><td>36</td><td>0.9</td></tr><tr><td><i>Education</i></td><td></td><td></td><td></td><td></td></tr><tr><td>< high school</td><td>23</td><td>1</td><td>22</td><td>1</td></tr><tr><td>high school</td><td>35</td><td>0.8</td><td>34</td><td>0.8</td></tr><tr><td>> high school</td><td>42</td><td>1</td><td>44</td><td>1</td></tr><tr><td><i>Occupation</i></td><td></td><td></td><td></td><td></td></tr><tr><td>white collar and professional</td><td>24</td><td>0.9</td><td>25</td><td>0.9</td></tr><tr><td>white collar, semi-routine</td><td>23</td><td>0.7</td><td>23</td><td>0.7</td></tr><tr><td>blue collar, high skill</td><td>12</td><td>0.5</td><td>12</td><td>0.5</td></tr><tr><td>blue collar, semi-routine</td><td>39</td><td>0.8</td><td>38</td><td>0.9</td></tr><tr><td>never worked</td><td>3</td><td>0.3</td><td>3</td><td>0.3</td></tr><tr><td><i>Income (equivalized for family size)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>< 50% median</td><td>22</td><td>1</td><td>21</td><td>1</td></tr><tr><td>50–100% median</td><td>31</td><td>1</td><td>30</td><td>1</td></tr><tr><td>> median</td><td>47</td><td>2</td><td>49</td><td>2</td></tr><tr><td>% below poverty</td><td>11</td><td>0.7</td><td>11</td><td>0.8</td></tr><tr><td>% poverty to 184% poverty</td><td>16</td><td>0.8</td><td>15</td><td>0.8</td></tr><tr><td>185% poverty to median income*</td><td>25</td><td>1</td><td>25</td><td>1</td></tr><tr><td>> median*</td><td>47</td><td>2</td><td>49</td><td>2</td></tr><tr><td><i>Work and health</i></td><td></td><td></td><td></td><td></td></tr><tr><td>not currently in labor force</td><td>25</td><td>0.7</td><td>21</td><td>0.7</td></tr><tr><td>employment affected by health</td><td>10</td><td>0.4</td><td>0</td><td>-</td></tr><tr><td>death with <1 year follow-up</td><td>0.3</td><td>0.07</td><td>0</td><td>-</td></tr></table> |
101756274042bb558ea624d7579826c80f11dece9a3131493e4bd15a1dc88b96.png | simple | <table><tr><td>Variable</td><td>Number of cases</td><td>%</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Male</td><td>116</td><td>54</td></tr><tr><td> Female</td><td>98</td><td>46</td></tr><tr><td>Age, y</td><td></td><td></td></tr><tr><td> < 70</td><td>120</td><td>56</td></tr><tr><td> ≥ 70</td><td>94</td><td>44</td></tr><tr><td>T-category</td><td></td><td></td></tr><tr><td> T2</td><td>33</td><td>15</td></tr><tr><td> T3</td><td>181</td><td>85</td></tr><tr><td>Cancer specific survival, y</td><td></td><td></td></tr><tr><td> < 5</td><td>105</td><td>49</td></tr><tr><td> ≥ 5</td><td>109</td><td>51</td></tr><tr><td> Censored</td><td>156</td><td>73</td></tr></table> |
9fbf079761b461a40050ebcc7a3bd22891cb5a37876100ef1ee6906ee94f926f.png | complex | <table><tr><td>Variable</td><td>Variable groups</td><td>Treatment sought (%)</td><td>COR (95% CI)</td><td>AOR (95% CI)</td></tr><tr><td rowspan="2">Age of caregivers</td><td><30</td><td>103 (92.0)</td><td>2.5 (1.02–5.91)*</td><td>3.40 (1.27–9.10)**</td></tr><tr><td><underline>></underline>30</td><td>70 (82.4)</td><td>1.00</td><td>1.00</td></tr><tr><td rowspan="2">Place of residence</td><td>Rural</td><td>107 (91.5)</td><td>2.27 (0.95–5.40)*</td><td>2.80 (1.01–7.70)**</td></tr><tr><td>Urban</td><td>66 (82.5)</td><td>1.00</td><td>1.00</td></tr><tr><td rowspan="4">Educational status</td><td>Illiterate</td><td>103 (86.6)</td><td>1.00</td><td></td></tr><tr><td>Read and write</td><td>26 (92.9)</td><td>2.02 (0.44–9.34)</td><td></td></tr><tr><td>Primary</td><td>25 (89.3)</td><td>1.29 (0.26–4.79)</td><td></td></tr><tr><td>Secondary or above</td><td>19 (86.4)</td><td>0.98 (0.26–3.71)</td><td></td></tr><tr><td rowspan="3">Religion</td><td>Christian</td><td>121 (89.6)</td><td>1.00</td><td></td></tr><tr><td>Muslim</td><td>18 (94.7)</td><td>2.08 (0.26–16.81)</td><td></td></tr><tr><td>Traditional</td><td>34 (79.1)</td><td>0.44 (0.17–1.10)*</td><td></td></tr><tr><td rowspan="3">Ethnicity</td><td>Gumuz</td><td>66 (82.5)</td><td>1.00</td><td></td></tr><tr><td>Agew</td><td>79 (90.8)</td><td>2.09 (0.83–5.30)*</td><td></td></tr><tr><td>Amhara</td><td>28 (93.3)</td><td>2.97 (0.63–13.94)*</td><td></td></tr><tr><td rowspan="2">Family size</td><td>≤5</td><td>106 (89.1)</td><td>1.34 (0.57–3.16)</td><td></td></tr><tr><td>≥6</td><td>67 (85.9)</td><td>1.00</td><td></td></tr><tr><td rowspan="3">Occupation of respondents</td><td>Farmer</td><td>45 (81.8)</td><td>1.00</td><td></td></tr><tr><td>Housewife</td><td>109 (90.5)</td><td>2.02 (0.81–5.01)*</td><td></td></tr><tr><td>Merchant/government employee</td><td>19 (90.5)</td><td>2.11 (0.42–10.56)</td><td></td></tr><tr><td rowspan="3">Average monthly income (ETB)</td><td>≤500</td><td>68 (87.2)</td><td>1.00</td><td></td></tr><tr><td>501–1000</td><td>42 (91.3)</td><td>1.54 (0.46–5.24)</td><td></td></tr><tr><td>>1000</td><td>63 (86.3)</td><td>0.93 (0.36–2.37)</td><td></td></tr><tr><td rowspan="2">Malaria knowledge</td><td>Poor</td><td>95 (82.6)</td><td>1.00</td><td>1.00</td></tr><tr><td>Good</td><td>78 (95.1)</td><td>4.11 (1.35–12.51)*</td><td>4.65 (1.38–15.64)**</td></tr><tr><td rowspan="2">Perceived susceptibility</td><td>Low</td><td>99 (84.6)</td><td>1.00</td><td>1.00</td></tr><tr><td>High</td><td>74 (92.5)</td><td>2.24 (0.85–5.93)*</td><td>3.63 (1.21–10.88)**</td></tr><tr><td rowspan="2">Perceived severity</td><td>Low</td><td>87 (86.1)</td><td>1.00</td><td></td></tr><tr><td>High</td><td>84 (87.5)</td><td>0.94 (0.40–2.22)</td><td></td></tr><tr><td rowspan="2">Perceived benefits of malaria treatment</td><td>Low</td><td>87 (86.1)</td><td>1.00</td><td></td></tr><tr><td>High</td><td>86 (89.6)</td><td>1.38 (0.58–3.29)</td><td></td></tr><tr><td rowspan="2">Perceived barriers to treatment-seeking</td><td>Low</td><td>106 (93.0)</td><td>1.00</td><td>1.00</td></tr><tr><td>High</td><td>67 (80.7)</td><td>0.32 (0.13–0.78)*</td><td>0.18 (0.06–0.52)**</td></tr><tr><td rowspan="2">Cues to action</td><td>Low</td><td>102 (85.0)</td><td>1.00</td><td></td></tr><tr><td>High</td><td>71 (92.2)</td><td>2.09 (0.79–5.52)*</td><td></td></tr><tr><td rowspan="2">Perceived self-efficacy</td><td>Low</td><td>106 (87.6)</td><td>1.00</td><td></td></tr><tr><td>High</td><td>67 (88.2)</td><td>1.05 (0.44–2.54)</td><td></td></tr></table> |
79d8cb4a3b583c3f760820489bc8aeb11fc48f85663a1e9946ba028d408135a4.png | complex | <table><tr><td>SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS</td><td colspan="6">QUALITY OF LIFE</td></tr><tr><td></td><td>Physical</td><td>Psychological</td><td>Level of independence</td><td>Social relationships</td><td>Environment</td><td>Spirituality/Religion/Personal beliefs</td></tr><tr><td>Age*</td><td>-0.01</td><td>0.04</td><td>-0.17<sup>†</sup></td><td>-0.03</td><td>0.10</td><td>0.03</td></tr><tr><td>Duration of diabetes in years (since first diagnosis)**</td><td>-0.02</td><td>0.09</td><td>-0.17<sup>†</sup></td><td>-0.02</td><td>0.09</td><td>0.07</td></tr><tr><td>Fasting Glucose mmol/L**</td><td>-0.08</td><td>-0.15<sup>†</sup></td><td>-0.00</td><td>-0.09</td><td>-0.18<sup>†</sup></td><td>-0.00</td></tr><tr><td>HbA1c %*</td><td>-0.05</td><td>-0.05</td><td>-0.00</td><td>-0.00</td><td>-0.11</td><td>0.00</td></tr></table> |
53eefa60bb5dcc1cec563ca61fffd2016a32f1b3acfb950ecd327bdf0d4d0cbe.png | simple | <table><tr><td>Tissue</td><td>Male <i>P</i> Value</td><td>Male<i>ρ</i></td><td>Female <i>P-</i>Value</td><td>Female<i>ρ</i></td></tr><tr><td>Brain</td><td>8.71E−07</td><td>0.05504</td><td>2.81E−08</td><td>0.06247</td></tr><tr><td>Cerebellum</td><td>1.71E−19</td><td>0.10246</td><td>9.25E−21</td><td>0.10539</td></tr><tr><td>Kidney</td><td>3.97E−126</td><td>0.26420</td><td>3.37E−07</td><td>0.05751</td></tr><tr><td>Heart</td><td>4.13E−66</td><td>0.19308</td><td>7.14E−20</td><td>0.10423</td></tr><tr><td>Liver</td><td>5.91E−12</td><td>0.07786</td><td>NA</td><td>NA</td></tr><tr><td>Testis</td><td>6.92E−83</td><td>0.21132</td><td>NA</td><td>NA</td></tr></table> |
f9cc263cd6d194ea8722f387813ecf2afb2d8050c4a179a46e6eb08b0561a7b3.png | complex | <table><tr><td rowspan="2">Year*</td><td rowspan="2"><i>N</i><sub>a</sub>†</td><td colspan="3">Microsatellites – <i>N</i><sub>b</sub></td><td colspan="2">MtDNA – <i>N</i><sub>bf</sub></td></tr><tr><td>mlne‡</td><td>Tempo <i>F</i><sub>S</sub>§</td><td>ldne¶</td><td>mlne‡</td><td><i>F</i><sub>c</sub>**</td></tr><tr><td>1997</td><td>7532 (5359, 9997)</td><td>1609 (867, 7408)</td><td>711 (398, 3362)</td><td>1072 (565, 7388)</td><td>1136 (528, ∞)</td><td>876 (291, 4341)</td></tr><tr><td>1998</td><td>7427 (4910, 10 927)</td><td>1364 (814, 3644)</td><td>291 (165, 1180)</td><td>882 (512, 2822)</td><td>966 (465, ∞)</td><td>1149 (335, 32 493)</td></tr><tr><td>1999</td><td>4910 (3263, 7147)</td><td>934 (644, 1600)</td><td>143 (94, 277)</td><td>∞ (1398, ∞)</td><td>1261 (429, ∞)</td><td>711 (215, 4582)</td></tr><tr><td>2000</td><td>4978 (3426, 7885)</td><td>769 (550, 1243)</td><td>165 (98, 528)</td><td>326 (251, 456)</td><td>1006 (398, ∞)</td><td>921 (250, ∞)</td></tr><tr><td>2001</td><td>4224 (2748, 6986)</td><td>832 (572, 1435)</td><td>250 (148, 903)</td><td>520 (373, 833)</td><td>536 (291, 1989)</td><td>398 (130, ∞)</td></tr><tr><td>2002</td><td>3012 (1779, 5525)</td><td>1162 (720, 2758)</td><td>291 (165, 1113)</td><td>688 (459, 1320)</td><td>2334 (666, ∞)</td><td>733 (237, ∞)</td></tr><tr><td>2003</td><td>2323 (1405, 4109)</td><td>943 (621, 1828)</td><td>246 (112, ∞)</td><td>1188 (618, 10 040)</td><td>1551 (702, ∞)</td><td>1203 (353, 9634)</td></tr><tr><td>2004</td><td>979 (526, 1999)</td><td>4377 (1337, ∞)</td><td>1341 (367, ∞)</td><td>∞ (1901, ∞)</td><td>15 647 (1475, ∞)</td><td>13 832 (943, ∞)</td></tr><tr><td>2005</td><td>2200 (883, 5301)</td><td>1909 (934, 5311)</td><td>608 (282, ∞)</td><td>814 (469, 2678)</td><td>5566 (984, ∞)</td><td>2320 (528, ∞)</td></tr><tr><td>2006</td><td>1366 (741, 3387)</td><td>1314 (764, 3867)</td><td>389 (232, 1274)</td><td>1390 (269, ∞)</td><td>2817 (845, ∞)</td><td>1574 (331, ∞)</td></tr><tr><td>2007</td><td>984 (614, 1738)</td><td>19 054 (1775, ∞)</td><td>429 (188, ∞)</td><td>852 (515, 2268)</td><td>2146 (724, ∞)</td><td>2597 (496, ∞)</td></tr><tr><td>2008</td><td>1364 (888, 2474)</td><td>514 (402, 711)</td><td>107 (54, ∞)</td><td>3876 (860, ∞)</td><td>1189 (630, 4390)</td><td>773 (264, 2119)</td></tr><tr><td>2009</td><td>1183 (679, 2763)</td><td>1587 (881, 6219)</td><td>840 (425, 34 487)</td><td>821 (491, 2295)</td><td>747 (443, 1824)</td><td>581 (228, 1498)</td></tr><tr><td>2010</td><td>524 (270, 1326)</td><td>3970 (1355, ∞)</td><td>5494 (671, ∞)</td><td>12 391 (1393, ∞)</td><td>1677 (630, ∞)</td><td>1395 (429, 14 405)</td></tr></table> |
f911743f5bd88d1c5bf8496320bafd1e59154f955ffd614507ae3abb518eb5bb.png | simple | <table><tr><td>Demographics</td><td>Week 4</td><td>Week 8</td><td>Week 12</td></tr><tr><td>Age (year)</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>159</td><td>129</td><td>106</td></tr><tr><td> Mean ± SD</td><td>63.8 ± 13.1</td><td>63.9 ± 13.5</td><td>63.4 ± 13.8</td></tr><tr><td> Interquartiles</td><td>54–74</td><td>54–74</td><td>54–74</td></tr><tr><td> Median (Range)</td><td>65 (30–89)</td><td>66 (30–88)</td><td>64 (30–88) </td></tr><tr><td>Karnofsky performance status (KPS)</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>151</td><td>124</td><td>104</td></tr><tr><td> Mean ± SD</td><td>71.9 ± 13.1</td><td>72.6 ± 11.8</td><td>72.5 ± 12.5</td></tr><tr><td> Interquartiles</td><td>60–80</td><td>70–80</td><td>70–80</td></tr><tr><td> Median (range)</td><td>70 (30–90)</td><td>70 (40–90)</td><td>70 (40–90) </td></tr><tr><td>Worst pain</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>159</td><td>129</td><td>106</td></tr><tr><td> Mean ± SD</td><td>5.13 ± 2.67</td><td>4.84 ± 2.58</td><td>4.75 ± 2.44</td></tr><tr><td> Interquartiles</td><td>3–7</td><td>3–7</td><td>3–7</td></tr><tr><td> Median (range)</td><td>5.0 (1–10)</td><td>5.0 (1–10)</td><td>4.0 (1–10) </td></tr><tr><td>Average pain</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>159</td><td>129</td><td>106</td></tr><tr><td> Mean ± SD</td><td>3.57 ± 2.28</td><td>3.60 ± 2.20</td><td>3.33 ± 2.12</td></tr><tr><td> Interquartiles</td><td>2–5</td><td>2–5</td><td>2–5</td></tr><tr><td> Median (range)</td><td>3.0 (0–10)</td><td>3.0 (0–9)</td><td>3.0 (0–9) </td></tr><tr><td>Current pain</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>159</td><td>129</td><td>106</td></tr><tr><td> Mean ± SD</td><td>2.69 ± 2.49</td><td>2.33 ± 2.26</td><td>2.41 ± 2.37</td></tr><tr><td> Interquartiles</td><td>0–4</td><td>0–4</td><td>0–4</td></tr><tr><td> Median (range)</td><td>3.0 (0–10)</td><td>2.0 (0–10)</td><td>2.0 (0–9) </td></tr><tr><td>Total daily morphine equivalent (mg)</td><td></td><td></td><td></td></tr><tr><td><i>n</i></td><td>143</td><td>115</td><td>94</td></tr><tr><td> Mean ± SD</td><td>101.4 ± 162.5</td><td>91.6 ± 133.2</td><td>119.6 ± 194.5</td></tr><tr><td> Interquartiles</td><td>0–135</td><td>0–135</td><td>0–210</td></tr><tr><td> Median (range)</td><td>30 (0–904)</td><td>32 (0–832)</td><td>24 (0–1080) </td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>88 (55.35%)</td><td>70 (54.26%)</td><td>62 (58.49%)</td></tr><tr><td> Female</td><td>71 (44.65%)</td><td>59 (45.74%)</td><td>44 (41.51%)</td></tr><tr><td>Pain site</td><td></td><td></td><td></td></tr><tr><td> Lower limb</td><td>94 (59.12%)</td><td>76 (58.91%)</td><td>74 (69.81%)</td></tr><tr><td> Upper limb</td><td>63 (39.62%)</td><td>50 (38.76%)</td><td>29 (27.36%)</td></tr><tr><td> Other</td><td>2 (1.26%)</td><td>3 (2.33%)</td><td>3 (2.83%)</td></tr><tr><td>Primary cancer site</td><td></td><td></td><td></td></tr><tr><td> Prostate</td><td>46 (28.93%)</td><td>41 (31.78%)</td><td>32 (30.19%)</td></tr><tr><td> Breast</td><td>37 (23.27%)</td><td>31 (24.03%)</td><td>28 (26.42%)</td></tr><tr><td> Lung</td><td>41 (25.79%)</td><td>28 (21.71%)</td><td>24 (22.64%)</td></tr><tr><td> Bladder</td><td>10 (6.29%)</td><td>8 (6.20%)</td><td>6 (5.66%)</td></tr><tr><td> Pancreas/gastric</td><td>5 (3.14%)</td><td>0 (0.00%)</td><td>1 (0.94%)</td></tr><tr><td> Others</td><td>20 (12.58%)</td><td>37 (17.5%)</td><td>15 (14.15%)</td></tr><tr><td>Dose fractionation</td><td></td><td></td><td></td></tr><tr><td> Single</td><td>100 (62.89%)</td><td>72 (55.81%)</td><td>67 (63.21%)</td></tr><tr><td> Multiple</td><td>59 (37.11%)</td><td>57 (44.19%)</td><td>39 (36.79%)</td></tr></table> |
e6ecf114830e532f028e89b7f275578facb10f51d5811bc86cb4c9b8eca4bdfc.png | simple | <table><tr><td>Disease Duration (Years)</td><td>Number (n)</td><td>Age (Years, Mean)</td><td>Female * (%)</td><td>BMI * (kg/m<sup>2</sup>, Mean)</td><td>Pos. Fam. History * (%)</td><td>RF Pos. * (%)</td><td>ACPA Pos. * (%)</td><td>Rheumatoid Nodules * (%)</td><td>Extra-art. Manifest * (%)</td><td>MTX Pre-exposed * (%)</td><td>TNF Pre-exposed * (%)</td></tr><tr><td>all</td><td>7850</td><td>59.9</td><td>74.4</td><td>26.0</td><td>20.6</td><td>70.8</td><td>62.2</td><td>22.7</td><td>72.9</td><td>81.9</td><td>57.7</td></tr><tr><td><5</td><td>2535</td><td>57.0</td><td>69.2</td><td>26.2</td><td>15.0</td><td>60.8</td><td>54.4</td><td>7.1</td><td>52.3</td><td>83.1</td><td>42.4</td></tr><tr><td>≥5–10</td><td>1990</td><td>58.8</td><td>74.2</td><td>26.4</td><td>21.5</td><td>69.6</td><td>63.9</td><td>15.6</td><td>61.8</td><td>84.1</td><td>61.8</td></tr><tr><td>≥10–15</td><td>1250</td><td>60.8</td><td>76.7</td><td>26.2</td><td>22.1</td><td>75.6</td><td>66.5</td><td>26.3</td><td>81.1</td><td>83.5</td><td>65.2</td></tr><tr><td>≥15–20</td><td>788</td><td>62.2</td><td>77.0</td><td>25.7</td><td>25.4</td><td>79.3</td><td>64.0</td><td>36.3</td><td>84.5</td><td>81.2</td><td>69.3</td></tr><tr><td>≥20–25</td><td>500</td><td>63.3</td><td>79.2</td><td>25.5</td><td>25.6</td><td>81.1</td><td>73.2</td><td>41.1</td><td>85.7</td><td>75.1</td><td>67.2</td></tr><tr><td>≥25–30</td><td>325</td><td>65.3</td><td>81.8</td><td>24.8</td><td>24.3</td><td>85.5</td><td>74.7</td><td>51.5</td><td>86.3</td><td>76.3</td><td>67.8</td></tr><tr><td>≥30–40</td><td>333</td><td>66.5</td><td>82.9</td><td>25.2</td><td>26.7</td><td>79.6</td><td>70.2</td><td>50.8</td><td>91.0</td><td>77.0</td><td>64.4</td></tr><tr><td>≥40</td><td>129</td><td>71.5</td><td>86.0</td><td>24.9</td><td>31.0</td><td>84.3</td><td>69.4</td><td>56.7</td><td>66.7</td><td>66.7</td><td>62.7</td></tr></table> |
5d560703e1a427ef1f2f015fa4ee9e449a447cf1c59f575d2cfcd1d43f2f81cd.png | simple | <table><tr><td>HPA</td><td>Position</td><td>Common allele</td><td>Rare allele</td><td>Residue variety in β-integrins</td></tr><tr><td>1</td><td>33</td><td>Leu</td><td>Pro (Val)</td><td>A, D, E, G, K, L, M, N, P, Q, S, T, V, Y</td></tr><tr><td>4</td><td>143</td><td>Arg</td><td>Gln</td><td>A, E, G, K, N, Q, R, S, T, V</td></tr><tr><td>6</td><td>489</td><td>Arg</td><td>Gln</td><td>A, D, E, G, H, K, N, P, Q, R, S, T, V</td></tr><tr><td>7</td><td>407</td><td>Pro</td><td>Ala</td><td>D, E, H, I, K, L, P, Q, R, S, T, V</td></tr><tr><td>8</td><td>636</td><td>Arg</td><td>Cys</td><td>D, E, G, H, K, L, N, P, Q, R, S, T, Y</td></tr><tr><td>10</td><td>62</td><td>Arg</td><td>Gln</td><td>D, E, F, H, I, K, L, N, Q, R, S, T, V</td></tr><tr><td>11</td><td>633</td><td>Arg</td><td>His</td><td>A, D, E, G, H, K, L, N, Q, R, S, T, V</td></tr><tr><td>14</td><td>611</td><td>Lys</td><td>del</td><td>D, F, H, K, L, N, Q, R, S, Y</td></tr><tr><td>16</td><td>140</td><td>Thr</td><td>Ile</td><td>A, D, E, G, K, L, N, Q, R, S, T, V</td></tr></table> |
45efeb9d6c64991895700dbb52735e6db53058fa2621e4e3a67d970c9c5ffe53.png | complex | <table><tr><td>Demographic or Clinical Characteristic</td><td colspan="2">No. of Patients (<i>N</i>= 48)</td><td>%</td></tr><tr><td>Age, years</td><td></td><td></td><td></td></tr><tr><td> Median</td><td></td><td>56.6</td><td></td></tr><tr><td> Range</td><td></td><td>29-77</td><td></td></tr><tr><td>ECOG performance status</td><td></td><td></td><td></td></tr><tr><td> 0</td><td>19</td><td></td><td>39.6</td></tr><tr><td> 1</td><td>23</td><td></td><td>48</td></tr><tr><td> 2</td><td>6</td><td></td><td>12.5</td></tr><tr><td>Primary tumor intact</td><td>11</td><td></td><td>23</td></tr><tr><td>Skin ulceration</td><td>19</td><td></td><td>40</td></tr><tr><td>Lymph node stations clinically involved</td><td></td><td></td><td></td></tr><tr><td> Groin only (stage III)</td><td>11</td><td></td><td>23</td></tr><tr><td> Deep inguinal or pelvic (stage IV)</td><td>28</td><td></td><td>58.3</td></tr><tr><td>Distant metastasis</td><td>21</td><td></td><td>43.7</td></tr><tr><td>History of smoking</td><td>40</td><td></td><td>83</td></tr><tr><td> Current</td><td>6</td><td></td><td>12.5</td></tr><tr><td> Former</td><td>34</td><td></td><td>70.8</td></tr><tr><td>Prior treatment</td><td></td><td></td><td></td></tr><tr><td> Chemotherapy</td><td>19</td><td></td><td>39.6</td></tr><tr><td> Radiation therapy</td><td>5</td><td></td><td>10.4</td></tr><tr><td>Presentation of disease</td><td></td><td></td><td></td></tr><tr><td> Primary</td><td>17</td><td></td><td>35.4</td></tr><tr><td> Recurrent</td><td>31</td><td></td><td>64.6</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.